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ABSTRACT
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels of 
the nicotinic superfamily. They are found widely in the autonomic nervous system and in 
selected regions of the central nervous system and are thought to be of importance in the 
progression and/or treatment of a number of disorders. Despite all this the exact role of 
cholinergic neurotransmission remains unclear and current cholinergic drug treatments leave 
a lot to be desired. As such nAChRs remain areas of immense interest and potential.
One of the problems with nAChR research has been that the simple receptors 
obtained in heterologous expression systems probably bear little resemblance to the more 
complex stoichiometries seen in vivo. Therefore my PhD dealt with the characterisation of 
some more complex nAChR compositions and the development of research tools to aid in the 
research of not just nAChRs but other ligand-gated and voltage-gated ion channels with 
complex compositions. In this I primarily used two-electrode voltage clamp methods in 
Xenopus laevis oocytes.
My initial research investigated the role of P3 subunit incorporation into a range of 
nAChRs; surprisingly this subunit, which produced only subtle effects when incorporated into 
a3p4 receptors, completely abolished the currents produced by all other pair and homomer 
receptors tested. Similar findings were obtained when hippocampal neurones in primary 
culture (which have a7-like responses) were transfected with the P3 subunit. This suggests a 
possible major role for P3 in nAChR regulation.
One widely used method of constraining receptor stoichiometry is the use of 
“tandem” subunits. My research however uncovered serious flaws in this method which may 
render it worse than useless. Subsequent work showed that expression of “pentamer” 
constructs has greater potential, as it allows much greater control over receptor composition 
yet avoids the problems seen with the tandem approach.
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CHAPTER 1 
Introduction
1.1 History of acetylcholine.
The history of our understanding of the acetylcholine (ACh) ligand-gated ion 
channel (LGIC) is in many ways the history of our understanding of pharmacology.
From long before Europeans arrived in the Americas the Native Americans have 
used tobacco as an entheogen and shortly after colonisation tobacco products were being 
widely smoked, chewed, “dipped” and sniffed recreationally across Europe. The tobacco 
industry was one of the main driving forces in the colonisation of what was to become the 
Southern US and tobacco excise taxation provided a third of the US government’s 
internal revenue up until 1883. The main active ingredient in tobacco, nicotine, is named 
after Jean Nicot who was praising the recreational and medicinal benefits of tobacco as 
far back as 1550. It was not long before some of its less desirable effects became 
apparent with King James VI of Scotland and I of England denouncing it as a “custome 
lothsome to the eye, hatefull to the Nose, harmefull to the braine, dangerous to the Lungs, 
and in the blacke stinking fume thereof, neerest resembling the horrible Stigian smoke of 
the pit that is bottomelesse" in his famous polemic A Counterblaste to Tobacco (1604). 
Punitive tariff rates were to follow in a pattern which was to become common. The 
alkaloid itself was first isolated in 1828, its molecular formula elucidated in 1843 and its 
first synthesis achieved in 1904. Given all this, pharmacologists seem to come onto the 
stage late. In 1856, Claude Bernard, arguably the greatest physiologist of all time, 
published his most famous work demonstrating that a Central American arrow poison 
called curare, a cholinergic antagonist, selectively blocked the motor nerve endings 
(Frutton, 1979). In 1892 Langley definitely proved that nicotine, an ACh agonist, could
20
potently activate neurones (Langley & Anderson, 1892) and this provided the basis for 
Langley to make the first explicit formulation of receptor theory, the idea that “receptive 
substances” on cells combined with pharmacologically active compounds as their specific 
physiological targets, in 1905 building on the “side-chain” theory of Ehrlich (Langley, 
1905; Ehrlich, 1897). Nicotine and curare were then extensively used by Langley and led 
to him postulating the presence of excitatory and inhibitory “receptive substances” in 
effector cells. As such the nicotine receptor became the first to be recognised and named 
(Langley, 1907), though the pharmacological action of choline and ACh on the adrenal 
medulla had already been described by Hunt in 1900 (Hunt, 1901). In 1914 Dale 
identified two types of ACh action and named them muscarinic and nicotinic, due to the 
different actions of the ACh agonists, muscarine and nicotine, a nomenclature which 
remains today (Dale, 1914; Dale et al. 1936). In 1920 Vagusstoff, later identified as ACh, 
became the first recognised neurotransmitter with Loewi’s demonstration that activation 
of the vagus nerve could affect frog hearts even at a distance (Loewi, 1921). The ACh 
nicotinic receptor was the focus of the seminal work by del Castillo and Katz which 
remains the basis of models of drug-receptor interactions (del Castillo & Katz, 1957). In 
the 1950s the ACh receptor claimed another first when it became the first receptor to be 
studied electrophysiologically (Katz & Thesleff, 1957) and from this many of the 
different techniques of electrophysiology were developed. The muscle-type nicotinic 
ACh receptor (nAChR) remains the best characterised of all LGICs (reviewed in 
Changeux, 1990). So as can be seen many of the major milestones of pharmacology, and 
biological sciences in general, have revolved around ACh receptors. However despite the 
long and successful history of scientific research into ACh there still remain many
21
questions to be answered and so ACh transmission remains the centre of a lot of scientific 
research.
1.2 Acetylcholine and pathophysiology
Cholinergic neurotransmission is not only of importance to the history of 
pharmacology but also as a potential target for therapy. Acetylcholine is thought to be of 
importance in the progression and/or treatment of a host of diseases including (but not 
exclusively) Parkinson’s disease, Alzheimer’s disease, Huntingdon’s chorea, 
schizophrenia, neuropathic pain, epilepsy (particularly the extremely rare autosomal 
dominant nocturnal frontal lobe epilepsy), Tourette’s syndrome, myasthenia gravis, 
attention deficit disorder and ulcerative colitis. Given the morbidity and mortality 
attributed to smoking there is also a lot of interest in pharmacological approaches 
(particularly nicotinic) to smoking cessation, and these may also be of use in treating 
other addictions. Paradoxically, many of the “pleasurable” aspects of smoking such as 
anxiolysis, analgesia, improved learning and memory, cognitive enhancement and hunger 
suppression are of also of great interest. If  these, along with the putative neuroprotective 
effects of smoking, could be mimicked safely and non-addictively it would be of great 
benefit. Hence, not only is cholinergic research of great historical interest and a good 
starting place to hone experimental techniques and approaches but there is also a 
considerable amount of potential for cholinergics in a wide range of fields.
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1.3 Divisions of the cholinergic system
Cholinergic receptors are divided up in a variety of ways depending on their 
receptor superfamily subunit composition, their location in the body, their actions, their 
pharmacology etc. One of the oldest divisions was initially based purely on differences 
in pharmacology, some receptors were observed to be activated by muscarine while 
others were activated by nicotine, it was only later these differences were shown to 
correspond closely to the main physiological functions of ACh in the body.
1.3.1 Muscarinic acetylcholine receptors
Muscarinic acetylcholine receptors are so-called as they were found to be 
activated by muscarine, one of the active principles of the fly agaric mushroom, Amanita 
muscaria. They are G protein-coupled receptors found in the autonomic nervous system 
(ANS) and also extensively in the central nervous system (CNS). They are also found 
widely in non-neuronal tissues such as the parietal cells of the stomach, exocrine glands, 
smooth muscle, vascular endothelium, and in the heart (atria and cardiac conducting 
tissues). These receptors are thought to mediate the majority of the inhibitory and 
excitatory effects of ACh on central neurones and the peripheral tissues (Caulfield, 1993), 
the effect of their action being dependant on the downstream actions of the receptor such 
as the activation of phospholipase C, inhibition of adenylate cyclase or activation or 
inhibition of an ion channel.
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1.3.2 Nicotinic acetylcholine receptors
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels 
(LGICs) found in the ANS, somatic nervous system (SNS) and parts of the CNS. 
Ligand-gated ion channels mediate fast signal transmission at synapses and produce their 
effects by allowing the movement of ions across the cell membrane. This can affect the 
cell either directly, by changing the electrical potential of the cell by altering the internal 
concentrations of specific ions, or indirectly, by regulating the internal concentration of 
an ion, usually Ca , which in turn affects the activity of a range of other proteins. The 
majority of my research was concentrated on the nAChRs, particularly the neuronal 
nAChRs although a little work was also carried out on 5 -HT3 and Glycine al ion 
channels. Much of the work, particularly that carried out on concatenated ion channel 
subunits, is of wider practical relevance within the nicotinic superfamily.
The nAChRs are made up of by a pentamer of subunits of which 17 have been so 
far discovered in vertebrates. These are named a l-a lO , p i-[34, y, 8 and s. These are 
further sub-divided into two groups, the muscle (a l, pi, y, 8 and e) and neuronal 
nicotinic (a2-a l0 , p2-p4) subunits.
1.4 Structure of the nicotinic acetylcholine receptors
Despite the differences between the different subunits and the two main classes of 
receptors they form, a number of characteristics are consistent. Both muscle and 
neuronal nicotinic receptors are formed in the cell membrane by a pentamer of subunits 
arranged around a central ion-permeable pore (Figure 1 .IB). Each subunit itself is made
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up o f a large extracellular N-terminal, four transmembrane domains (labelled TM1- 
TM4), a large cytoplasmic loop between TM3 and TM4 and a relatively short extra­
cellular C-terminal (Figure 1.1 A).
COOH
Figure 1.1: A) Representation of the four transmembrane domains of one subunit, 
showing the long extracellular ligand binding N-terminal (NH2) domain 
with cysteine bond. The pore lining TM2 domain is highlighted in blue.
B) A representation of the nAChR as seen from above. The five TM2 
domains (highlighted in blue) create the pore-lining region. The non-TM2 
domains (TM1, TM3-4) are represented by a structural ring in the 
membrane surrounding the TM2 domains. (Adapted from Boorman, 2002)
O f the two types, and in fact o f  all the LGICs, the muscle nicotinic remains the 
best characterised, although most o f what is known for the muscle nAChRs probably 
holds for the neuronal nicotinics, and the other LGICs.
The large N-terminal is thought to contain the residues important in forming the 
binding site. The TM2 domain is thought to have a dominant a-helical structure 
conformation which lines the channel pore and contains the residues which govern the 
ion channel’ s selectivity and conductance (Karlin &  Akabas, 1995). Between TM3 and 
TM4 there is a long cytoplasmic loop which is involved in targeting the receptor to
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specific parts of the subsynaptic membrane (Williams et al. 1998) and contains a number 
of possible phosphorylation sites (their exact function is presently unclear, Moss et al 
1996). The principal binding domain of the muscle nicotinic was thought to be formed 
within the tertiary structure of the a l subunit, created by interactions between three 
separate segments of aromatic residues and the pair of adjacent cysteines specific to a 
subunits (cysteine 192 and cysteine 193; Torpedo a l numbering). These cysteines in the 
extracellular N-terminal domain are the feature that classifies a subunit as an a subunit. 
Three sections of residues, termed loops A, B and C, are conserved throughout all 
a nAChR with the exception of the a5. The a5 is most similar in terms of amino acid 
sequence to [33 despite its classification as an a (as it possesses the adjacent cysteine 
residues 192 and 193). An argument could be made that both subunits should be 
renamed. The three loops form a binding pocket that can interact with the ester moiety of 
the ACh molecule (Karlin & Akabas, 1995) (see Figure 1.2.).
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Figure 1.2. Ribbon diagrams of a single a subunit viewed parallel with the membrane 
plane, in orientations such that the central axis of the pentamer (vertical 
line) is (a) at the back and (b) to the side. The a helices are shown in 
yellow, the (3-strands are in blue and red (inner and outer respectively). 
Locations of the N and C terminal, the Cys-loop disulphide bridge and the 
three binding loops are indicated, (from Unwin, 2005).
The structure o f the membrane-associated Torpedo ACh receptor has been imaged 
by the group o f Unwin using electron microscopy, most recently at a resolution o f 4 A
W149
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(Unwin, 2005). This receptor is a large (290 kDa) glyco-protein that extends about 160 
A normal to the membrane plane and is made up of five subunits; 2 a subunits, and a 
single copy of the p, y and 8 subunits. The four transmembrane domains are a-helical 
segments arranged symmetrically so that the TM2 domain lines the pore (Miyazawa et al. 
2003) while the other three domains coil around each other to shield the inner ring from 
the lipids. An intracellular a-helix of the TM3-TM4 loop makes up the wall of the 
vestibule (Miyazawa et al. 1999). In the N-terminals, the ligand-binding domains 
produce two long, central cavities of around 20 A in diameter about 40 A from the 
membrane surface on opposite sides of the pore. Higher resolution data from the snail 
ACh-Binding Protein (AChBP), a soluble protein of similar form to the ligand-binding 
domains of nAChRs, suggests they are organised around two sets of p-sheets packed into 
a curled p-sandwich, joined through the disulphide bridge forming the Cys loop (Brejc et 
al 2001). The pore itself is a narrow, water-filled path across the membrane and contains 
the channel “gate”, a constricting hydrophobic girdle which constitutes an energetic 
barrier to ion permeation (Beckstein & Sansom, 2004). Another smaller vestibule is 
shaped by the intracellular domain with narrow lateral openings to allow the movement 
of ions (Miyazawa et al. 1999) (see Figure 1.3). Cross-sections of the two vestibules are 
shown in Fig. 1.4.
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Figure 1.3: Electrostatic potential surface representations showing entry/exit 
windows for cations between the helices of different subunits of 
the muscle nicotinic receptor on the intracellular side of the 
membrane. The window between 5 and p is shown on the left and 
the window between y and a5 are on the right. The location of the 
intracellular membrane surface is indicated by the horizontal bar 
and the sphere in the 5/p window is the size of a potassium ion 
(2.7 A diameter). Exposed charged side-chains are labelled, 
(from Unwin, 2005)
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Figure 1.4: Central sections showing the inner surface of (a) the extracellular and (b)
the intracellular vestibules. Both vestibules are lined by an excess of 
negatively charged groups, promoting a cation-stabilising electrostatic 
environment. Exposed side-chains are labelled and the locations of the 
membrane pores (arrows) and membrane surfaces (horizontal bars) are 
indicated, (from Unwin, 2005)
(A) View looking towards the a 5-p  subunit-subunit interface
(B) View looking towards the subunit with y and (3 on either side.
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The two structures of particular interest to us are the ACh-binding sites and the 
channel gate.
1.5 The ACh-binding site
Single channel data has shown that for full function of the receptor, two ACh 
molecules have to bind to the receptor the final proof of which was shown by Colquhoun 
& Sakmann, 1985. Monoliganded openings do occur but they are usually rare and minor 
events unless very low concentrations of ACh are used or the receptor contains a 
mutation. As mentioned earlier, it was originally assumed that the two ACh molecules 
bind solely to the two a subunits, however it was later suggested that the ACh-binding 
sites are found at the interface between an a and non-a subunit. The a-only binding 
model was championed originally by Unwin due to his early electron microscopy 
findings, however in his most recent papers (see for instance Unwin, 2005) he appears to 
have back-tracked somewhat from this hypothesis. Earlier imaging at lower resolutions, 
9A (Unwin, 1993) and 4.6A (Miyazawa, 1999) showed that the a subunits differed most 
from the non-a subunits, not in the interface regions, but closer to the centre of what we 
now know is a p-sandwich. As the a subunits displayed weaker densities in their centre, 
this led this region to be identified as the putative ACh-binding site. Imaging in 2005 at 
the higher resolution of 4A revealed that the more open appearance was a consequence of 
the distinct inner- and outer-sheet arrangements in the a subunits. As an example, the 
p9-pl0 hairpin of the a subunits is around 1.5 A further from the oppositely facing inner 
p2 and P6 strands than it is in the other subunits at the level of the binding sites. 
Therefore the earlier identification was a mistake and the putative binding site is closer to
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the y and 5-subunit interfaces putting them in locations equivalent to those found in the 
ACh-Binding protein (Brejc et al. 2001). Unwin also notes a number of sites of potential 
contact between the a l subunits and the y or 5 subunits, however he maintains that the y 
and 5 subunits, particularly the p5 and p6 strands merely help shape the binding pocket, 
while the a l subunit binds directly. For instance, he identifies the conserved Y190, 
Y198 and Cl 92 sidechains of the C-loop and the W149 of the B-loop in the a l subunit as 
coordinating with the bound ACh analogue, carbamylcholine, in the complex with 
AChBP (Celie et a l  2004).
The two resulting distinct types of binding site, ay and a5, would account for 
binding site non-equivalence. The high affinity ACh binding site is thought to be formed 
at the a-8 interface (with the low affinity at the a-y, see Fig. 1.5.), on the basis of the 
affect of site directed mutagenesis on the binding affinity of d-tubocurarine at Torpedo 
nAChRs (O’Leary et al. 1994).
Single channel data has confirmed that the two binding sites display different 
binding affinities for ACh (Zhang et al. 1995). This leaves an interesting question about 
the neuronal nicotinic receptors, are the two ACh-binding sites of a receptor such a3(34, 
presumably formed at the interface between the a3 and p4 subunits, equivalent?
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Figure 1.5: Interpretation of the ACh-binding region of the closed channel at the
interface between the a and the y subunits, showing the loops B and C (a 
subunit), the adjacent strands, (35 and (36 (y subunit) and the attached 
amino acid side-chains. The slab is of the upper part of the Ach-binding 
region, viewed from the synaptic cleft. Some key residues implicated in 
ACh binding are labelled, the Ca backbone and side-chains are in red (a) 
and blue (y). A salt-bridge is indicated between aD152 and yR78 is 
thought to be involved in stabilising the B loop, (from Unwin, 2005).
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1.5.1 The snail ACh-Binding Protein
One useful experimental tool which has come to light recently has helped 
immeasurably in the study of the ACh-binding site of nAChRs, namely a soluble protein 
that binds ACh and is released into the synaptic cleft of Lymnaea stagnalis, the great 
pond snail, imaginatively called the snail ACh-Binding Protein (Smit et al 2001). 
Recordings from snail glial cells show that the AChBP is released into the synaptic cleft 
from perisynaptic glial cell after activation of a-bungarotoxin sensitive nAChRs by 
presynaptically released ACh. The release of the AChBP is thought to dampen down 
cholinergic transmission by sequestering ACh molecules in the synaptic cleft.
Radiolabelling has shown that the protein can also bind a-bungarotoxin and that 
known nicotinic agonists and antagonists can displace the radiolabelled a-bungarotoxin 
in a concentration dependent manner so the ACh-BP must have an ACh binding site that 
is similar to that of nAChRs (Smit et al. 2001).
This was confirmed when the amino acid structure of the AChBP was shown to 
be analogous to that of subunits of the nAChR family without the transmembrane 
domains i.e. mostly the extracelullar ligand-binding domain. The N-terminal domain of 
the AChBP contains a cysteine loop analogous to the loop formed by cysteine 128 and 
142 in the nicotinic AChR subunits (with the slight difference that the two Cys are 
separated by 12 residues in AChBP and 15 residues in the nAChRs). The closest 
sequence similarity is with nAChR a subunits, containing the adjacent cysteine residues 
(Cys 192 and Cys 193). The majority of the residues involved in forming the loops in the 
subunit interface model of the binding site are also conserved, those being Tyr 93, Trp
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149, Tyr 190, Tyr 198 and Trp 55 (numbering of Torpedo a l) and as mentioned above is 
quoted as proof of the a-y/a-5 binding site model.
The crystal structure of the AChBP indicates that 5 identical AChBP ‘protomers’ 
form a pentameric cylinder 62 A high, 80 A diameter surrounding a central hole of 
approximately 18 A (Brejc et al. 2001). Positive and negative sides have been identified 
for each protomer, allowing the protomers to form dimer interfaces with their neighbours, 
with the first protomer interfacing its plus side with its neighbour’s negative side. At 4.6 
A resolution these dimensions of the AChBP pentamer are found to be in good agreement 
with those of the Torpedo nAChR although small differences became apparent at 4 A 
(Miyazawa et al. 1999). The AChBP pentamer is also analogous to the nAChR in its 
orientation with the N-terminal domain at the extracellular face of the nAChR and the C- 
terminal at the cytoplasmic.
Two cavities have been identified in the AChBP (Brejc et al. 2001). The first is a 
large uncharged, hydrophobic pocket framed by P-strands which is thought to be 
analogous to the pocket that was originally thought to be the ACh binding pocket of 
Torpedo (Miyazawa et al. 1999). A distinct second cavity, which can be occupied by a 
HEPES molecule in the crystal, has been suggested as the location of the ligand-binding 
site (Brejc et al. 2001) (see Fig. 1.6.). Residues lining this second cavity are conserved 
from the presumed ACh binding site of the muscle nAChR. These are located close to 
the outer edge of the pentamer, at the interface between the protomers. Aligning the 
amino acid sequence of the AChBP with the nAChR subunits, reveals that many of the 
binding site loops of the AChBP are conserved in the nAChR subunits (see Table 1.1). 
This has made the AChBP a useful tool for investigating ACh-binding in the nAChRs,
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has added evidence for the binding site controversy detailed above and has opened up 
interesting areas o f research using AChBP chimeras (Bouzat et al. 2004).
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Figure 1.6: Representation of the structure of the AChBP binding site with and
without agonist bound.
A) Superposition of the ribbon structure of the AChBP (subunits c 
and d shown) unbound (brown) and with 5 molecules of ACh 
bound (blue). Note the mobile C-loop highlighted in red.
B) Close-up superpositions of the C-loop for the ACh-free 
structure (brown), with ACh bound (blue) and with 
carbamylcholine bound (green). Side-chains of Cys187, Cys188 
and Tyr185 are shown together with Trp143 and Trp53 in 
orientations obtained with 5 molecules of ACh-bound (from Gao et 
al. 2004)
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Loop D A E B F C
No. 53 55 89 104 106 112 114 143 145 164 185 187 188 192
AChBP W Q Y R V L M W W Y Y C C Y
a1
Torpedo
R R Y L D M T W Y T Y C C Y
a1 Human R K Y L Q T T w Y N Y C C Y
a2 Human W K Y F H V w Y D Y C C Y
(x3 Human W K Y L K T I w Y D Y C C Y
a4 Human W K Y F Q T w Y D Y C C Y
a6 Human W R Y L K T T w Y D Y C C Y
a7 Human W Q Y L N Q L w Y G Y C C Y
a8 Human W Q Y L N Q I w H N Y C C Y
a9 Human W R Y V R T D w Y D Y C C Y
alO Human W R Y V R R D w H D Y C C Y
PI
Torpedo
F N M L Q S Q Y Y A S D P Y
pi Human Y D L V S R Q Y Y T P D P R
(32 Human W T Y V S F L W Y D P D S Y
04 Human W K Y I R L L W Y D P D P Y
a5 Human W T F V R T T W Y D D C C Y
03 Human W K F I K V T W Y D D V Y Y
y Torpedo W E E L Y Y L Q Y D W L T F
y Human W E E L S Y L Q Y A P A P H
5 Torpedo W D Q L R T L L Y A P K F Y
S Human w E E L Y Y L L Y G P A P R
e  Human w G E L Y T L Q Y A H G A E
Table 1.1: Alignment of muscle and neuronal nAChR amino acid sequence with the
residues of the AChBP model of the ACh binding site. Note the 
conservation of residues in the binding loops of nicotinic subunits and the 
AChBP.
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1.6 The channel gate
Although it is widely accepted that the channel gate is in the pore-lining TM2 domain, 
there still remains debate over its exact nature and location. There are two hypotheses for 
the location of the channel gate.
Sequentially mutating the residues of the TM2 domain of a l to cysteine provides 
the main evidence for the first hypothesis, first advanced by Arthur Karlin and co­
workers. Methanethiosulfonate-ethylammonium (MTSEA) can covalently react with the 
inserted cysteine residue and block the channel. This is only possible when MTSEA can 
reach the cysteine residue. When the channel is open, it allows access to MTSEA to the 
whole of TM2. When the receptor is not activated, the channel is closed and allows 
MTSEA access only as far as the channel gate. Comparing the extent and rate of block in 
each case for a series of cysteine mutants gives an indication of the location of the 
channel gate. This work suggested that the location of the channel gate is near the 
intracellular end of the channel, at least as close as the 3rd residue downstream from the 
NH2-terminal end of TM2 (Leu 3') (Akabas et al. 1994).
In contrast, the majority of the rest of the data indicates a more extracellular 
location of the channel gate. There is a hydrophobic amino acid residue at the 9' position 
in many LGICs and in the majority of nAChRs subunits and for glycine, GABAa, 5 -HT3 
and the invertebrate glutamate-gated chloride channels (GluCl) this 9' residue is a leucine 
(Labarca et al. 1995) (see Figure 1.7). Mutations of this residue to make it become more 
hydrophilic decrease the EC50 value of the receptors, a phenomenon we make liberal use 
of in this thesis. These mutations do not affect the receptor binding site, as is shown by 
the unchanged Kd value of d-tubocurarine in mutated muscle nAChRs (Filatov & White,
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1995) suggesting an effect on gating. Single channel data from a7 homomeric receptors 
mutated this way show that although the mutation does not affect the main conductance 
state, it does introduce a higher-conducting second state, results which were interpreted 
as the mutation disrupting the desensitised state of the receptor to make it conducting 
(Revah et al. 1991). The most likely explanation of this is that the 9' residues constitute 
the channel gate. Data from homomeric pi GAB A also support the view that 9' 
mutations affect gating, mutating the 9'Leu here results in spontaneous, non-liganded 
openings, indicated by an increase in holding current in the absence of agonists (Chang & 
Weiss, 1998). These spontaneous openings are sensitive to picrotoxin at much higher 
concentrations than the wild-type.
Note that if only one out of the five 9' leucines is mutated to threonine (i.e. in the 
y subunit of muscle nAChR) only a reduction in ECso is observed with no additional 
conductance state (Filatov & White 1995).
Some of the discrepancies may be explained by electron microscopy of the 
muscle nAChRs which showed the closed channel being occluded near the midpoint of 
the channel around the 9' residues (Figure 1.7A) by bends in the a helices thus forming 
the channel gate (Unwin, 1998). Higher resolution imaging however showed that the 
leucines were too far apart to fully occlude the pore but rather they left a hole of around 
3.5A in diameter in the centre, large enough to allow the passage of hydrated Na+ and K+ 
ions (Unwin, 2000). Therefore to prevent the movement of ions through the pore Unwin 
proposed that the channel is “closed” by a hydrophobic “girdle”, spanning between the 9' 
residue and the conserved 13' residue, rather than a single “gate”. This girdle located a 
turn of the a helix above the 9’ would stop ion permeation by preventing the partial
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stripping of the hydration shell from Na and K and so preventing them “squeezing’ 
through the “hole” in the gate (Unwin, 2005) (see Figure 1.8).
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Figure 1.7: Interpretation of the closed-channel gate at 9 A. (from Unwin, 2000)
(a) Channel in profile showing the positions of the pore-lining M2-rods 
(black lines), the ACh-binding pocket (arrow) and the estimated limits of 
the lipid bilayer (dotted lines).
(b) Helical net plot of the amino-acid sequences around the segment M2 
of the Torpedo a-subunit. Highlighted are the conserved leucine residue 
thought to form the gate (cross) and other residues (dots) shown to affect 
the binding affinity of open channel blockers and ion flow through the 
open pore.
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Figure 1.8: Higher resolution maps suggest that the gate is made up of a 
hydrophobic girdle (yellow) created by leucine and valine side-chains 
(from Unwin 2000).
1.7 The open pore
The binding of ACh induces changes in the structure of the receptor which results 
in the opening of the channel and thus allows the permeation of ions through the pore. 
Analysis of the structure of Torpedo nAChRs suggests that the extracellular domains of 
the subunits of the muscle nAChRs can exist in two conformations (Unwin, 2005). In the 
closed channel one conformation is characteristic of the two a subunits, the other 
characteristic of the three non-a subunits. On an axis normal to the membrane plane, the 
inner sheets of the p-sandwich of the a subunits binding domain are rotated 10° relative 
to the non-a subunits. Several interactions between different subunits have been 
identified that may stabilise this “special” conformation of the a subunits. On the
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binding of ACh, the conformation of the a subunits changes to one similar to the non-a 
subunits and the ligand-bound AChBP (Unwin et al. 2002) (see Figure 1.9.). 
Comparison of the unbound a subunits of the muscle nAChRs with the ligand-bound 
AChBP protomers provides insight into the local disturbance caused by the binding of 
ACh. A representation of the structural changes produced by the binding of ACh to the 
AChBP is shown in Figure 1.6. From the comparison with the ligand-bound AChBP, in 
muscle nicotinics it would seem that the binding of ACh causes a twisting of cty which 
pulls the p subunit away from as, allowing as to twist into the space vacated by p. These 
disturbances cause further small rotations of the other subunits, resulting in the kinked 
TM2 a helices twisting to the side and disrupting the gate-forming residues (Unwin,
1998). This has a two-fold effect. First, the twisting of the a helices transiently increases 
the pore diameter allowing ion permeation. Secondly, it exposes the polar side chains of 
threonine and serine residues found at 2' which are thought to constitute the channel 
selectivity filter (see Figure 1.10). It is these residues which are thought to render the 
channel permeable to only Na+, K+ and to a lesser extent Ca2+ under normal physiological 
conditions.
Site directed mutagenesis of the TM2 of Torpedo nAChRs has indicated that four 
hydrophilic residues in and close to the TM2 domain of each subunit face the pore. The 
residues at three of these positions (-4', -1' and 20') are charged and are the main 
determinants of the single channel conductance of these receptors expressed in oocytes 
(Imoto et al. 1988; 1991). These residues are present in each subunit and as such create 
hydrophilic rings at the -4', -1', 2' and 20' positions of the TM2 which, when the channel 
is closed, act to prevent movement of ions through the pore. They are named the
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cytoplasmic ring (-4'); the intermediate ring (-1'), central ring (2') and the outer ring (20'). 
The cytoplasmic, intermediate and outer rings have a net negative charge due to the side 
chains of the residues present, whereas the central ring is hydrophilic and uncharged. 
The net charges and hydrophilic nature of these rings is conserved throughout most of the 
nicotinic subunits. The net effect of these negative charges is to make the nAChRs 
cation-conducting.
Reducing the net negative charge on the cytoplasmic, intermediate or outer ‘rings’ 
by inserting a positively charged or neutral residue results in a decrease in the single 
channel conductance of Torpedo nAChRs, with the conductance decrease being 
proportional to the change in net charge in the ring, independent of which subunit carries 
the mutation (Imoto et al. 1988). The greatest decrease in conductance was observed 
when the mutation was inserted into the outer ring. With the appropriate set of mutations 
the channel can even be made anion conducting! (Galzi et al. 1992).
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Figure 1.9: (previous page) Comparison of the ACh-binding regions in the a-subunit 
with the ligand-bound ACh-Binding Protein provides clues to how the 
local rearrangement caused by ACh initiates the extended conformational 
change to open the channel. The a subunit is in the closed-channel 
conformation whereas AChBP is an analogue of the open or desensitised 
state. Closure of the B and C loops around the bound agonist changes 
the orientation of the B loop (large arrow in (b)) and twist of the (39-(310- 
hairpin (twisted arrow in (b)). These changes are thought to drive the 
clockwise rotations of the inner sheets, favouring the open-channel 
extended conformation, (from Unwin, 2005).
(a) Simplified Ca traces of the ligand-binding region of the a-subunit with 
residues of interest highlighted.
(b) The equivalent region of AChBP complexed with carbamylcholine.
(c) The two regions superimposed after alignment to a common rotation 
axis and extension to include the two (31-(32 loops which are connected to 
the B loops through the inner sheets (arcs).
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Figure 1.10: Transient configuration of M2 rods around the open pore and 
interpretation at 9 A. (from Unwin, 1995)
(a) A barrel of a-helical segments, having a pronounced twist, forms in the 
cytoplasmic leaflet of the bilayer, constricting the pore maximally at the 
cytoplasmic membrane surface. The bend in the rods.(as shown in 
Fig.1.7A) are no longer pointing inwards but have rotated to the side.
(b) Schematic representation of the most distant three rods with a 
tentative alignment of the amino-acids with the densities suggesting that a 
line of polar residues (serines and threonines) should be facing the inner 
pore.
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Figure 1.11: Schematic drawing of the opening mechanism. Binding of ACh to both a- 
subunits initiates a concerted disturbance at the level of the binding 
pockets, which lead to small (clockwise) rotations of the a-subunits at the 
level of the membrane. The rotations destabilise the association of bent 
a-helices forming the gate and favour the alternative mode of association 
in ehich the pore is wider at the middle of the membrane and most 
constricted at the cytoplasmic membrane surface . (from Unwin, 2000).
1.8 Subunit topology
The topology of the muscle nicotinic receptor, i.e. the order in which the subunits 
are arranged around the pore, has been the subject of much debate (reviewed by Karlin 
and Akabas, 1995), fortunately for us the neuronal nicotinic receptor combinations we 
deal with in the present work are less complicated so the topology should be reasonably 
straightforward. Homomeric receptors can obviously only adopt one topology while, 
assuming rotational symmetry, ap receptors (2 copies of a:3 copies of p) can only 
produce two different topologies with the a subunits either together or separated by a 
single p (and vice versa for the putative 3:2 form), of which the second topology is most 
likely given what we know of the topology of the muscle nicotinic. It is only when a 
third subunit (such as p3) is introduced that multiple different topologies become 
possible. Our work on the incorporation of p3 into the a3p4 receptor showed the p3 had
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minimal effect on the pharmacology of competitive antagonists. This suggests that either 
the sequence in the binding domain of (33 is too similar to that of (34 to cause a change or 
that p3 does not participate in the binding site. If  the second hypothesis holds, (33 
becomes analagous to the non-binding site subunit in the muscle nicotinic, the pi, in 
which case a clockwise topology of a3p4a3p3p4 becomes most likely. This is however 
not certain and it is not clear whether this would hold for the other types of triplet 
receptor such as a5-containing and the other putative p3 receptors. It had been hoped 
that the use of concatenated subunits would help us resolve these questions for both 
muscle and nicotinic nAChRs. Problems with the concatamer technique, at least in its 
tandem+monomer form, have meant that this hope hasn’t materialised (see below).
1.9 Neuronal nicotinic acetylcholine receptors
Whilst the muscle nicotinic receptors are very well characterised, the nAChRs 
found throughout the peripheral and central nervous system, the neuronal nicotinic 
acetylcholine receptors, are much less well-understood. It is this class of receptor the 
majority of my research would be focussed on.
1.9.1 Comparison of the muscle and neuronal nicotinic 
receptors
The differences between the muscle and neuronal nicotinic receptors have been 
known for over 50 years since the work of Paton and Zaimis (Paton & Zaimis 1949, 
1951) described the specific effects of decamethonium and hexamethonium in blocking 
nicotinic activity on neuromuscular and ganglion nAChRs respectively.
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Both receptors are known to be cation-conducting, pentameric ligand-gated ion 
channels, found on post-synaptic membranes and are activated by two molecules of 
acetylcholine or nicotine. Also, like muscle nicotinics, functional neuronal nicotinics 
require at least two a subunits (not a5) to be present because the a  subunits provide an 
essential part of the ACh-binding site. There is also a lot of common features in the 
structure and function of the two types of receptor such as the TM2 domain and it is 
likely the residues which are of importance in the muscle receptor will also be of 
importance in the neuronal, so the study of the structure of the muscle receptor and the 
ACh-Binding Protein will also be of interest to those studying neuronal receptors.
The human a l (muscle) and a3 (neuronal) subunits share a 51% amino acid 
sequence identity showing a common evolutionary ancestor but when compared with the 
76% identity between Torpedo and human a l subunits it is clear the neuronal and muscle 
subunits diverged a long time ago (Le Novere & Changeux, 1995). One of the most 
obvious differences between the two types of nAChRs is the sheer number of neuronal 
nicotinic subunits. We do not know whether this diversity has an adaptive value, 
especially since pharmacological and biophysical characterisation of native receptor 
types only shows relatively few classes (a7, a6*, a4p2* and a3p4*). As noted above, 
work on the 8 and y subunits of muscle nicotinic has shown a developmental switch in 
which these subunits are involved and that this switch gives different properties to the 
resulting adult and embryonic receptors. Separate but related genes on different 
chromosomes code for the 12 neuronal nicotinic subunits (a2, a3, a4, a5, a6, a7, a8, 
a9, a 10, p2, P3 & p4) and so provide for a potentially vast number of different receptor 
combinations although the likelihood is that most would not be functional. Even taking
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only the most basic homomeric, pair and triplet combinations which are known to form 
receptors (even if not always particularly functional ones) in heterologous expression 
systems, around 20 different types of nAChRs combinations are known. Nevertheless 
work on native receptors suggests that nAChRs made up by at least four different 
subunits do form and this would increase the number of possible receptor combinations 
many times (Forsayeth & Kobrin, 1997; Conroy & Berg, 1998). Clearly, it is important 
to determine which nAChR combinations are functional, in what ratios subunits 
participate and how incorporation of each subunit affects the receptors characteristics.
1.9.2 Localisation of the neuronal nicotinic receptors
Neuronal nAChRs are found in both the sympathetic and parasympathetic 
divisions of the ANS and in a number of regions of the CNS. nAChRs are also found in 
other non-neuronal tissues such as striated muscle, epithelia, lymphocytes, granulocytes, 
skin and bone (for a review see Gotti et al. 1997). The physiological role, if any, of the 
nAChRs in these non-neuronal tissues is unclear. Nevertheless, these receptors may be 
activated pharmacologically in smokers. One disturbing possibility, for instance, is that 
the nAChRs present in the lung may play a role in the proliferation of cancers in smokers 
(both active and passive) and may even suppress the activity of anti-cancer drugs such as 
the retinoids (Schuller et al. 2000; Chen et al. 2002).
1.9.3 Function of the neuronal nicotinic receptors
In the ANS, ACh acts on nAChRs as a classical fast excitatory neurotransmitter 
in a manner very similar to that at the NMJ and as such governs fast synaptic
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transmission between preganglionic and postganglionic neurones in both the sympathetic 
and parasympathetic systems.
In comparison to the ANS, such examples of cholinergic neurotransmission 
utilising nAChRs in the CNS are fairly rare and so neuronal nAChRs are thought to have 
a predominately modulatory, presynaptic role. While CNS neuronal nAChRs are found 
in both presynaptic and postsynaptic membranes (McGehee et al. 1995; Coggan et al. 
1997), their physiological role is not yet known. It is not even known whether 
presynaptic nAChRs can actually be activated by synaptically released ACh. In contrast, 
exogenous application of nicotinic agonists (including nicotine self-administration by 
smokers) is known to produce widespread effects on the CNS.
The activation of presynaptic neuronal nAChRs may occur at the presynaptic 
terminal and also the preterminal level. The activation of these nAChRs by nicotinic 
agonists may enhance the release of a variety of neurotransmitters. Evidence of this has 
been shown using in vivo microdialysis where systemically administered nicotine was 
seen to increase the release of dopamine from ascending dopaminergic pathways, 
predominantly in the cell-body areas (Wonnacott, 1997) and, more recently, endogenous 
cholinergic activity has been shown to regulate dopamine release in the striatum (Zhou et 
al 2001).
At the postsynaptic level, nicotinic agonists can depolarise neurones in several 
brain areas though whether all the nAChRs expressed in the CNS (both pre- and 
postsynaptic) are ever activated by synaptically released ACh remains an unanswered 
question. Currently hard evidence for the involvement of postsynaptic neuronal nAChRs 
in fast synaptic transmission in the CNS exists for only a few synapses, namely in the
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spinal cord, between recurrent axons from spinal motoneurons and Renshaw cells (Eccles 
et al. 1954), in the retina (Feller et al. 1996) and in the ferret visual cortex (see Roerig et 
al. 1997; reviewed Sivilotti et al. 2000). More recently, synaptic transmission at nAChRs 
in rat hippocampal organotypic cultures and slices has also been reported (Hefft et al.
1999). Nevertheless, it appears that nicotinic synapses contribute little of the excitatory 
drive to the postsynaptic cell that receives them. However it may be that neuronal 
nAChRs, specifically those containing the a l  subunit, are involved in development in the 
CNS. However, the data is limited and any role is still controversial (reviewed by Role & 
Berg, 1996).
Irrespective of the physiological function of nAChRs, and of their role in smoking 
and its effects on such complex behaviours as addiction, learning and memory, it has also 
been noted that the localisation, number and function of neuronal nicotinics can be 
affected in a number of diseases of the CNS. The most noted of these is the marked 
decrease in numbers of nAChRs present in patients suffering from Alzheimer’s disease 
but the neuronal nicotinics are also thought to play a role in the progression and/or 
pathophysiology of Parkinson’s, schizophrenia, Tourette’s syndrome, epilepsy and lung 
tumour development (for reviews see Gotti et al. 1997 and Lindstrom, 1997). Anecdotal 
evidence indicates a strong correlation between schizophrenia and smoking addiction 
with 70% of schizophrenic individuals being found to smoke currently, 54% of which 
were classified as heavy smokers compared to around 35% and 11%, respectively, for 
non-schizophrenics (McCreadie et al. 2003). It has been argued that this could be self- 
medication for schizophrenics who claim tobacco helps ameliorate their symptoms 
although these observations could be just as easily be interpreted as schizophrenics being
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more susceptible to addiction or tobacco-smoking being a causal factor in schizophrenia, 
some reports have even indicated that nicotine addiction may actually be a side-effect of 
anti-psychotic medication (see de Haan et al. 2005 for an example). Additionally, the 
a l  subunit gene contained in the chromosome 15 loci has also been indirectly linked to a 
neurological deficit in schizophrenia (De Luca et al. 2004). The neurochemical changes 
underlying schizophrenia remain a poorly understood field with even the cherished 
dopamine hypothesis under fire so it isn’t surprising that the exact role of the cholinergic 
system remains unclear. Smoking has also been claimed to be neuroprotective in 
Alzheimer’s, although the use of pharmacological therapies aimed at the cholinergic 
system has only met with limited success so far (van Duijn et al. 1994, although see 
Almeida et al. 2002 for evidence of smoking being a risk factor in Alzheimer’s).
There is however at least one disease state where the role of neuronal nicotinics 
can not be disputed. A rare form of inherited epilepsy, autosomal dominant nocturnal 
frontal lobe epilepsy (ADFNLE) is known to be due to mutations in either the nicotinic 
a4 or P2 subunit (Steinlein et al. 1995, 1997, for review see Combi et al. 2004). Six 
mutations have been identified so far, four in the a4 and two in the (32. The four a4 
mutations are made up of three missense mutations (S252F, S256L and T265I) and an 
insertion of a leucine at position 263. The two (32 mutations both affect the same 
conserved valine residue at position 287 with it being replaced by either a leucine or a 
methionine (Combi et al. 2004). Not all affected families carry these mutations which 
only account for 12% of ADFNLE cases, suggesting that this disease is genetically 
heterogenous and is more likely to be a collection of closely related disorders rather than 
a singular disease. Other specific forms of idiopathic generalised epilepsy have been
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linked to the region of the human genome containing the p3 subunit, indicating a 
functional role for 03 in the CNS which was surprising considering the supposedly 
“orphan” status of p3 at the time (Dumer et al. 1999).
Knock-out studies have now been carried out to try and shed light on the role of 
the cholinergic system, for instance the use of gene targeting in mouse embryonic stem 
cells has highlighted interesting features. Mesencephalic dopamine-containing neurons 
in p2 knock-out mice have been shown to have lost the normal response to nicotine. 
Behaviourally the mice do not show intravenous nicotine self-administration unlike their 
wild-type counterparts (Picciotto et al. 1998). Both a4 and p2 knock-out mice also show 
a marked reduction in nicotine-elicited antinociception, incidentally providing further 
evidence that a402* receptors are likely to be a major neuronal nAChR subtype 
(Marubio et al. 1999). When a3 or both p2 and p4 are knocked-out the mice are seen to 
survive until birth but display impaired growth and increased perinatal mortality, effects 
thought to be due to the impairment in function of autonomic ganglia where a3p4* 
receptors are predominately expressed (Xu et al. 1999). Evidence of this was seen in the 
bladders of the survivors where impaired autonomic activity resulted in a hypertrophied 
mucosa and an increased tendency towards urinary infections and stones.
a l  and a9 knock out mice surprisingly displayed no obvious phenotype (Urtreger 
et al. 1997; Vetter et al. 1999). As a9 was only thought to be present in cochlear hair 
cells (Elgoyhen et al. 1994) the development and function of cochlear efferent neurones 
were studied in these a9 knock-out mice. The majority of outer hair cells in these knock­
out mice were found to be innervated by only a single large terminal rather than the
54
multiple smaller terminals seen in wild-type animals, which may indicate a role for a9 in 
the maturation of synaptic connections.
Knock-in studies have also been carried out, with the insertion of gain-of-function 
mutations. Mice homozygous for the a7L250T mutation display a marked decline in a l  
protein levels in the brain with extensive apoptosis of neurones throughout the 
somatosensory cortex particularly in layers 5 and 6. Such mice die within 24 hours of 
birth. In comparison, mice heterozygous for this mutation display only a 25-30% 
reduction in a l  protein levels and are otherwise viable, anatomically normal with wild- 
type-like levels of apoptosis in the brain (Orr-Urtreger et al. 2000). Analysis of cultured 
hippocampal neurones from the heterozygous mice however did reveal an abnormal al~ 
like current with a slower desensitising component and a greater sensitivity to low 
concentrations of nicotine as would be expected from the incorporation of the a l  
mutation. Another gain-of-function mutation, a leucine to alanine 9' point-mutation in 
mice a4 subunits has highlighted the importance of a4* receptors in nicotine-induced 
reward, tolerance and sensitisation (Tapper et al. 2004).
Of particular interest to our group has been the work on (33 knock-out mice. The 
initial work showed that these mice had increased locomotor activity which was thought 
to be due to alterations in the nicotine-induced dopamine release in the striatum and/or 
other areas of the CNS where p3-containing receptors are present in the pre-synapse 
(Cordero-Erausquin et al. 2000). Null-mutation mice also showed enhanced nicotine- 
stimulated dopamine release from striatal synaptosomes, increased activity in the open- 
field arena (Cui et al. 2003) and reduced anxiety in the elevated plus maze (Booker et al.
2000). Preliminary results have also shown that mice lacking the p3 subunit showed
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much higher tyrosine hydroxylase activity (Butt et al. Society for Neuroscience 
Conference 2004). These effects of (33 knock-out may tie in with the observed induced 
decrease in nAChR activity produced by (33 insertion in the majority of nAChR subtypes 
as reported in Chapter 6 .
1.9.4 Diversity of the neuronal nicotinic receptor
One of the main causes of the difficulty in characterising the neuronal nicotinic 
receptors compared to the muscle is the greater number of neuronal nAChR subunits 
which have been identified. Currently nine a  subunits {a l through to #10) and three (3 
subunits {ftl to f t1) are known and whereas the composition of muscle nAChRs is 
consistent, there are a variety of ways functional neuronal nAChRs can form. 
Theoretically thousands of different subunit combinations are possible. However, 
thankfully, work with heterologous expression systems has suggested that there are a 
number of restrictions on which subunit combinations can form a functional receptor. 
“Traditionally” two basic types of combinations of subunit were thought to form 
functional neuronal nAChRs. a7, a8 and a9 can form functional homomeric receptors 
i.e. they are capable of forming a LGIC using five copies of themselves. These channels 
are sensitive to a-bungarotoxin. whereas a2, a3, a4 and a 6 can only form a functional 
receptor when expressed together with p2 or p4 subunits to give the so called “pair” 
receptor (Luetje & Patrick, 1991; Fucile et al. 1998). This simple separation of receptors 
into homomeric and heteromeric is now known to be flawed with evidence existing for 
both a9al0 and a7p3 pair receptors (Sgard et al. 2002; Palma et al. 1999).
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However these compositions are only minimal requirements and don’t necessarily 
mean that in vivo only these homomeric and pair combinations are present. Neuronal 
cells express multiple nicotinic subunits including the so-called “orphan” receptor 
subunits, a5 and (33, which remain well conserved in a wide variety of species. It would 
seem uncharacteristically wasteful for cells to retain and produce such proteins if they 
had no function. We now know that a5 and (33 can only be assembled into functional 
receptors when co-expressed with another two different subunits, for instance as a4(32a5 
or a3(34(33 receptors (referred to as ‘triplet’ receptors).
It is worth noting that it is official IUPHAR nomenclature to qualify the 
composition of a nAChR as -say- a3pl* where the asterix indicates that there may be 
other subunits involved. Such caution has proven to be well-founded with the discoveries 
that a\0  can form a “pair” receptor with a9 (Elgoyen et al. 2001) and that the main 
nAChR in chick parasympathetic ciliary ganglia is made up of three or four different 
subunits (a3p\o& and a3plp\c6) (Vemallis et al. 1993; Conroy & Berg, 1995); the 
receptor composition is even more complex in chick sympathetic ganglia (Listerud et al. 
1991; Yu & Role, 1998). c6 subunits have been shown to form “triplet” receptors with 
other combinations and the incorporation of an a5 subunit has also been shown to lead to 
significant changes to the properties of the receptor such as single channel conductance 
and desensitisation properties (Ramirez-Latorre et al. 1996; Sivilotti et al. 1997; 
Gerzanich et al. 1998; Nelson & Lindstrom, 1999). Recently the last “orphan” subunit 
p3 has also been shown to be incorporated into “triplet” receptors (Groot-Kormelink et 
al. 1998). Because of the similarity between a5 and p.3 both in amino acid sequence, 
evolution, incorporation into receptors and putatively in role, there are calls to reclassify
c6  and /33 into a third non-or, non-/? group of nAChR subunits (Le Novere & Changeux,
1995). The incorporation of P3 into an a3p4p3 triplet receptor was only shown by the 
use of a reporter mutation approach (Groot-Kormelink et al. 1998) while more extensive 
work only highlighted subtle effects caused by the P3 insertion into the a3p4 nAChRs 
(Boorman et al. 2003). The examination of the effect of p3 insertion into other nAChR 
combinations, varying the stoichiometry of pair receptors and the development and 
evaluation of tools to restrict and report LGIC receptor stoichiometry would form the 
bulk of the work covered in this thesis.
1.9.5 Stoichiometry of neuronal nicotinic receptors
The different stoichiometries of neuronal nAChRs are summarised in Figure 1.12.
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Homomeric
( a )  =  a7, a fl or a9
Heteromeric, pair
Heteromeric, pair
( T )  = ot2, 0(3,
or ocB
( ? )  = [32 or |J4
Heteromeric, triplet
0 = 5
□r (33
Figure 1.12: Different stoichiometries of neuronal nAChRs
In the previous section we have discussed the homomeric or heteromeric 
composition o f nAChRs. Among heteromers, ‘■pair’ receptors are pentamers with an a:p 
stoichiometry originally thought to be 2:3, as shown by radiolabelling and single channel 
studies on chick a4p2 receptors expressed in oocytes and from our own reporter mutation 
work (Anand et al. 1991; Cooper et al. 1991; Boorman et al. 2000) but as covered in 
Chapter 9 this sort o f receptor may also exist in a 3:2 ratio.
1.9.6 Characterising neuronal nicotinic acetylcholine receptors
The pharmacology o f neuronal nAChRs was also recognised to depend on their 
subunit composition, which allowed neuronal nAChRs to be characterised to some extent
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by their sensitivity to different agonists and antagonists (see for example Luetje & 
Patrick, 1991; Chavez-Noriega e /«/. 1997).
Unfortunately for neuronal nAChRs, it is only now that, with the discovery of 
conotoxins, a reasonable set of true competitive antagonists of neuronal nicotinic receptor 
are becoming available. Previously there was only trimetaphan, which at low 
concentrations is a competitive antagonist on rat parasympathetic ganglion nAChRs 
(Ascher et al. 1979). a-Conotoxins are small cyclical peptides found in fish-eating 
marine snails. There is a huge diversity of conotoxins which act on a variety of nAChR 
combinations often with a good selectivity for a particular subunit interface. For instance, 
a-conotoxin-Iml is selective for homomeric a7 or a9 with almost an order of magnitude 
difference in affinity compared to ‘pair’ neuronal nAChRs expressed in Xenopus oocytes 
(Johnson et al. 1995) and acts competitively at a-bungarotoxin sensitive (i.e. a7- 
containing) neuronal nAChRs in rat hippocampal neurons (Pereira et al. 1996). In 
contrast the a-conotoxin AuIB is selective for a3(34 over other ‘pair’ neuronal nAChRs 
expressed in Xenopus oocytes, although it has not been shown to act competitively (Luo 
et al. 1998). Of most interest to us are the a-conotoxin M il, which may be selective for 
(33-dependant receptors and the a-conotoxin PIA, which is selective for a6/a3 [32(33 
nAChRs (McIntosh et al. 2000; Dowell et al. 2003). This continuing research on 
conotoxins offers the tantalising prospect of soon having a large library of truly subtype 
selective antagonists. Other compounds which are known to show a degree of selectivity 
between nAChRs combinations include methyllycaconitine (MLA) which has been 
shown to act competitively on a l  homomeric receptors expressed in Xenopus oocytes, 
demonstrating around a million-fold affinity for a l  over ‘pair’ receptors (Palma et al.
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1996). It has also been shown that strychnine acts competitively on a-bungarotoxin 
sensitive neuronal nAChRs and (at very high concentrations) as an open channel blocker 
on a-bungarotoxin insensitive neuronal nAChRs (mostly a4|32) in rat hippocampal 
neurones (Matsubayashi et al. 1998). Finally Dihydro-beta-Erythroidine (DH(3E) has 
been shown to act competitively on a l  and a4p2 expressed in Xenopus oocytes (Bertrand 
et al. 1992) and to be reasonably selective for the latter. These compounds have 
provided useful tools for the study of nAChR combinations.
The nature of the (3 subunit is also known to have an affect on the sensitivity of 
neuronal nAChRs to antagonists (Cachelin & Rust, 1995). This paper reported that a3p4 
receptors are markedly more sensitive to block by mecamylamine, pentolinium, 
hexamethonium and trimetaphan than a3p2. However, the rank order of antagonist 
potency was found to be unchanged by the different p subunits.
The expression of the human nAChRs in Xenopus oocytes has allowed their 
characterisation with the nicotinic antagonists, DHpE, d-tubocurarine (d-Tubo) and 
mecamylamine (Meca) and the nicotinic agonists, acetylcholine, nicotine, cytosine and 
l,l-dimethyl-4-phenylpiperazinium (Chavez-Noriega et al. 1997). This demonstrated 
that the each subunit composition (with both the a and p subunits being of importance) 
produced an unique selectivity profile. For some agonists a lower «h was observed for 
p2-containing receptors compared to p4-containing nAChRs. Of the antagonists, DHpE 
and d-Tubo act reversibly on ap pair and a l  homomers, whereas Meca produces an 
incomplete reversible block. The a4p4 was found to be more sensitive to Meca than 
a4p2, while Meca was equally potent at a2p2, a4p2 and a l. These three receptor 
subtypes could be differentiated by their different sensitivities to DHpE and d-tubo with
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a2|32 being equally sensitive, a4p2 being more sensitive to DHpE than d-tubo and a l  
being more sensitive to d-tubo than DHpE (Chavez-Noriega et al. 1997). Neuronal 
bungarotoxin (NBT) has been reported to potently block a3p2 receptors, but has no 
affect on a2p2 responses to ACh when expressed in Xenopus oocytes (Luetje et al. 
1993). To further examine this, chimeras of a2 and a3 were created and showed that it 
was the first 181 amino acid residues in the ligand-binding N-terminal domain that were 
important for the NBT sensitivity of a3p2 receptors. Replacing the first 195 amino acid 
residues of a3 with the corresponding residues of a2 was found to abolish the block by 
100 nM NBT on the resulting a3195ct2p2 receptor (Luetje et al. 1993). However, it was 
also found that to achieve block by 100 nM NBT on a2p2 receptors, the first 215 amino 
acid residues in the ligand-binding N-terminal domain had to be replaced with the 
corresponding residues of a3, producing an a2215ct3p2 receptor.
Similarly, Harvey and Luetje reported that NBT and DHpE are more potent at 
blocking a3p2 than a3p4 when expressed in Xenopus oocytes (Harvey & Luetje, 1996). 
Chimeras of P2 and P4 were use to show that, in the ligand-binding N-terminal domain, it 
is the first 133 amino acid residues that play an important role in DHpE and neuronal 
bungarotoxin (NBT) sensitivity of a3p2 and a3p4 receptors (Papke et al. 1993; Wheeler 
et al. 1993; Harvey & Luetje, 1996). Replacing these residues of the p2 with the 
corresponding residues of p4 produced DHpE and NBT potencies equal to a3p4 
receptors in the resulting a3p2133p4 receptor (Harvey & Luetje, 1996). These findings 
show that the potencies of both DHpE and NBT on ‘pair’ receptors are determined by the 
nature of both the a and the p subunits.
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1.10 The P3 subunit
The (33 subunit was first cloned and identified as a neuronal nAChR subunit from 
rat brain (diencephalon) cDNA libraries in 1989 (Deneris et al. 1989). It was named (33 
as it lacked the adjacent cysteine residues 192 and 193, in common with all neuronal (3 
subunits. Initial in situ hybridisation probes revealed that (33 was expressed along with 
a2-a4 and P2 in the rat medial habenula (ventromedial part), substantia nigra pars 
compacta, ventral tegmental area (Le Novere et al. 1996; Charpantier et al. 1998) and in 
the reticular nucleus of the thalamus and the mesencephalic nucleus of the trigeminal 
(Liu et al. 1998). Expression of p3 was also reported in the rat locus coeruleus (Le 
Novere et al. 1996). RT-PCR analysis by Anderson showed that p3 is co-expressed with 
in a2-a7, p2 and p4 in the Scarpa’s ganglia and with a3, a5-a7, a9, p2 and p4 in 
vestibular end-organs of the rat, the organs responsible for transducing linear and angular 
linear acceleration of the head (Anderson et al. 1997). Immunoprecipitation studies have 
shown that P3 is expressed together with p4 in rat striatum, cerebellum and also faintly in 
the hippocampus (Forsayeth & Kobrin, 1997). RT-PCR data has also demonstrated the 
expression of p3 in the spiral ganglia of the rat cochlea (Morley et al. 1998). Northern 
blot analysis of RNA isolated from various regions of the chick CNS showed p3 
expression in: retina, telencephalon, cerebellum and spinal cord (Hernandez et al. 1995). 
In the periphery, p3 mRNA was found to be expressed in developing trigeminal and 
dorsal root ganglia, with low levels detectable in superior cervical and sympathetic 
ganglia. Polymerase chain reaction (PCR) analysis of the cochlea of the mouse has
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shown the co-expression of |33 with (32 and a2-a6 (Drescher et al. 1995). The co­
localisation of a6 and (33 has become of particular interest as covered in Chapter 6 . 
Analysis of the amino acids sequence of chick (33, found it to align most closely with the 
chick a5 subunit. a5 and (33 have similarities in amino acid sequence, including having 
both identical amino acids and conservative substitutions (6 8 .2 % amino acid sequence 
similarity in chick; Hernandez et al. 1995; 80% in human, Groot-Kormelink et al. 1998). 
These subunits were therefore classified in a separate group within the nAChR 
phylogenetic tree (Tsunoyama & Gojobori, 1998). The a5 and (33 shared another 
similarity in that both were initially considered “orphan” subunits for failing to appear to 
participate in functional “pair” receptors. For instance, Deneris et al. (1989) were unable 
to express functional (33 containing receptors with any of the known neuronal nAChR a 
subunits (a2-a4 at the time) leaving the (33 with no known function. Since then the a5 
has been shown to participate in a functional “triplet” receptor (Ramirez-Latorre et al. 
1996; Wang et al. 1996; Sivilotti et al. 1997).
All these findings presented a bit of a quandary. It was clear from the work 
covered above that the (33 was present and expressed in discrete parts of the brain yet 
(like the a5 before it) it didn’t appear to participate in functional receptors, as expressed 
by heterologous expression systems such as the Xenopus oocyte. Tackling this problem 
to show, first, that the (33 could participate in forming a functional receptor and then 
elucidate what effect the incorporation of the p3 subunit has on these receptors has been 
one of the major areas of study for our group over the last seven years. In 1998 a reporter 
mutation approach showed that 03 can form a functional a3(34(33 ‘triplet’ receptor when 
expressed with an a3p4 pair (Groot-Kormelink et al. 1998). More recently the
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incorporation of p3 into a ‘pair’ a7p3 receptor has also been demonstrated by Palma et 
al. (1999). The work of Groot-Kormelink et al. 1998 was followed up by my group and 
formed the basis of this current study. Having shown that the P3 subunit could co- 
assemble with the a3 and [34 to form a functional receptor our group proceeded to show 
that the stoichiometry of the a3(34(33 receptor was 2:2:1 (Boorman et al. 2000) however, 
despite exhaustive work, we failed to show dramatic effects on the function of a3(34 
receptors caused by the incorporation of the (33 subunit.
We knew the receptor was expressed in vivo in high concentrations in discrete 
nuclei, we knew that p3 knock-out studies showed effects on the behaviour of mice and 
we knew that functional receptors could be formed incorporating this subunit yet it 
appeared that this subunit had no significant effect on the function of nAChRs. 
Addressing this conundrum would be the main thrust of my PhD.
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Chapter 2 
Aims of the Project
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The primary aim of my PhD was to research the p3 subunit of the neuronal 
nicotinic acetylcholine receptor. In particular I set out to determine if p3 co-assembles 
with neuronal nicotinic subunits other than a3(34 and if it did, with what stoichiometry 
and with what effect on the properties of these receptors
A secondary and complementary goal was to adapt, develop and evaluate 
techniques to aid in, primarily, the study of the p3 subunit but which would also be of 
further use in studying other ligand-gated (and even voltage-gated) ion channels beyond 
the nicotinic family. As such, dosing protocols, reporter mutations and concatemeric 
constructs.
A final objective was, time permitting, to use these above techniques to study 
other aspects of the neuronal nicotinic story and as such, variations in the stoichiometry 
of the a3p4 receptor were also examined.
The chapters which follow will cover the progress I made in accomplishing these
aims.
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CHAPTER 3
Materials & Methods
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3.1 Materials
Acetylcholine chloride (ACh.), collagenase (Type 1A), glycine (Gly.) mineral 
oil (M-5904), sodium chloride (NaCl), potassium chloride (KC1), magnesium chloride 
(MgCb), calcium chloride (CaCL), sodium hydrogen carbonate (NaHCOs), Tris 
buffer, tricaine, atropine sulphate, sodium hydroxide (NaOH), hydrochloric acid 
(HC1), trimetaphan camyslate, N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulphonic 
acid) (HEPES), 5-hydroxy-indole (5-HI), were from Sigma-Aldrich, Poole, Dorset, 
UK. Heat-inactivated horse serum (NHS), penicillin and streptomycin were from 
Gibco BRL, Paisley, UK. Ethanol was from Merck Ltd, Poole, Dorset, UK. 
Axoclamp 2B was from Axon Instruments, Foster City, CA, USA. The 0.22//M pore 
filters (Millex-GV) were from Millipore, Bedford, USA. The Xenopus laevis toads 
were from Blades Biological, Edenbridge, Kent, UK. Clark borosilicate glass 
GC150TF was from Harvard Apparatus Ltd, Kent, UK. The QuikChange™ Site- 
Directed Mutagenesis Kit was from Stratagene, Amsterdam, NL. The SP6  Mmessage 
Mmachine kit was from Ambion (Europe) Ltd., Huntingdon, UK.
3.2 Construction of cRNA for oocyte expression
The preparation of the complementary ribonucleic acid (cRNA) was carried 
out by Uta Schneiders, Jenny Davie, Martina Theuer, Kasia Bera, Skevi Krashia and 
Dr. Paul Groot-Kormelink and so only a brief description of this protocol will be 
given here. Complementary deoxyribose nucleic acid (cDNA) for the human a l, a3, 
a4, a 6 , a l ,  p i, p3 and @4 neuronal nicotinic subunits and the a l glycine subunit 
(GenBank™ accession numbers Y16281, Y08418, Y08421, Y16281, Y08420, 
Y08415, Y08417, Y08416 and NM 000171, respectively) containing only coding
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sequences and an added Kozak consensus sequence (GCCACC) immediately 
upstream of the start codon (Groot-Kormelink & Luyten, 1997) were sub-cloned into 
the pSP64GL vector, which contains 5'- and 3'-untranslated Xenopus y^ -globin 
regions (Akopian et al., 1996). The mutants in subunits were created using the 
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene; mutagenesis primer used 
5 '-GTCGACAGAAAAGACTTCTTCGATAACGGAGAATGG-3') and the full- 
length sequence was verified. All cDNA/pSP64GL plasmids were linearised 
immediately downstream of the 3' untranslated /?-globin sequence and cRNA was 
transcribed using the SP6  Mmessage Mmachine kit (Ambion (Europe) Ltd., 
Huntingdon, UK). cRNA quality and quantity were checked by gel-electrophoresis 
and comparison with RNA concentration and size markers. The cRNA was stored at 
-80°C and was kept on ice during injection.
Tandem constructs were created by first producing a linker DNA fragment 
(based on Im et al. 1995) by hybridisation of two complimentary olgionucleotides; 5'- 
GGCCGCTCAGCAACAGCAGCAACAGCAGCAAG-3' and 5 -
AATTCTT GCT GCT GTT GCT GCTGTT GCT G AGC-3'. The resulting double­
stranded DNA linker contains a 5'-end Notl restriction site overhang (underlined) and 
a 3'-end Eco-RI restriction site overhang (underlined), separated by 25 nucleotides 
(the first nucleotide [bold] is inserted to bring the Notl site [8 -cutter] back into the 
correct reading frame, whereas the next 24 nucleotides code for the eight glutamine 
amino acids). The constructs themselves were created by using three unique 
restriction sites; EcoRI (upstream of the start codon of all subunits and the 3 '-end of 
the linker), Notl (downstream of the coding sequence of all subunits and the 5 '-end of 
the linker), and Agel (between the Myc and His epitope sequences of the in the 
pcDNA3.1/Myc-His version C vector). A three way ligation resulted in the following
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tandem circular plasmid: * [AgeI...His-epitope...stop codon...pcDNA3.1/Myc-His C 
vector...EcoRI _ subunit A _NotI] * [Notl _ linker _ EcoRI] * [EcoRI _ subunit B 
_NotI...Myc-epitope...AgeI] * (where * represents the ligation sites and [ ] represents 
purified DNA fragments digested with the restriction sites indicated in bold). To 
remove the epitope tags (Myc- and His-) all tandems were subcloned in the 
corresponding pcDNA3.1 vector, using a unique restriction enzyme site in subunit B. 
For instance, cutting the tandem upstream of the start codon (of subunit A) and 
somewhere in subunit B and transferring this fragment in the same position of subunit 
B, previously cloned in the pcDNA3.1 vector. Finally, all the tandem constructs were 
also subcloned in the pSP64GL vector. The length of the extracellular linkage of the 
different tandem constructs differs depending on the extracellular region downstream 
of TM4 of the first subunit and the length of the signal peptide of the second subunit 
(see Table 7.2). The 9' mutant tandems were created by swapping the corresponding 
DNA fragments (using unique enzyme restriction sites upstream and downstream of 
the L9'T mutation) from ol3l279T (for P4_cx3L279T) and p4U72T (for p4L272Tjx3). The 
a3_p4, P4_a3, p4_a3L279T, and P4L272T_a3 tandem constructs cloned in the 
pSP64GL vector were sequenced fully to check for PCR and/or cloning artifacts. All 
other tandem constructs were sequenced only at the outer ends to check for cloning 
artifacts (Groot-Kormelink et al 2004).
Pentameric constructs were produced from intermediate tandem and trimer 
constructs. The tandem constructs were created as described above. Trimer 
constructs were created by cutting and ligating different parts of the tandem and 
monomeric plasmids described above. The first trimer [p4_p4_oc3/ pSP64GL] was 
created by ligating three DNA-fragments; p4_a3/pSP64GL*EcoRI-XbaI (4583bp), 
p4/pcDNA3. l/Myc-His*EcoRI-ApaI (1486bp), and p4-ot3/pSP64GL*XbaI/ApaI
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(1814bp). The mutated [p4L272T _p4_a3/pSP64GL] trimer was created as above 
except for the first DNA-fragment being p4L272T_a3/pSP64GL*EcoRI-XbaI 
(4583bp). Pentameric constructs were created by cutting and ligating different parts 
of the tandem and trimer plasmid constructs described above. The first pentameric 
construct [p4_p4_a3_p4_a3/pSP64GL] was created by ligating three different DNA- 
fragments; P4_p4_cx3/pSP64GL*KspI-XbaI (6176bp), ct3_p4/pcDNA3.1 /Myc- 
His*KspI-ApaI (2986bp), and p4_a3/pSP64GL*ApaI-XbaI (1814bp). Mutant 
pentameric constructs [p4L272T_p4_a3_p4_a3/pSP64GL,
P4_p4_a3_p4_a3L279T/pSP64GL, and p4L272T_p4_a3_p4_a3L279T/pSP64GL] were 
created as above except for using the corresponding mutated p4_a3L279T/pSP64GL 
and/or p4L272T_p4_a3/pSP64GL DNA-fragments. All trimer and pentameric 
constructs were checked for cloning artifacts by a minimum of five different 
restriction enzyme digests.
3.3 cRNA electrophoresis
The RNA electrophoresis was carried out by Dr. Groot-Kormelink. A 1.5% 
agarose gel was prepared using the IX  gel prep/running buffer (NorthemMax-Gly™ 
system; Ambion). RNA samples (including the 0.24-9.5 Kb RNA ladder; GIBCO 
BRL) were diluted 1:1 with Glyoxal sample loading dye (Ambion) and incubated at 
50°C for 30 min before loading. Samples were separated at 5 V/cm for 3 h and RNAs 
were visualized by UV transillumination and a photograph taken (Groot-Kormelink et 
al. 2004).
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3.4 Western Blotting
The Western Blotting was carried out by Dr Groot-Kormelink, oocyte protein 
samples were incubated at 75°C for 8 min just before loading (20 /A each sample) on 
a 8% Tris-Glycine polyacrylamide gel containing 2% SDS together with the SeeBlue® 
prestained protein standard (Invitrogen). After PAGE-SDS the proteins were 
transferred to nitrocellulose membrane (0.2 jum, protran BA83; Schleicher-Schuell). 
The blots were probed with rabbit antiserum to a3 or p4 (diluted 1:200 from 5-ml 
stock solution; Research & Diagnostic antibodies, WR-5611 [a3] and WR-5656 [[34]) 
followed by HRP-labeled goat anti-rabbit IgG (diluted 1:10,000, 10 //g/ml stock 
solution from supersignal® west femto chemiluminescence substrate kit; Pierce 
Chemical Co.). After washing, blots were visualized using the supersignal® west 
femto chemiluminescence substrate kit (Pierce Chemical Co.) and exposure to biomax 
light films (Kodak) (Groot-Kormelink et al. 2004).
3.5 Xenopus laevis oocyte preparation
Large, female South African clawed toads {Xenopus laevis; X. laevis) (Blades 
Biological) with large ovarian lobes (these are usually noticeable in the intact animal) 
were selected. The X. laevis were anaesthetised by immersion in a 0.4% 
weight/volume (w/v) solution (pH=5.6) ethyl m-aminobenzoate (tricaine, 
methanesulphonate salt; Sigma) for over 30 minutes. Anaesthesia was confirmed by a 
lack of reaction to a bone-pinch. Once anaesthesia was confirmed, the X. laevis was 
killed by decapitation and destruction of the brain and spinal cord in accordance with 
Home Office guidelines. The ovarian lobes were then removed and washed of blood
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and other bodily fluids in modified Barth’s solution (88mM NaCl, ImM KC1, 
0.82mM MgCl2, 0.77mM CaCl2, 2.4mM NaHC03, 15mM Tris (Sigma), 50 U/ml 
penicillin and 50 //g/ml streptomycin (Gibco BRL); made up in HPLC water (Merck); 
pH adjusted to 7.4 using NaOH and HC1; sterilised by double filtration through a 
sterile 0.22//M pore Millex-GV filter (Millipore). All work on oocytes was carried out 
at a room temperature of 18-20°C (controlled by air conditioning).
After washing, smaller, dying and dead cells were removed from the ovarian 
lobes using forceps, to increase the effectiveness of the enzyme. Clumps of ovarian 
tissue containing around 60 large, healthy-looking cells each were treated with 
collagenase (Type 1 A, 245 collagen digestion units per ml in Barth’s solution) for 65 
minutes at 18°C while being shaken at approximately 2Hz. After this treatment the 
clumps were washed with 60ml Barth’s solution and kept at 4°C overnight. The 
following day, mature (Stage V-VI), healthy oocytes were manually defolliculated 
using forceps.
3.6 Injection of cRNA
The cytoplasm of the vegetal pole of the defolliculated oocytes were injected 
with in vitro made RNA (46nl/oocyte) with a fire-polished, sharp pipette (12-16 jum 
tip opening; back filled with mineral oil (M-5904; Sigma) using a Drummond 
Nanoject injector (Figure 3.1.). A successful injection was confirmed visually by a 
“plumping up” of the oocyte.
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Figure 3.1: Injection of cRNA into the vegetal pole of X. laevis oocyte. Adapted 
from the thesis of James Boorman, 2002.
After injection, the oocytes were placed in individual wells o f 24 
m ultiwell plates and incubated at 18°C for approximately 60 hours in modified 
Barth's solution containing 5% volume/volume (v/v) heat-inactivated horse serum 
(Gibco BRL) to aid in the healing o f the injection wound (Quick et al. 1992). The 
amount o f cRNA injected varied between combinations. The aim was to obtain 
experimental data from oocytes expressing the different nicotinic receptors at levels 
that would be roughly comparable, sufficiently high to give a good signal to noise 
ratio, but low enough to avoid excessive series resistance errors (see section 3.6). In 
order to maintain this level stable from week to week from one batch o f oocytes to 
another, the actual cRNA concentration injected was adjusted appropriately. I f  
required, different cRNA concentrations were injected in order to ensure that at least 
one batch gave an expression level that satisfied our requirements.
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3.7 Injection of cDNA
The procedure was similar to that outlined for cRNA, with the difference that 
cDNA has to be injected in the nucleus of the oocyte. This is helped by the fact that 
the nucleus is relatively large and is located in the animal pole of the oocyte. The 
injections are therefore done blind, into the animal pole, and somewhat deeper than 
cRNA injections, using a volume of 23nl/oocyte and a fine, fire-polished, sharp 
pipette (12-14 //m tip opening; back filled with mineral oil (M-5904; Sigma) mounted 
on a Drummond Nanoject injector. The post-injection treatment of the DNA-injected 
oocytes was the same as that described above for cRNA-injected oocytes. Of the 
oocytes injected with a3 + P4 cDNA («=6 ), all gave robust expression of channels 
with only one oocyte producing a relatively low current (70nA) the rest being in the 
range of 4-13 //A, this corresponds well with the circa 98% success rate obtained from 
cRNA injections and is of a comparable range to the currents seen with high injection 
concentrations of cRNA.
3.8 Electrophysiological recording
After approximately 60 hours incubation, the cells were stored at 4°C and were 
used from between three and twelve days after injection. Cell viability and expression 
levels have been shown to remain adequate for up to two weeks (Groot-Kormelink et 
al. 1998). Due to oocyte-batch variability, the optimal concentration of cRNA 
injected to record from, was determined on a week-to-week basis, aiming to achieve a 
maximum ACh-evoked current of 1-1.5 juA. The oocytes were held in a 0.2 ml bath 
and perfused at 4.5 ml/min with modified Ringer solution (150mM NaCl, 2.8 mM, 
2mM MgCb, lOmM HEPES, pH adjusted to 7.2 with NaOH and HC1) containing
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0.5 |TM atropine solution (to block endogenous muscarinic AChRs) (Davidson et al. 
1991) and voltage clamped at -70mV, using the two-electrode voltage clamp (TEVC) 
mode of an Axoclamp-2B amplifier (Axon Instruments). The Ringer was made up in 
de-ionised water (DI H2O) which was always stored in glass (rather than plastic) 
containers to avoid contamination with plasticisers, which have been shown to inhibit 
nAChRs (Papke et al. 1994). Electrodes were pulled from Clark borosilicate glass 
GC150TF (Harvard Apparatus Ltd.) and filled with 3M KC1. The electrode resistance 
was 0.5-1.5 MQ on the current-passing side. Experimental results were included in 
the analysis of dose response curves only if the total amplitude of the holding current 
( I h )  together with the agonist evoked current was below 2juA, in order to keep series 
resistance errors below 2mV (Figure 3.2.). Larger currents (and therefore greater 
errors) were accepted only if the purpose of the experiment was to establish whether a 
given combination actually formed a functional receptor. In this case, an approximate 
measurement of expression level was all that was needed, as the differences between 
these positive “results” (functional receptors) and the negatives they were compared 
to, were in the order of lOOx.
Additionally, if  the Ih of the oocyte exceeded 1//A the cell was judged to be 
dead or dying and was discarded.
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Figure 3.2: A simple representation of the TEVC circuit. Showing the high 
impedance unity-gain preamplifier (A1); the high gain current injecting 
amplifier of the Axon voltage clamp amplifier (A2); MEVi recording 
electrode (MEV); current injecting electrode (MEi); Ref, bath ground 
AgCI pellet (Ref); measured membrane potential (Vm); amplified 
measured membrane potential (s); clamp command potential (Vcmd)- 
(adapted from the thesis of James Boorman, 2002 and Axon Guide)
94- •A  nominally Ca" -free Ringer solution was used in order to minimise possible 
distortions due to the contribution o f the oocyte’ s endogenous calcium-gated chloride 
conductance which can be activated by calcium entry through nAChR channels 
(Sands et al. 1993). Mock-injected oocytes (injected w ith 46ul o f M illiQ  water, 
n = \9 ) confirmed that there were no endogenous ACh- or Gly-activated channels in 
the oocytes. Aliquots o f 200mM ACh were made up in plasticiser-free DI H2O and 
frozen at -20°C until required. Once defrosted the aliquots were either used or 
discarded. ACh solutions (prepared daily from the frozen stock aliquots) were 
applied via the bath perfusion system onto the oocyte for a period o f time sufficient to
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allow the establishment of a stable plateau (at low ACh concentrations) or the 
beginning of a sag after a peak (at higher ACh concentrations). Application of ACh 
was stopped after two minutes if no response was seen. Any resulting inward current 
was recorded on a flat bed recorder for later analysis. There was a minimum interval 
of 5 minutes between ACh applications to allow the nAChRs to recover from any 
short-term desensitisation and channel block as this was found sufficient to ensure 
reproducible responses to the same ACh concentration. Any changes in the agonist 
sensitivity of the receptors during the time-scale of an experiment (run-down and run­
up) was compensated for by establishing a reproducible response to a standard 
concentration of ACh (approximately EC20, the agonist concentration that produces a 
20% of the maximum response) at the start of the experiment. The standards were 
judged to be reproducible if three successive applications were within 5% of each 
other so, for example, the a3p4 dose-response curves were obtained from recordings 
where the variation in the first and third standard compared to the second were 103.8 
± 1.7% and 96.2 ± 1.4% n=36, respectively. The EC20 was used for every third 
agonist application after that and these responses were compared to the established 
standard response obtained at the start of in order to calculate the degree of 
rundown/runup and so compensate for it.
3.9 Negative controls
In some cases, we needed to establish if a combination produced functional 
receptors. The choice of the amount and ratio of cRNA to be injected into the oocytes 
for these ‘negative controls’ was guided by the amount of cRNA expressed to produce 
responses in all the functional combinations tested. For instance in the tandem 
experiments, the functional tandem combinations were all found to produce excessive
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currents (2//A+) when injected at a ratio of 2ng //A of tandem to 0.5ngIjA of monomer, 
therefore this was used as the test concentration for other tandem + monomer 
combinations (or just 2ngI/A for tandem-only injections) whereas for the /73 
experiments an excessive 1 Ong//d monomer to 200ng///l f33 was used to ensure that a 
“negative” result was due to a non-functional receptor combination rather than too 
low a level of expression. After the usual incubation time, oocytes were clamped at -  
70mV and were checked to see if they had any significant response to an application 
of ImM ACh; a response was deemed to be significant if it was over lOnA from a low 
noise base-line. For each combination, at least six oocytes from at least two different 
batches were tested before concluding that that combination was unable to form a 
functional receptor. Each batch was from a different frog, processed on different 
experimental weeks. Every week we made sure that we injected at least one “positive 
control”, namely a subunit combination known to have high functional expression. In 
all functional combinations tested ImM was found to be a maximal or supra-maximal 
concentration of ACh. Higher concentrations began to show significant levels of 
channel block, so ImM was chosen as a good compromise of potency, channel block 
and cost.
3.10 Data analysis
Rundown/runup compensation was calculated using the Excel™ (Microsoft) 
spreadsheet programme by linear interpolation between EC20 standards. 
Concentration-response curves were fitted separately with the Hill equation with 
individual response being equally weighted in order to obtain estimates of Imax, EC50 
and «h (Figure 3.3.) using least squares fitting by the CVFIT programme (courtesy of 
D. Colquhoun and I. Vais, available from www.ucl.ac.uk/pharmacology/dc.html).
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Figure 3.3: The Hill equation. I, response; lmax, maximum response; EC50, agonist 
concentration which produces 50% of the maximum response; nH, Hill 
coefficient.
Tables and results report the averages and standard errors of the mean for the 
values obtained from the fit of the individual dose response curves (as these gave a 
more robust estimate of interoocyte variability). In the figures we show pooled dose- 
response curves that were obtained by normalising the data as follows. Once the 
individual concentration-response curves had been separately fitted they were 
normalised to the fitted /max for that experiment; all the normalised responses for a 
given combination were then pooled. The pooled normalised datapoints were then 
fitted again with the Hill equation (with weight given by the reciprocal of their 
variance) as a free fit to give an average EC so and «h for each combination. 
Parameter estimates were similar to those obtained by fitting each curve separately.
When two-components were detected in the concentration-response curve, 
free fits of the individual dose response curves were attempted. These were usually 
poorly defined because of the large number of parameters fitted (vs. the number of 
datapoints). In the of case of p4_a3 + P4LT, robust fits were usually achieved by 
fitting all dose-response curves for a combination simultaneously with the constraint 
that EC so and nw values for the two components should be the same across oocytes,
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while the proportion of the current in the first component was allowed to vary from 
one oocyte to the other. The multicomponent curves obtained for a3p2 and a4|32 
were fitted with individual two-component fits and pooled as this was found to be 
sufficient to produce reasonable fits.
Analysis of whether EC50 or Hill slope values were significantly different 
between different receptor combinations were carried out using an unpaired two-tailed 
Student’s t-test. Functional expression levels for “knock-out” mutations and P3- and 
p3 -containing receptors were tested for significance using a Kruskal-Wallis one­
way non-parametric ANOVA and Dunn’s post-hoc multiple comparisons test at 
5%significance. Significance testing was performed using Graphpad Prism version 
4.03 (Trial) for Windows, GraphPad Software Inc. San Diego, California USA 
(www.graphpad.com), and StatCrunch version 4.0, a free online resource 
(www.statcrunch.com, West & Ogden, 1997).
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CHAPTER 4
Protocol Optimisation
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The majority of the experiments to be carried out involved comparing the dose- 
response curves of different combinations of nAChR subunits in order to detect any 
changes in the receptors’ characteristics caused by, for example, the insertion of a p3 
subunit or a subunit carrying a reporter mutation. However, these dose-response curves 
were not to be interpreted in a mechanistic sense in order to model the channel activation 
process. Such work is not feasible from macroscopic dose-response curves. This is first 
of all is because the parameters of the dose-response curves, such as EC5o and Hill slope, 
depend on both the binding and gating constants of the mechanism and these constants 
therefore cannot be independently determined. Secondly, the experimental dose-response 
curve depends on the whole mechanism, including desensitisation and agonist channel- 
block. The extent of the contribution of desensitisation depends greatly on the speed of 
equilibration of the agonist at the receptor level which is inevitably slow with a cell as 
large as an oocyte and also varies with the experimental conditions. This slow “on-flow” 
of agonist compared to the relatively rapid desensitisation and channel block was 
particularly a problem with a7-containing receptors, although at the highest 
concentrations of ACh, it was a factor in all the combinations tested. Note that 
desensitisation does still take place and distorts macroscopic responses even if no sag is 
detectable in the response to sustained applications (Feltz and Trautmann, 1982). 
Relatively minor variables such as the volume of the bath, the bore of the agonist tube, 
the height of the solutions, the positioning of the waste tube and even regularity of 
maintenance would all affect the speed of solution exchange in the bath and therefore the 
“on” and “off’ rates of agonist application and so affect the responses seen. Add to that 
differences in the intervals between applications, Ringer recipes, agonist preparation etc.
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and the potential for large systematic differences between different research groups exist. 
This means that the comparison of such things as ECso values between different labs is 
not particularly informative therefore, all the results produced during my PhD were to be 
compared to our own internal standards and controls and considerable effort went into 
maintaining consistent experimental conditions.
The first aim of my project was to establish how to obtain dose-response curves in 
an efficient, reliable and consistent way. The first thing examined was the different 
merits of different dosing-order protocols.
4.1 Investigation of the effect of dosing order on the 
results of experiments.
The examples shown in Figures 4.1 to 4.3 are from experiments which had a 
protocol requiring the testing of around 12 different concentrations of agonist plus their 
standards. Instinctively most experimenters use an ascending dose order when carrying 
out a concentration-effect experiment i.e. they start with the lowest drug concentration 
and work their way up through higher concentrations until they obtain a plateau for the 
maximum response. However as will be shown this isn’t the most efficient method for a 
number of reasons. For instance, it is fairly common for a cell to die during an 
experiment thus ending it, and power cuts and fire alarms halting experiments are 
certainly not unknown. If  this happens during an experiment with an ascending dose 
order before the responses have reached a maximum (e.g. Figure 4.1 A) then the results 
obtained are of little use, as without a clearly defined maximum response an accurate 
EC50 cannot be obtained and the Hill coefficient is poorly estimated and so this can cause
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a lot of wastage. However, if a cell prematurely dies during an experiment with a 
descending dose order (i.e. starting with the highest concentration and working towards 
the lowest) as is shown in Figure 4. IB then something of the results can still be salvaged. 
As can be seen this incomplete concentration-effect curve still gives reasonable estimates 
for maximum response, EC20, EC50 and Hill coefficient and could, at a push, be used in 
the final fitting. The curve seen in Figure 4.1 A on the other hand is of little use 
whatsoever (other than as a warning) despite representing nine dose “points” and over 
three-quarters of an experiment compared to the six points, half an experiment, shown in 
Figure 4. IB.
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Figure 4.1: Examples of incomplete concentration-effect curves.
A. Three-quarters complete ascending concentration-effect curve for p4LTa3 
+ p4LT (maximum extrapolated from other p4LTa3 + p4LT curves)
B. Half complete descending concentration-effect curve for a3 +P4.
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Even in more extreme examples such as the four-point “curve” in Figure 4.2 the 
descending protocol allows a reasonable approximation of maximum response, EC50 and 
Hill coefficient, though the curve itself would not be included in the final analysis. A 
four-point ascending curve wouldn’t even be worth plotting. This makes the descending 
protocol more efficient as it reduces wastage.
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Figure 4.2: Extreme example of an incomplete descending concentration-effect 
curve. Points fitted with a smoothed line in Excel.
There are also a number of more minor advantages in using a descending over 
ascending drug application protocol. A quick glance at Figure 4.1 A shows that in 
hindsight the points for 0.2pM and 0.5 pM were probably unnecessary, were ultimately a 
waste of time, Ringer and agonist and had they not been done, in all probability, the 
experiment may have been completed before it was interrupted. However at the start of
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the experiment the experimenter had to guess at where he thought the bottom of the curve 
would be and in this case he guessed too low. On a descending protocol, however, that 
problem is avoided as for all combinations I checked where the maximum response was 
before starting on the dose-response experiments and in the majority of cases ImM ACh. 
was found to be near the peak of the dose-response curve of any combination, only when 
two or more channel mutations are present does the maximum differ significantly 
therefore as a rule-of-thumb starting the “descent” from ImM minimises wasted 
applications. Examination of the curves produced shows that no combination peaks 
higher than 2mM and most peak within the 50pM-lmM range. Even in the cases where 
multiple mutations mean a maximum current is evoked at a lower concentration, 
desensitisation and channel block were not sufficiently large to render a ImM ACh. 
application a false negative (see Methods section 3.9).
Another advantage, any errors in the responses obtained are identified by drawing 
them as a graph during the experiment allowing any unexpected results to be repeated 
either confirming or correcting them. The graph however can only be drawn in its 
normalised form once the maximum response has been established. Therefore, for the 
descending protocol where the maximum is established early on this graph can be drawn 
during the experiment allowing rapid identification of any outliers whilst for the 
ascending protocol where the maximum is established last the graph can only be drawn 
and problems identified after the experiment is finished by which point it may be too late 
to correct or confirm. It also takes less time to simultaneously draw the graph and do the 
experiment than to do the experiment and then draw the graph.
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A further advantage of the descending protocol is that as the lower concentrations 
of drug are usually made up from the higher concentrations, therefore for the ascending 
protocol, before the experiment can be started nearly all the different drug concentrations 
have to be made up whilst for the descending protocol they can be made up during the 
experiment thus saving time. All these small advantages not only make the descending 
protocol more sensitive for identifying problems but also makes it quicker to do; a typical 
descending protocol takes about 30 minutes less than the equivalent ascending protocol.
Additionally, as stated in the methods, dose-response curves were only accepted 
for the final fits if their total current i.e. the holding current and the agonist-evoked 
current did not exceed 2pA for all the application of ACh included in the final curve 
therefore by testing the highest concentrations first over-expressing oocytes can be 
identified and the recording halted whereas with the ascending protocol this may not 
become apparent until near the end of the experiment. This can be compounded by the 
fact that the holding current of the oocyte tends to increase during the experiment so a 
1700nA agonist-evoked response at the start of an experiment may add to a holding 
current of lOOnA to give a total current of 1800nA, well within the maximum-allowed 
current, whereas near the end of an experiment the holding current may have crept up to 
350nA putting the response over the limit and therefore rendering that experiment void. 
Of course this problem is usually, although not always, cancelled out by the run-down of 
agonist-evoked responses during the experiment, however it remains an advantage of the 
descending protocol when the oocytes are in poor health with high holding currents or on 
the occasions where there is either no run-down or actual run-up.
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A potential disadvantage of the “descending” sequence is that applying high 
concentrations at the beginning of the experiment may produce long-lasting 
desensitisation that distorts the subsequent data, however as long as all combinations are 
tested using the same protocol this should be less of an issue, as mentioned earlier we 
were more interested in comparisons between different combination types rather than the 
actual “platonic” values of a particular receptor’s properties.
The alternative solution for obtaining good estimates of DR curves parameters 
would be to only get one response and standard from each oocyte (Covemton & 
Connelly, 2000). This method though is laborious and inefficient and, as stated, we are 
more interested in getting consistent internal values for these parameters for comparison 
purposes rather than accurate values for a mechanistic study. Therefore in this case 
efficiency of data collection is more important than accuracy.
Figure 4.3 shows a typical example of two cells from the same batch of oocytes, 
from the same week, injected by the same type (a3(34) and concentration of cRNA 
(0.3:0.3 ng), tested on the same day, by the same experimenter, using the same Ringer, 
ACh and glass electrodes, at the same temperature. The only difference between the two 
sets of results is that the top one was carried out using an ascending protocol and the 
bottom by a descending protocol. As can be seen the ascending protocol has produced a 
curve without a clear maximum and a shallower slope. Even if the highest concentration 
of ACh used here (2mM) was producing the maximum response for this curve (of which 
we cannot be sure) it would produce values for the ECso and nW way off what is expected 
for ab{&. When analysed by the CVfit programme this experiment gave an EC so of 
344//M and a rjw of 1.03 with a warning that this curve was poorly defined. The
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descending protocol on the other hand can be seen to give a definite maximum at 500//M 
and the steep slope expected. Curve fitting gave a well-defined ECso of 106//M and a 
Hill slope of 1.74, both of these are within the range of our previously determined values 
for ocbf3\.
The advantages of a descending protocol (as described above) meant we decided 
to adopt a descending protocol for future experiments. Although we are more interested 
in relative differences in values rather than the “true” platonic values we had to see how 
using a descending protocol affected our values in order to compare them with our own 
past experiments using ascending protocols. To do this the well-characterised a3p4 
nAChRs were examined and compared using ascending and descending protocols. 
Figure 4.4. show a comparison between the curves produced by ascending and 
descending protocols and Table 4.1 compares the values obtained with previously 
published results.
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Figure 4.3: Concentration-effect curves for oocytes injected with 0.3ng//4:0.3ng//4 a3 
and 4 cRNA to ACh, recorded on 21/05/02.
A. Ascending protocol.
B. Descending protocol.
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Figure 4.4: Comparison of concentration-effect curves to ACh derived for <*3/?4 
nAChRs using ascending and descending protocols. Max. response 
(inward current) normalised to 1. The descending protocol (blue squares 
n= 10) produces a curve slightly to the left of the ascending protocol (red 
circles, n=4).
No. poorly 
defined.
n = ACh EC50 
(MM)
«H
c&p\ (Up) 6/11 4 185 ±11 1.61 ±0.12
(Down) 0/14 10 134 ± 6 1.73 ±0.11
Gerzanich et al. (1995) - - 160 -
Wang et al. (1996) - - 163 1.9
Chavez-Noriega et al. (1997) - - 203 2.2
Groot-Kormelink et al. (1998) - - 180 1.8
Table 4.1: Comparison of values obtained for ascending and descending protocols
and published results for ACh on a3j34 nAChRs.
94
As can be seen from Table 4.1. although there is a difference between the EC50 
and «H values for the ascending and descending protocols (185 vs 134 //M  ; 1.61 vs 1.73) 
these are quite small with a slight leftward shift and steepening of the curve . When 
looking at the raw data (Table 2.) it is clear that the descending protocol is much more 
efficient with not a single curve out of 14 being poorly defined compared to 6 out of 11 
for the ascending protocol. When curves are excluded for other reasons (mainly for 
exceeding the 2jliA limit for the uncompensated inward current plus holding current) 
there is no significant difference between the numbers lost for the two protocols though 
marginally more ascending curves are omitted (2 out of 6 vs 4 out of 14). Interestingly, if 
we applied, before recording started, a large concentration (ImM) of ACh, the dose- 
response curve obtained with an ascending protocol becomes similar to that obtained with 
a descending protocol (data not shown).
A random protocol would avoid bias introduced by changes in the preparation in 
time. However, it would be of less use if the responses are not independent and it was 
decided that it really wasn’t feasible because it would be awkward and confusing 
practically and it would suffer the same problems as the ascending protocol with 
premature cell death, no monitoring graph and prolonged experiment time. Table 4.2 
summarises the pros and cons of the three dosing protocols.
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Dosing order Pros Cons
Up Traditional 
All previous work 
Less carry-over desensitisation 
Preferred by supervisor.
Ill-defined maximum. 
Overestimates maximum. 
Overestimates EC50. 
Premature cell death. 
Longer. 
Inefficient
Down Well-defined maximum. 
More reliable. 
Shorter.
Allows problem monitoring. 
Efficient.
Underestimates maximum. 
Underestimates EC50.
Random Avoids bias Awkward. 
Premature cell death. 
Longer. 
Long-term desensitisation. 
Inefficient.
Table 4.2: Summary of pros and cons of the three types of dosing protocol.
4.2 Discussion
In conclusion, these results show that a descending dosing protocol is superior in 
a number of ways to both random and ascending dosing protocols and produces values 
comparable to other published results. All the experiments in this thesis use a descending 
dosing protocol
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CHAPTER 5
Development of a Dominant 
Negative (33 Subunit Mutation
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As we have covered in Groot-Kormelink et al. 1998, Boorman et al. 2000 and 
Boorman et al. 2003, the 03 subunit can co-assemble with a3 and 04 subunits to form 
a functional receptor with a stoichiometry of 2:2:1 (a3:04:03). The insertion of this 
03 subunit produced only subtle changes in the receptor compared with the a304 pair 
receptor e.g. decreased potency of lobeline, increased slope conductance and 
decreased channel mean opening time and left most of the properties of the pair 
receptor unchanged. In fact the triplet receptor was so similar to the pair receptor that 
it required the use of a reporter mutation to prove the 03 subunit was actually 
incorporated into the receptor at all (Groot-Kormelink et al. 1998). One of the main 
thrusts of my PhD research was to check to see if  any other 03-containing receptors 
could be created and if so what effects (if any) did the incorporation of the 03 have.
We were faced with the possibility that any other 03-containing receptors 
would be as similar to their corresponding pair receptors as the a30403 receptor was 
to the a304. The reporter mutation approach used to show incorporation of 03 into 
a304 receptors requires comparing dose-response curves (e.g. the VT mutation used 
in Groot-Kormelink et al. 1998) so we decided to try to develop a dominant negative 
03 subunit mutation (03K0) which would allow 03-containing receptors to be quickly 
flagged up. The simple co-injection of the pair with the 03KO would show the 03 
subunit was incorporated by knocking out the functional expression of the pair 
receptor (obviously using multiple batches, expression of functional combinations in 
the same batch etc. as a control to rule out any injection problems etc.). The 
development of such a mutation would also give us a potentially useful research tool 
for the functional knockdown of neuronal nicotinic receptors (say in organotypic 
preparations).
98
My colleagues Paul Groot-Kormelink and Jenny Davies produced a range of 
mutated p3 subunits shown in Table 5.1 which were dubbed the “Delilah” (DEL) 
mutations and numbered accordingly.
Position -4' -3' O' 1' 2’ 3' 4' 5' 6' 7' 8' 9* 10*1112 13* 14* 15' 16*17* 18* 19' 20* 21*-2' - r -1*
nAChR a 7 D S G E K I S L G I T V L L S L T V F M L L V A E I
nAChR p3 D E G - E K L S L S T S V L V S L T V F L L V 1 E E I
Glycine a l D A A - E R V G L G I T T V L T M T V Q S S G s R A S
GABAC p 1 R A V p A R V P L G I T T V L T M S T 1 1 T G V N A S
Delilah mut 1 D E G p E K L S L S j o V L V S j y F L L V 1 E E j
Delilah mut 2 D E U p A K L w L b T 3 v L y s L T V L v 1 u E
Delilah mut 3 D : E G p A K L s L s T S V t \ / c L I T F L L y 1 e ' F i
Delilah mut 4 D E G p A K L s L s T S V l_ V S L T V F L L V s E N s
Delilah mut 5 D E G p A K L G I s I S V L V s 1L* T V F L L V 1 E E ii
Delilah mut 6 D E G p A K L G L s T1 3 \/ L V s L T T F L L V 1 ’ E r E i
Delilah mut 7 D £ G p A K L S L s "T S V ! V s L T T F L L V 1 . E N s
Delilah mut 8 D E G p A K L G L s I s V f \ f 3 i T V F L L V 1 E N i
Delilah mut 9 D E G p A K L G L s T s V s L "T T F L. L V 1 E N i
Delilah mut 10 : D E G p A K L G L s I s V V s L I T c L S G 1 E N i
Delilah mut 11 D E G p A K L G L s I s V L V s L T T s S G 1 R N i ;
Delilah mut 12 .....: D S G p A K I G L s I s V L V s I T T F L s G ( E N i
Delilah mut 13 D S G p A K L G L 3 T s V i V s L i T F S s G I R N !
Table 5.1: The TM2 sequences of the human nAChR a l  and p3 subunits, the
rat Glycine a1 and the human GABAC p1 subunits compared with 
the mutations inserted (in bold) to create the Delilah subunits. 
Residues are numbered according to Miller (1989) where 0' position 
is the first residue of M2.
The choice of mutations was based on the work of Galzi et al. where the TM2 
residues of the cation-selective a l  nAChR were mutated to TM2 residues of anion- 
selective receptors of the glycine and GABA families ultimately producing an anion- 
selective a l  receptor (Galzi et al. 1992). Their work showed that the minimum set of
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mutations required to produce this cation-to-anion switch were a proline insertion at 
position -1', the charged -1' glutamate mutated to neutral alanine and the substitution 
of threonine for valine at 13’. This proline insertion is commonly found in anionic but 
not cationic receptor subunits and has been suggested to cause a major change in the 
secondary structure of a section of M2 (Galzi et al. 1999). The -1' glutamate is part of 
the intermediate ring of charge thought to control ion permeability in the muscle 
nicotinic receptor (Imoto et al. 1988) and a swap to a neutral alanine in this position 
may be necessary to allow the passage of anions. Finally, 13' residues are susceptible 
to sulfhydryl reagent modification both in the absence and in the presence of agonist 
(Akabas et al. 1994) and they are thought to form part of the channel gate (Unwin 
2005).
The findings of Galzi and co-workers have since been repeated for the 5-HT3a 
receptor (Gunthorpe and Lummis, 2001) and reversed to produce a cation-selective 
glycine channel (Keramidas et al. 2000).
For our work, the first major difference was that here we would be dealing 
with the mutation of only a single subunit, whereas previously the work has involved 
homomeric receptors, in which all the subunits in the pentamer would be mutated, 
therefore we would use the 3 “minimal” mutations identified by Galzi as a starting 
point and then mutate further residues of the TM2 in case a single copy of the 
“minimal” mutations weren’t enough to produce a complete knock-out of the 
receptor. The second difference is that we were dealing with the P3 subunit rather 
than the a l  but as can be seen from Table 5.1 the TM2 sequences are very well 
conserved between the two subunits and the only differences are relatively minor, 
certainly less than the differences between cationic and anionic channels, so this 
didn’t pose a problem.
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The three “Galzi” mutations were sequentially introduced (DELI through to 3) 
and from these, constructs of subunits with additional mutations (in other positions 
thought to be of importance in channel conductance) were produced (DEL4 through 
to 13). No preparation of the DEL8 construct was successful, the sequenced 
minipreps were found either not to contain the required mutations or to include 
additional mutations. It was therefore decided not to continue to attempt to produce 
DEL8 as it was judged that the effects of mutating residues at positions 2', 13' and 20' 
would be adequately explored by the DEL4, 5, 6, 7 and 9 subunits. Time constraints 
meant DEL 12 was not created initially as it was deemed to be a lesser priority as the 
effects of its mutations were thought to be covered by the mutation set in D ELI3. 
This left us with 11 usable mutated subunits to test.
As a first step in testing the effectiveness of these mutations, the mutant 03 
constructs were expressed in Xenopus oocytes (together with wild type a3 and 04 
subunit cRNA in a 1:1:20 ratio) and tested by the application of ImM ACh, a 
concentration that consistently produces maximum responses in a30403 receptors. 
Testing several of the mutated subunits within the same batch (i.e. the same frog and 
experimental week) of injections allowed a more precise direct comparison between 
the different combinations of mutations to check to see which one was the most 
powerful. In order to provide a baseline and to allow comparisons between different 
batches, a number of oocytes from each batch was injected with a30403WT (in a 
quantity equal to that of the mutant combinations).
There are a couple of flaws in this approach the main one being the variation 
in wild-type triplet receptor expression levels between batches,, however by repeating 
this experiment at least twice and ensuring that each batch was tested on the same 
days, using the same electrodes, the same Ringer and the same ACh we hoped to
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minimise the variation. It must also be remembered that these initial experiments 
were only intended as a pilot; once the most promising candidates had been identified 
they could then be re-tested under stricter conditions.
Table 5.2 and Figure 5.1 shows the results obtained from receptors containing 
Delilah-mutated (33 subunits. Figure 5.2 shows representative traces.
Combination Current 
± SEM
(% )
n Batches P
value
(vs
WT)
a3(34p3wr 100 35 8 -
DEL1 24.8 ± 10.8 5 2 <0.05
DEL2 15.3 ± 1.1 5 2 < 0.001
DEL3 21.5 ± 4.2 5 2 < 0.001
DEL4 2.5 ±0.7 7 2 < 0.001
DEL5 32.7 ± 3.2 7 3 < 0.001
DEL6 11.3 ± 3.7 5 3 < 0.001
DEL7 44.8 ± 10.2 4 3 <0.05
DEL9 47.1 ±8.7 5 3 <0.05
DEL10 17.2 ±7.8 6 2 < 0.001
DEL11 32.1 ± 12.1 4 3 <0.01
DEL13 32.3 ± 16.3 5 3 < 0.001
Table 5.2: Currents obtained from receptors containing Delilah-mutated 03
subunits expressed as a percentage of the current obtained from a30403wr 
receptors on the same day. Statistical analysis by Kruskal-Wallis one-way 
nonparametric ANOVA followed by Dunn’s post hoc multiple comparisons 
test.
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DEL1 DEL2 DEL3 DEU DELS DELS DEL7 DEL9 DEL10DEL11DEL13
Combination
Figure 5.1: Comparison of the relative effectiveness of the Delilah-mutated 
(33 subunits expressed as a percentage of the current obtained 
from a3p4|33WT receptors fromlmM ACh on the same day.
As can be seen all the Delilah mutation combinations reduced the current 
produced by ImM ACh by at least half, which is very impressive considering there is 
likely only to be a single mutated subunit in the receptor. DEL4 is consistently the 
most powerful of the mutation combinations and as such could prove to be a very 
useful research tool. It isn’t clear why this particular combination of mutations should 
produce the most dramatic fall in whole-cell current particularly when considering 
most of the other DEL mutations had the same mutations plus a few more and would 
be expected to be more potent if anything. It is also surprising that Galzi’s “minimal” 
13' mutation should have less effect than the 20' mutation although this could be due 
to differences in the channel gate. Another thing we cannot tell from these results is 
whether the observed “reduction” in ACh-evoked current is genuinely produced by a
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Figure 5.2: Representative traces obtained from a3(34p3wr and Delilah mutant 
receptors (numbered) to 1 mM ACh at -70mV
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reduction in channel conductance or whether the effect is because the mutations have 
produced an increase in EC so and therefore ImM ACh is no longer producing a 
maximal response. It would seem most likely though that the effects are produced by 
a reduction in channel conductance, given the nature of the mutations. Nevertheless I 
sought further evidence that a change in ACh sensitivity was not involved in this 
effect and tested a small range of agonist concentrations.
Figure 5.3 shows the responses (normalised to the response obtained for ImM  
ACh in the same oocyte) obtained at ACh concentrations of 200/zM, 500/zM and 
ImM for a3p4|53WT («=9) compared to DELI (n=3), DEL2 (n= 3), DEL3 (n=3), 
DEL4 (n= 1), DEL5 («=3), DEL9 (n=3), DELI 1 («=1) and DEL 13 (n=l). As can be 
seen all the DEL combinations appear to have reached peak responses by ImM ACh, 
if  anything the EC so values may have even been decreased compared to the a3(34p3WT 
(black squares). It must be bome in mind that these are only partial dose response 
curves, which have not been compensated for run down and represent only very small 
n values. It may however be of future interest to see if this reduction in EC so by the 
DEL mutations is in fact real.
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Figure 5.3: Inward currents (±SEM) normalised to the response produced 
by 1mM ACh to ACh concentrations of 200^M, 500//M and 
1mM for a3p4p3WT (black squares) and various DEL 
combinations (see box).
For the purposes of our work it doesn’t matter whether DEL4 is producing its 
effect by reducing channel conductance or increasing EC so as the observed effect a 
massive reduction of response to ImM ACh is the same and would show the 
incorporation of the mutated p3 subunit into the receptor tested which was all that we 
required from the mutant at this point.
All these were questions to be left for some future research project as our 
primary aim was to develop a dominant negative mutation of the p3 subunit in which 
we have succeeded. So now armed with the VT and VS “positive” P3 mutations 
developed for the Groot-Kormelink et al. 1998 paper and the negative DEL4 we could 
now proceed with the testing of other combinations of subunits with the p3 subunit.
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CHAPTER 6
The effect of co-expressing the |33 
subunit with other nAChRs subunit
combinations
107
A manuscript for this has been submitted for publication.
As described in Chapter 1, the (essentially artificial) criterion for classifying a 
subunit as a lies in the presence of two adjacent cysteines in the first extracellular 
domain (Boulter et al. 1990; Couturier et a l  1990). The successful expression of 
homomeric and “pair” heteromeric nAChR left two subunits as “orphans”, the a5 and the 
(33. These subunits are quite similar in sequence and have been classed together in tribe 
III-3 of the nicotinic evolutionary tree (Corringer et al. 2000) Both a5 and (33 are 
expressed in high levels in discrete areas of the brain or autonomic nervous system 
(Winzer-Serhan & Leslie, 2005; Azam et al. 2002). and immunoprecipitation shows that 
a5 forms one of the main synaptic nAChRs in chick ciliary ganglia (Conroy & Berg, 
1995). All of this suggests that, rather than being “evolutionary baggage”, both the a5 
and (33 subunits must be capable of participating in functional receptors in vivo and 
should have some function.
In 1996, both the groups of Role and Lindstrom showed that a5 could produce 
functional triplet receptors along with a4(32, a3(32 and a3(34 in heterologous expression 
systems (Ramirez-Latorre et al. 1996; Wang et al. 1996). This a5 incorporation was 
shown to produce a reduction in ACh sensitivity and increase in single channel 
conductance compared to the “parent” pair receptor (Ramirez-Latorre et al. 1996; 
Sivilotti et al. 1997; Nelson & Lindstrom 1999). The effects produced were dependent 
on the nature of the parent pair so, for instance, a5 incorporation into an a3(34 receptor 
has less effect on ACh sensitivity but does change the desensitisation and calcium 
permeability of the receptor (Gerzanich et al. 1998). Our group has since shown that the
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a3p4a5 receptor contains a single copy of the a5 subunit and it is likely that this 2:2:1 
stoichiometry holds for all a5-containing triplet receptors (Groot-Kormelink et al. 2001).
With the incorporation and effect of the a5 subunit being shown our group has 
worked to replicate this work with its sister subunit, the p3. Previously we have proven 
the incorporation of the (33 subunit into a functional recombinant a3 (34(33 receptor 
(Groot-Kormelink et a\. 1998), with a stoichiometry of 2:2:1 (Boorman et al. 2000) just 
as with the a5, but with the difference that the a3(34(33 receptor is very similar to the 
a3p4 receptor (Boorman et al. 2003) in ACh sensitivity, Hill slope, calcium 
permeability, rank order of potency of agonists and sensitivity to competitive antagonists. 
The only noticeable difference in the macroscopic properties of the triplet receptor was a 
three-fold decrease in the potency of lobeline compared to ACh.
Differences were however noticeable at single channel level: (33 incorporation 
decreased mean opening times and burst length and increased single channel slope 
conductance. At first sight, this would suggest that any effects of p3 incorporation on 
a3p4 receptors are fairly minor and it would be hard to justify a significant functional 
role for the p3 subunit on the a3p4 receptor in vivo beyond faster decay kinetics.
This was a little disappointing however, as with the a5 subunit, it was likely that 
the actual effect of the subunit incorporation would be dependent on the nature of the 
parent pair and so it was possible more dramatic effects would be seen by p3 co­
assembly with other nAChR combinations.
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6.1 The |i3vs reporter mutation
Groot-Kormelink et al. 1998 detected the insertion of the p3 into the a3[34p3 
receptor through the use of a valine-to-threonine (VT) 9' mutation in the p3’s TM2 
domain. However, the literature indicates that a more powerful and therefore noticeable 
“gain-of-function” mutation would be produced by mutating the 9' valine to a serine
\jo
(VS) so we set out to see whether this is true for p3 .
The p3vs mutation was produced and checked by Dr Groot-Kormelink using the 
method described in Groot-Kormelink et al. 1998. This new subunit cRNA was then co­
injected with a3 and p4 cRNA with a ratio of 1:1:20 (a3:p4:p3vs) into oocytes in order 
to produce a pure population of a3p4p3vs receptors with a stoichiometry of 2:2:1. Dose- 
response curves were produced for the a3p4 (1:1) and a3p4p3vs receptors and are shown 
in Figure 6.1. Ideally the a3p4p3 (1:1:20) receptor should have been used for 
comparison purposes, however as we had already shown that the a3p4p3 receptor 
produced dose-response curves indistinguishable from a3p4 (Boorman et al. 2003) it 
seemed an inefficient use of time to duplicate the work done previously and as the a3p4 
receptor was being characterised by me anyway for other experiments, it seemed sensible 
to use that instead. My more recent a3p4 results were used rather than those previously 
published by our group to compensate for any operator differences and to take into 
account the different protocol used (detailed in Chapter 4).
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Figure 6.1: The (33vs subunit is inserted into the a3p4 receptor to produce an 
a3p4p3vs receptor as shown by the shifted EC50 value. Concentration- 
response curves for a3p4 receptors (squares) and for the a3p4p3vs 
receptors (circles) {n = 15 and 4, respectively). Lines are fits of the data 
with the Hill equation.
All responses were recorded from Xenopus oocytes voltage clamped at 
-70 mV in nominally calcium-free solution.
Figure 6.1 shows that the p3vs subunit has been incorporated into the a3(34 
receptor and so has produced the large shift in EC 50 value. Comparison o f these results 
(a3|34 1:1 : ECso = 149 ± 7 //M , m  = 1.69 ±  0.05, «=15; «3p4p3vs : 12.9 ± 1.1
pM , «h = 1.14 ± 0.05, n=4, ECso and »h: P < 0.0001, two-tailed Student’s t-test) with 
those obtained in Groot-Kormelink et al. 1998 (a3p4 1:1 : ECso = 180 ± 17 //M , «H =
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1.81 ± 0.09, n=7; a30403VT : EC50 = 42.6 ± 2.8 //M, nH = 1.25 ± 0.04, n=9) shows that 
the VS mutation has a much greater effect on EC so value than the VT mutation and so 
will provide a more noticeable effect if this subunit is incorporated. The only other 
explanation, that the (33vs subunit is incorporated in more than one copy (unlike the 03VT 
subunit) into the a3(34 parent seems highly unlikely and so can be ignored. Figure 6.2 
shows responses to ImM ACh for a304 (1:1), a30403 (1:1:20) and a30403vs (1:1:20): 
neither the time course of the response to ImM ACh nor its amplitude were grossly 
changed by the insertion of the 03 or 03vs subunits.
<c
8 L
1 min o304 030403 o30403vs
Figure 6.2: Examples of current responses elicited by 1mM ACh on the three 
types of a304* receptors.
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6.2 p3vs controls
Before the (33vs could be used, some control experiments needed to be carried 
out. The wild-type (33 subunit doesn’t form functional homomeric or pair receptors, and 
we had to check that was true of the (33vs in the highly unlikely event that a TM2 
mutation would massively change the properties of the subunit. Thus p3vs cRNA was 
injected at a high concentration either alone (10ng//d) or together with a l, a3, a4, a6, (32 
or (34 cRNA at a ratio of 1:20 (10:200 ng///l) into oocytes. After incubation, oocytes 
were tested with ImM bath-applied ACh. None of these combinations proved functional 
(all «=10).
6.3 Co-assembly of the (33 subunit with a3 and |32 
subunits
Having proved p3 co-assembly with the a3 and p4 subunits, we proceeded 
to test p3 with other combinations and started with a3p2. Wildtype p3 subunit cRNA 
was co-injected with a3 and p2 subunit cRNA at the ratio of 1:1:20 into oocytes. For 
comparison purposes, a3 and p2 cRNA was also injected into oocytes within the same 
batch to produce a3p2 nAChRs. Whilst we observed robust functional expression in the 
a3 + p2 injected oocytes («=13), the a3 + p2 + p3 injected oocytes responded to ImM 
ACh with much smaller currents (4.3 ± 1.2 % of those measured in the a3p2 control 
oocytes, n=9). Even if we injected less p3 construct and used a ratio of 1:1:1 («=7),
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responses to ImM ACh were effectively halved (55.0 ± 32.8 % of the a3(32 control 
oocytes).
The fact that increasing the amount of (33 construct expressed decreased the size 
of the functional response strongly suggests that receptors a3|32-type receptors that 
incorporate (33 are somehow “less functional” or indeed completely non-functional. The 
residual response we recorded could be produced by a3(32 receptors without (33. These 
could be expected to be present in larger numbers after the 1:1:1 injections than after 
1:1:20 injections.
This dominant negative effect of (33 was totally unexpected, so what could have 
caused this decrease in current? One possibility that I easily tested and excluded was that 
the (33 subunit has caused the EC50 value to increase massively and that at ImM ACh I 
am no longer measuring the maximum receptor response: similar results were obtained 
with the application of 20mM ACh concentration, the practical maximum ACh 
concentration possible using my standard stock solutions.
How could the incorporation of the (33 subunit reduce the total maximum current 
response to ACh of the cell (Imax)?
Imax is dependent on a number of factors summarised in the equation in Figure 6.3.
Im ax ”  N  •  Popen *  Y * V
Figure 6.3: Equation for the maximum cell current (Imax) through a given 
receptor channel as a function of the number of receptor channels 
present (N), the maximum Popen value of the receptor (Popen), the 
conductance of the channel (y) and the driving force (V).
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The driving force V depends on the holding potential, which is clamped at -70 
mV and can be excluded, and on the reversal potential. The latter could change only if 
the permeability of channels containing (33 is grossly different (unlikely, given that the 
TM2 sequence of p3 is very similar to that of nicotinic a subunits and that incorporation 
of (33 does not affect the calcium permeability of a3(34 receptors; Boorman et al. 2003) 
or if the expression of (33 has somehow destroyed the physiological ionic gradients in the 
oocyte, which is highly unlikely.
This leaves the other three variables to consider. N, the number of the receptors 
present at the cell surface could have been reduced, if p3 is interfering with receptor 
assembly or trafficking. Perhaps the maximum Popen of the resulting receptor has been 
reduced and therefore the receptor is in the membrane in large numbers but just doesn’t 
happen to be particularly functional. Finally it is also possible that y, the single-channel 
conductance of the receptor has been reduced. Perhaps it was a combination of all three.
We can test for an effect on the number of receptors (N) in the cell membrane by 
measuring the total number of specific binding sites through the use of radioliganded 
binding studies. Dr. Patricia Harkness has carried out this work which will be mentioned 
later on in this chapter (and excludes major decreases in surface expression).
Has p3 reduced the single-channel conductance (y) of the receptor? This doesn’t 
seem too likely. If  the p3 subunit replaces a “classical” p in the pentamer, p3 should 
actually increase single channel conductance, because of net -2 change in the charge of 
the outer ring of charges in TM2. Indeed we found that a3p4p3 has a higher 
conductance than a3p4 (Boorman et al. 2003).
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This leaves us with the possibility that it is the Popen of the receptor that is 
changed by |33 incorporation into a3(32. A way to test that is to express rather than (33, 
the (33vs mutant subunit. This is because it is likely that the main effect of the V to S 
mutation in the 9’ position of TM2 is to destabilize the closed state and favour the 
opening of the receptor. So by co-injecting a3(32 with (33vs at a 1:1:20 ratio this could 
counteract any Popen lowering effect of the (33 subunit in its wild-type form.
6.4 Rescue of the a3p2p3 receptor by P3vs
6 0 s
Figure 6.4: Examples of current responses elicited by 1mM ACh on 
the three types of a3(32* receptors.
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Figure 6.4 shows representative traces of the responses to ImM ACh for a3p2, 
a3(32p3 and a3p2(33vs. As can be seen the p3vs appears to have reversed the effect
y c
caused by (33 on oc3p2-containing receptors. The response of a3p2p3 receptors to 
ImM ACh (n=4) averaged 104 ± 25 % of those of a3p2 («=13) receptors. This strongly 
suggests that the effect of p3 on Imax is due to a reduction in the Popen of the receptor. It 
is difficult to see how an effect of p3WT on receptor number or on single-channel 
conductance could be reversed by expressing p3vs.
It is possible (though unlikely) that the rescue we observed is due to the fact that 
the mutant p3vs subunit (contrary to the WT subunit) is somehow not assembled and 
therefore what is being recorded is actually the response of pure a3p2 receptors. We can 
exclude this possibility by examining the concentration-response curves for a3p2 alone 
and a3p2p3vs in Figure 6.5. It is clear that the p3vs is incorporated along with the a3 
and p2 subunits to produce a distinct receptor.
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Figure 6.5: The p3vs subunit is inserted into the a3f32 receptor to produce a 
functional a3p2(33vs receptor. This insertion is confirmed by the shifted 
EC50 value due to the mutation in the (33 subunit. Concentration-response 
curves for a3p2 receptors (squares) and for the a3(32(33vs receptors 
(circles) (n = 4, for both). Note the two-component fit of the pair receptor 
compared to the single-component fit of the triplet receptor. It is possible 
that this is due to alternate stoichiometries for the pair receptor (see 
Chapter 9). Lines are fits of the data with the Hill equation.
All responses were recorded from Xenopus oocytes voltage clamped at - 
70 mV in nominally calcium-free solution.
Figure 6.5 shows that a3p2 produces a biphasic curve with two components 
having EC50 of 11.6 ± 9.4 and 238 ± 11//M («H = 0-62 ± 0.1 and 2.34 ± 0.32, 
respectively, n = 4). A possible explanation of this phenomenon is that a3p2 may exist 
in two different stoichiometric forms (probably 2a:3p and 3a:2p; see Chapter 9 and
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Nelson et al 2003 for a similar observation for a4p2 receptors). Both forms are present 
when a 1:1 cRNA injection ratio is used, but the insertion of the p3 subunit makes the 
curve monophasic, possibly because most receptors now are a3p2p3vs in a 2:2:1 ratio 
(a3p2p3vs: ECso = 0.19 ± 0.02 jaM, = 0.86 ± 0.03, n=4, comparison with a3p2 ECso: 
p < 0.05, nu‘. p < 0.005, two-tailed Student’s t-test). This work is covered in more detail 
in Chapter 9.
These data showed an unexpected effect for the p3 subunit, after leaving the 
a3p4p3 receptor infuriatingly similar to the a3p4 receptor suddenly the p3 was almost 
completely knocking out the a3p2 receptor, the question now was did the p3 co-assemble 
with any of the other nAChR subunit combinations and if so did they produce unchanged 
a3p4p3-like receptors or knocked-out a3p2p3-like receptors. The next one tested was 
p3 with a4 and p2.
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6.5 Co-assembly of the (33 subunit with a4 and |32 
subunits
Oo 60s
a4|32 a4p2p3 a4p2p3vs
Figure 6.6: Examples of current responses elicited by 1 mM ACh on the three types of 
a4p2* receptors.
Oocytes were injected with a4p2 (1:1), a4p2p3 (1:1:20) and a4p2p3vs 
(1:1:20) and their responses to ImM ACh are shown in Figure 6.6. Again the robust 
expression of the pair a4p2 receptor was knocked out by p3 incorporation but rescued by 
the co-injection of p3 . The average current response to ImM ACh of a4p2(33 (n=\l) 
was 1.7 ± 0.4 % of the response recorded in “control” a4p2 receptors, whereas in 
a4p2p3vs («=10) the response was 334 ± 33 % of a4p2 (n= 7). Similar results were seen 
with ratios to 1:1:1 (n = 5; 3.6 ± 0.8 % of control).
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Figure 6.7: (previous page) The p3vs subunit is inserted into the a4[32 receptor to 
produce a functional a4(32p3vs receptor compared to the non-functional 
cx4(32p3. This insertion is confirmed by the shifted EC50 value due to the 
mutation in the p3 subunit.
(A, B) Examples of current responses elicited by increasing ACh 
concentrations on the two types of receptors, a4p2 (Left) and a4(32|33vs 
(Right)
(C) Concentration-response curves for a4p2 receptors (squares) and for 
the a4(32|33vs receptors (circles) (n = 5 and 4, respectively). Note the 
two-component fit of the pair receptor compared to the single-component 
fit of the triplet receptor, indicating the pair receptor may be present in two 
stoichiometries. Lines are fits of the data with the Hill equation.
All responses were recorded from Xenopus oocytes voltage clamped at - 
70 mV in nominally calcium-free solution.
Figure 6.7 shows the dose-response curves for a4p2 and a4p2(33 combinations. 
Again we have a biphasic curve for the pair combination (a4p2: EC50 = 10.3 ± 4.2 //M, 
«h = 0.75 ± 0.08, and, for the second component EC50 = 166 ± 17 //M, «h = 6.86 ± 4.54, 
n=5; note that the slope of the second component is not well determined, but this does not 
affect our conclusions). This behaviour of the a4p2 receptor has been interpreted as 
indicative of two stoichiometries (Nelson et al. 2003). Again only one component is
yq
observed when the p3 subunit is co-expressed, possibly because most receptors formed 
contain a4p2p3vs in 2:2:1 ratio (ECso = 1-02 ± 0.12 juM, nn = 1.12 ± 0.10, «=4, 
comparison with a4p2, EC50: p < 0.001, the nu values were not significantly different, 
two-tailed Student’s t-test). At this point we decided rather than produce full dose- 
response curves for the remaining combinations we would just quickly test them with 
ImM ACh to get an idea of which, if any, combinations were functional.
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Figure 6.8: Examples of current responses elicited by 1mM ACh on the three types of receptors for a2p2 (A), a2p4 (B) and a4p4 
(C) background pair receptors alone (co-expressed with wildtype p3 or with p3vs. Note the knock-out of the response 
by the p3 and the rescue by p3vs. 9
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6.6 Co-assembly of the (33 subunit with a2(32, a2(34 and 
a4|34
Figure 6.8 shows that the (33 and (33vs subunits have the same effect when co­
injected with a2(32, a2(34 and a4(34 as they had on a3|32 and a4p2. The average current 
responses to ImM expressed as percentage of the response of the “control” pair receptor 
expressed alone were a2p2p3 (0 ± 0 %, 72=11), a2p2p3vs (372 ± 51 %, 72=10) a2p4p3 
(0.9 ± 0.3 %, n=5), a2p4p3vs (22 ± 5 %, «=8), a4p4p3 (2.7 ± 0.7 %, «=9), a4P4p3vs 
(72 ± 21 %, «=10) compared to the corresponding pair parent combination (a2p2: 72=12; 
a2p4 «=5; a4p4: 72=11, see Table 6.1). The p3 subunit appears to exert a strong 
dominant negative effect on all the functional pair receptor combinations with the 
possible exception of the a3p4 combination. We tested again this combination, 
measuring just responses to ImM ACh rather than dose-response curves and found that 
the a3p4p3 receptor produced around 73 ± 12 % the current seen with a3p4. The table 
below summarises all the results of p3 and p3vs coexpression with pair receptors.
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Combo
Injected
(1:1/1:1:20)
Response to 
1 mM ACh 
± SEM 
(nA)
Functional 
Expression as 
a Percentage 
± SEM 
(parent pair 
=100)
n
p value
(vs pair 
receptor)
p value
(vs pair + p3 
receptor)
a2 + (32 216 ± 36 100 ± 17 12 - -
a2 + (32 +J33 0 ±0 0 ± 0 11 <0.01 -
a2 + 32 + p3vs 799± 110 372 ± 15 10 <0.05 <0.001
a2 + p4 13450± 
1599
100 ± 12 5 - -
a2 + p4 + p3 124 ±42 0.9 ± 0.3 5 <0.01 -
a2 + 34 + 33vs 3018 ±678 22 ±5 8 NS <0.05
a3 + P2 1853 ±352 100 ± 19 13 - -
a3 ± p2 + P3 79 ±23 4± 1.2 9 <0.001 -
a3 + 32 + 33vs 1929 ±466 104 ±25 4 NS <0.05
a3 + p4 3583 ±290 100 ±23 16 - -
a3 + p4 + J33 2616 ±430 73 ± 12 34 <0.001 -
a3 + 34 + 33vs 2629 ± 680 73 ± 19 7 NS NS
a4 + p2 1083± 139 100 ± 13 7 - -
a4 + P2 + p3 18 ± 4 1.7 ±0.4 17 <0.01 -
a4 + 32 + 33vs 3621 ±355 334 ± 33 10 NS <0.001
a4 + p4 2556 ± 867 100 ±34 11 - -
a4 + p4 + p3 68 ± 17 2.7 ±0.7 9 <0.001 -
a4 + 34 + 33vs 1970 ±315 77 ± 12 10 NS <0.05
Table 6.1: Summary of the effect of co-injecting (33 and p3vs with various pair
combinations at a ratio of 1:1 and 1:1:20. Statistical analysis by Kruskal- 
Wallis one-way nonparametric ANOVA followed by Dunn’s post hoc 
multiple comparisons test. NS = not significant.
Our next question then was does this dominant negative effect of (33 also apply to 
native neuronal nAChRs?
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6.7 Effect of 03 on native nAChRs in primary 
hippocampal cultures (data courtesy of Dr Marco 
Beato)
Clearly, if we wish to transfect the (33 subunit into neurones we need either an 
organotypic slice or a dissociated primary culture. In our Dept, the latter technique is in 
routine use by Dr Phil Thomas, who kindly provided us with primary cultures of 
hippocampal neurones obtained from embryonic rats (E l7). Untransfected neurones 
were compared to hippocampal neurones transfected (Effectene©) with either a7, (33 or 
p3vs cDNA. Dr. Marco Beato recorded from these cells using whole-cell patch clamp at 
-70mV. 3mM ACh was applied using a U-tube to produce a rapid application of agonist. 
The neurones were co-transfected with green-fluorescent-protein (GFP) and only the cells 
which glowed green were considered transfected. The near totality (25 out of 27) of the 
untransfected neurones responded to 3mM ACh with fast inward currents: these are 
thought to represent responses through a7 receptors (for a review see Albuquerque, 
1997). The a7-nature of these responses was confirmed by transfecting with a7 
producing increased currents of the same type. These two findings provided us with 
controls to show the transfection worked and didn’t produce unexpected side-effects and 
an estimation of the proportion of false negatives we were likely to come across. 
Transfection with (33 had a striking dominant negative effect: 34 out of 38 transfected 
(i.e. fluorescing) neurones did not respond to 3mM ACh at all. Transfection with p3vs 
did produce a rescue of nicotinic responses and 48 out of 53 p3vs transfected neurones 
produced currents comparable to the a7 untransfected neurones. This is summarised in 
Figure 6.9.
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Figure 6.9: Summary of the average maximum currents elicited by 3mM ACh on 
hippocampal neurones either untransfected (Ctrl) or transfected with p3 
(P3) or p3vs (p3vs). Numbers in brackets above show the number of cells 
corresponding to the types of response shown in Figure 6.11. All 
responses were recorded from whole-cell patch-clamped neurones at -70 
mV in nominally calcium-free solution.
Figure 6.10 shows example responses obtained by Dr. Beato. As can be seen, 
while the (33 transfected neurones show no response to 3mM ACh, p3vs transfected 
neurones produce relatively large currents which are markedly different in shape from the 
untransfected, a7-only neurones, proof that the (33vs subunit has been incorporated into 
the a7 receptor.
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Figure 6.10: Examples of current responses elicited by 3mM ACh concentrations on 
neurones which were either untransfected or transfected with p3 or p3vs. 
All responses were recorded from whole-cell patch-clamped neurones at - 
70 mV in nominally calcium-free solution. Note the knock-out of the 
intrinsic receptors by the p3 subunit and their return and change of shape 
of their responses by the transfection of p3vs.
We then proceeded to test this effect for oocyte-expressed a7 receptors.
6.8 Co-assembly of the p3 subunit with a7 in oocyte- 
expressed receptors
Previously the co-injection of (33 subunit has been shown to reduce the ACh- 
evoked current of a7-injected oocytes without affecting the number of surface receptors 
measured by a- bungarotoxin binding (Palma et al. 1999). Co-injection of the p3 with 
a7 carrying a leucine-to-threonine mutation at residue 247 (a7L247T) produced a 
functional receptor markedly different with reduced nAChR activity, amplitude of 
current, transmitter sensitivity and faster rate of desensitisation when compared to the
128
nAChRs produced by a7L247T alone so it was clear that the [33 was co-assembling with 
the a l  subunits. The precise stoichiometry of the a7(33 heteromer remains unclear.
To check whether the a7(33 receptor would be “rescued” by our VS mutation in 
the p3 subunit(s) present, we co-expressed a l  with [33 or p3vs at ratios of 1:10 and 1:20 
and measured responses to ImM ACh. As before, co-expression with p3 almost 
abolished functional expression of the a7-containing receptor to 12.4 ± 3.5 % (1:10, 
h = 1 4 )  and 4.3 ± 2.3 % (1:20, 77= 8 )  of that of the a l  monomer alone reproducing the 
findings of Palma et al. 1999 and illustrating the relationship between amount of p3 
present and the resulting reduction in current (Table 6.2).
However, in this case the P3VS mutation failed to produce a significant recovery
y c
in the ACh-evoked current with a7p3 having 12 ± 3 % of the functional expression of 
the a l  receptor compared to 4 ± 2 % of a7p3. This result is in contrast to the “rescue”
y c
observed with p3 expression in hippocampal primary cultures by my colleague Dr 
Marco Beato (see above). An obvious difference in the experimental conditions for the 
work on oocytes and on neurones lies in the effective agonist application rate for the two 
systems. This is much slower for the oocyte, because of size of the oocyte, irrespective 
of the perfusion rate and bath volume. This factor poses an important limitation to the 
precision with which responses of a fast-desensitising receptor such as a l  can be 
measured. It is hard to know whether this likely underestimate of the real response could 
be greater for a l  + p3vs and thus introduce a systematic bias in our results. The ideal 
control would be to express a l  with and without [33 in a mammalian cell line.
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Unfortunately, successful expression of a l  in a mammalian cell line requires stable 
transfection and is far from trivial (Puchacs et al. 1994; Zhao et al. 2003)
It has recently been reported that 5-hydroxyindole (5-HI) potentiates a l  nAChR 
mediated currents in oocytes (Gurley et al. 2000). It is completely unclear what the 
mechanism is for this enhancement and whether it can be ascribed to a slowing of a l  
desensitisation, but we thought that it was worth testing on an empirical basis.
Table 6.2 summarises the maximum current recorded from ImM ACh in the 
presence and absence of 5mM 5-HI for all three receptor combinations. As can be seen, 
whereas in the absence of 5HI, P3VS only produced a marginal increase in the ACh- 
evoked current (33.6 ± 7.2 nA vs 11.8 ± 6.4 nA, «=8), this recovery was much more 
substantial in the presence of indole (383 ± 57 nA vs 98.4 ± 28 nA, n=S,p< 0.05 Kruskal- 
Wallis one-way nonparametric ANOVA and Dunn’s post hoc multiple comparisons test). 
Figure 6.11 shows some representative traces produced by ImM ACh co-applied with 
5mM 5-HI.
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Average max 
lm]
±
imum current to 
M ACh 
SEM 
nA) n
p value
(vs a l)
p value 
(vs a7p3)
control + 5mM Indole Ctrl Indole Ctrl Indole
a l 273 ± 54
(100%)
968 ± 145
(100%)
8 " “ "
a7p3 11.8 ±6.4
(4.3 ± 2.3 %)
98.4 ± 28.0
(10.2 ±2.9%)
8 <0.001 <0.01 "
a7p3vs 33.6 ± 7.2
(12.3 ±2.6%)
383 ± 57
(39.5 ± 5.9 %)
8 <0.05 NS NS <0.05
Table 6.2: Summary of the average maximum currents elicited by 1mM ACh for
oocytes injected with different a l  cRNA combinations in the presence and 
absence of 5mM 5-hydroxy-indole. All responses were recorded from 
Xenopus oocytes voltage clamped at -70 mV in nominally calcium-free 
solution. Statistical analysis by Kruskal-Wallis one-way nonparametric 
ANOVA followed by Dunn’s post hoc multiple comparisons test. NS = not 
significant.
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Figure 6.11: Examples of current responses elicited by 1 mM ACh on the three types of 
receptors for al*. a l  (left), a7(33 (middle) and a7p3vs (right). Note the 
knock-out of the response by the p3 and the rescue by p3vs. Also note 
the fast timescale of the responses.
It is hard to explain why the |33vs rescue of a l  responses could be observed only 
in 5HI and it would be pointless to speculate in the absence of data on the mechanism of 
action of 5HI. Nevertheless, this uncertainty does not affect our main finding that, for a l  
native and recombinant receptors functional expression was knocked out by P3 and 
resurrected by the p3vs subunit, in a pattern similar to that observed for other neuronal 
nicotinic combinations.
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6.9 p3 co-assembles with a6-containing receptors
It was ironic after spending so long trying to detect any major differences caused 
by the incorporation of the (33 subunit into a3(34 receptors that we should have had a 
clean sweep of knock-outs for all the major functional pair receptor combinations and the 
a l  monomeric receptor. One subunit we hadn’t tested was the a6 subunit. Importantly, 
this subunit appears to co-localise with (33 subunit in native tissues and a selective 
a6a3(32(33 conotoxin (a-conotoxin PIA) has been identified (Dowell et al. 2003). Would 
a6 receptors also be knocked-out by (33?
Despite there being plenty of evidence of functional a6 receptors in native tissues, 
functional a6 receptors are notoriously difficult to express in heterologous expression 
systems such as the oocyte. The a6 (cloned in 1991, Deneris et al. 1991) had previously 
been considered another “orphan” receptor as it doesn’t form functional receptors when 
expressed either alone or with any other single nAChR subunit. In 1997, the co­
expression of chicken a6 and human p4 in oocytes was found to produce only barely 
detectable currents to high concentrations of ACh with an average maximum of <100nA 
compared to 2-3 pA for the equivalent amount of a3p2 and a3p4 RNA (Gerzanich et al. 
1997). As will be shown in Chapter 7, we ourselves tried to produce p2_a6 and p4_a6 
tandem constructs, none of which were functional (Groot-Kormelink et al. 2004). We 
decided to test a6-containing receptors with the p3 and p3vs. The first test was to co- 
inject a6 and P3 or p3vs subunits (at a ratio of 1:20) to check whether they produced 
functional pair receptors. Unsurprisingly they failed to produce any response to ImM 
ACh (n= 19-20) as shown in Figure 6.12.
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Figure 6.12: Examples of current responses elicited by 1mM ACh on a6 and (33 pair 
receptors. Note the lack of response even in the presence of (33vs.
Having confirmed that a6 and p3 didn’t form a functional pair receptor we 
decided to look to see whether they could produce a functional triplet receptor by 
expressing the P3 with a6 and either p2 or p4 at a ratio of (a6:p2-4:p3) 1:1:20. In 
parallel we checked to see whether the function of a6p2 and a6p4 was improved by 
inserting the 9' leucine-to-threonine mutation (LT) into the p subunits we have used 
previously at a ratio of 1:1 (Boorman et al. 2000). Judging by the >75% sequence 
homology between a6 and a3 (Le Novere et al, 1995) the a6 would be expected to form 
a receptor of a 2:3 stoichiometry with p2 or p4 subunits. It was possible that this receptor 
does assemble and is present in the membrane and therefore it was possible that the 
presence of multiple copies of the LT mutation could improve this receptor’s function. 
Using a similar line of reasoning we also checked the effect of inserting the p3vs into a
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60s
possible a6p2-4p3 receptor (injection ratio 1:1:20). These were all injected into oocytes 
and tested with ImM ACh (Figure 6.13).
As can be seen the a6p2* receptors did not produce any significant ACh-evoked 
currents even with the presence of LT mutations or the p3 subunit. However with the 
p3vs larger responses began to appear (average response to ImM: 124 ± 27 nA, «=8). 
This pattern was repeated with the a6p4* receptors. All the pair and the wildtype triplet 
receptors produced small currents to ImM ACh, currents which were not increased by the 
presence of multiple LT mutations however the presence of the P3 subunit produced 
large currents (average response to ImM: 556 ± 140 nA, «=15). These findings are 
summarised in Table 6.3.
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Figure 6.13: Examples of current responses elicited by 1mM ACh on different a6* 
receptors. Note the lack of response in a6p2* receptors even in the 
presence of a6LT or p2LT, with small but noticeable currents apparent only 
when p3vs is added. Also note the size of responses in a6p4* receptors 
even in the presence of a6LT or p4LT compared with the large currents 
apparent when p3vs is introduced shown by the differences in scale used.
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Average 
maximum 
current to ImM 
ACh 
± SEM 
(«A)
n = p  value 
(vs pair)
p  value 
(vs (33 
receptor)
o632 3.0 + 2.5 8 - -
a6LT32 0 ± 0 4 NS -
a632LT 0.75 ± 0.75 4 NS -
a63233 1 ± 0.68 8 NS -
a63233vs 124 ±27 8 < 0.001 < 0.001
a634 49.4 ± 14.9 8 - -
a6LT34 31.8 ± 10.4 4 NS -
o634lt 14.3 ± 5.7 4 NS -
063433 13.7 ± 5.1 8 NS -
a63433vs 556 ± 141 8 < 0.001 < 0.001
Table 6.3: Summary of the average maximum currents elicited by 1mM ACh for
oocytes injected with different cRNA combinations. All responses were 
recorded from Xenopus oocytes voltage clamped at -70 mV in nominally 
calcium-free solution. Statistical analysis by Kruskal-Wallis one-way 
nonparametric ANOVA followed by Dunn’s post hoc multiple comparisons 
test. NS = not significant.
These results show that there is little or no functional expression following the 
expression of a6 with [32 or (34 and [33 and obviously beg the question of how receptors 
containing the a6 subunit can be functional in neurones. While it has been suggested that 
(33 may be important in the expression of such receptors (Kuryatov 2000), it is clearly not 
sufficient on its own to produce functional a6-containing receptors. The possibility is
137
that the a5 subunit is also required, as the surface binding produced by the expression of 
a6|34|33 is massively increased if a5 is co-expressed (Grinevich et al. 2005).
6.10 Conclusion
The progress of this project has following an interesting path and we have had 
more than our fair share of good fortune in the precise order we carried the experiments 
out.
P3 co-assembled with a3 and (34 subunits in oocytes but did not substantially 
change the properties of the resulting triplet receptor compared to the parent pair 
receptor. Subsequent testing of the (33 subunit with a2p2, a2p4, a3p2, a4p2, a4p4 and 
a l  receptors has shown that the P3 co-assembles and produces an almost complete 
knock-out of the functional expression of these receptors (see Figure 6.14 for a 
summary).
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Figure 6.14: Summary of the effect of p3 incorporation on a range of functional 
nAChR combinations injected into Xenopus oocytes. The effect is 
shown as a percentage of the current evoked by 1mM ACh 
compared to the equivalent amount of cRNA injected without the 
p3 (ratios = 1:1:20 or 1:20). All responses were recorded from 
Xenopus oocytes voltage clamped at -70 mV in nominally calcium- 
free solution.
Our interpretation o f these results, namely that p3 reduced the receptor’s 
maximum Popen value rather than the number o f receptors on the surface o f the cell was 
confirmed by the work o f Dr. Patricia Harkness who carried out binding studies on 
transiently transfected tsA cells (oocyte work was attempted but the levels o f all receptor 
types were too low to measure). Her findings for 3H-epibatidine on a3p4, a3p4p3,
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a3(34|33vs, a3(34p3KO (Delilah 4, see Chapter 5), a4f32, a4p2p3 and a4p2p3vs are 
shown in Figure 6.15.
Figure 6.15: Normalised binding of 3H-epibatidine to the surface of transiently 
transfected tsA cells corrected for protein (mean ± SEM, n=7, for all).
The binding studies show that the co-expression of {33 subunits has relatively 
minor effects on the surface expression of nAChRs. None of these small changes are 
sufficient to explain the approximately 97% decrease in a4p2 responses produced by p3
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co-expression in oocytes, or their reversal by p3vs expression. The same reasoning 
applies to a3p4 receptors, where the functional knockout produced by co-transfection 
with the Delilah 4 mutant, p3K0 (Chapter 5) is only associated with a small reduction in 
surface expression. From this data, along with our previous work, it is clear that for both 
Delilah 4 and the P3 wildtype, the reduction in cell current is due to a direct effect on the 
receptor’s properties rather than some general effect on expression levels. In both case 
large numbers of receptors are present, fully formed in the cell surface membrane but 
happen to not be very functional.
The similarity of the results that we obtained with a l  receptors in hippocampal 
neurones suggests that the effect of p3 may apply to native receptors in native tissues. 
This would mean p3 could have an important effect on the regulation of nAChR 
responses and potentially on all the aspects of nervous system transmission downstream 
regulated by nAChRs in turn.
So why is the a3p4 receptor “spared” when all the other functional combinations 
of nAChRs are knocked-out by p3 insertion? The maximum Popen value of a receptor is 
determined by the following equation, where E is the efficacy:-
E
Maximum Popen = -----------
E + 1
The value of E is only known for the muscle-type nAChR as its determination 
requires single-channel methods, so what follows is essentially plausible speculation. If
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the a3p4 had a particularly high E value of say 100, giving a maximum Popen value of 
0.99 and the insertion of a p3 subunit reduced the E value by 90% (for arguments’ sake) 
then the a3(34(33 receptor would still have an E of 10 and therefore a maximum Popen 
value of 0.909 and so the two receptors would be barely distinguishable from each other. 
However if the other receptors, for example a4p2, have low efficacies, for instance 1, the 
effect of a 90% reduction in E value would change the maximum Popen from a 
reasonable 0.5 to a barely detectable 0.091 causing a marked reduction in the Popen 
values and therefore in the recorded current. With no idea of the E values for neuronal 
nAChRs, or the amount it is reduced by p3 insertion, this remains purely speculation, 
although if it is correct you can see how it might explain our findings and the sparing of 
a3p4. It must be noted that the above maximum Popen equation only really holds for a 
simple del Castillo-Katz type receptor mechanism (del Castillo & Katz, 1957), as the 
receptor mechanism for the nAChR receptor is almost certainly more complicated than 
this a different maximum Popen equation is likely to hold (see Colquhoun, 1998 for some 
examples). This however doesn’t necessarily mean our speculation on an effect on E by 
p3 insertion is incorrect just that it may be more complicated than illustrated here and as 
such the above del Castillo-Katz maximum Popen equation is a handy rough first 
approximation. Further research into the possible effect of p3 on receptor E would 
require single channel recording and as such is, again, beyond the remit of my PhD.
So what role do these findings suggest for the p3 subunit in vivo?
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At its most general, if the (33 knock-out effect on the majority of nAChRs 
combinations occurs in vivo, it would give the P3 subunit the capability to act as a global 
“volume-control” for most neuronal nicotinic receptors. In principle, spatial and 
temporal changes in p3 expression could, if they occur, control overall nicotinic signals, 
while mostly sparing a3(34 (and maybe even up-regulating a6* receptors).
What this would mean to the nicotinic network as a whole is unclear at this time 
along with its significance, if any, to nicotinic pharmacology, pathophysiology, 
development and in addiction.
The expression of the P3 subunit is very localised in the CNS, where it is 
expressed mostly in dopaminergic and catecholaminergic areas. In these areas a variety 
of other subunits are expressed, including a3 and a4: if our results can be extrapolated to 
neurones, the presence of p3 would basically reduce the effect of receptors formed by a4 
and spare those formed by a3. It is hard to deduct what the functional consequences of 
this switch towards a3p4-type receptors would be, given that it is not clear what the 
physiological role of such receptors is and most importantly what are the physiologically 
relevant concentrations of ACh that activate them. The a3p4p3 triplet receptor was found 
to be almost indistinguishable from the a3p4 receptor with a stoichiometry of 2a:3p, 
however as will be shown in Chapter 9 the a3p4 can also exist in a stoichiometry of 
3a:2p with markedly different properties and pharmacology and we have evidence that 
this may be the dominant stoichiometry in vivo. In that case insertion of the p3 subunit
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may be a method of selecting for receptors which are 2a:3(3-like, which (as will be 
discussed) are more sensitive to ACh than receptors with 3 a subunits.
It is possible that in the midbrain dopaminergic neurones, the balance between 
oc4- and a6-type receptors is what is regulated by (33. Populations of a6(32* receptors are 
know to be co-expressed pre-synaptically in the same neurones as populations of a4(32* 
receptors. These neurones also have high levels of a5 and (33 expression (Azam et al. 
2002) so, if a6(32a5(33 receptors are functional, it could be that in these neurones, the 
levels of P3 would determine the balance between a6p2* and a4p2* mediated ACh 
current. What the physiological significance of this may be I cannot say, given that the 
biophysical properties of a6-type receptors have not been characterised.
The phenomenon of cells producing subunits which regulate the function of ion 
channels is not unknown, voltage-gated potassium channel are known to be differentially 
regulated by the KCNE proteins, one-transmembrane spanning subunits with intracellular 
are known to interact with a range of potassium channels producing a number of effects 
including the inhibition of KCNQ1 channels by the KCNE4 protein (Grunnet et al. 2002) 
and the NR3A subunit (Das et al. 1998) and the NR3B subunit (Nishi et al. 2001) of the 
NMDA receptor have been shown to have a similar dominant-negative effect on NMDA 
heteromeric receptors.
In conclusion, our research has highlighted a possible important effect for the p3 
in the regulation of neuronal nicotinic signals (and therefore all the systems downstream 
regulated by nAChRs).
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CHAPTER 7
Development and Evaluation of a 
Subunit Tandem Approach for
nAChRs
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This work has been published as:-
“Incomplete Incorporation of Tandem Subunits in Recombinant Neuronal Nicotinic 
Subunits” (2004) Paul J. Groot-Kormelink, Steven D. Broadbent, James P. Boorman and 
Lucia G. Sivilotti. J. Gen Physiol. 123 697-708
7.1 Background
Previously I have shown data obtained from relatively simple subunit 
combinations and in the majority of cases the assumption has been that the receptor 
populations have been “pure” i.e. the currents recorded from a cell have all come from 
one type of channel with a single make-up and stoichiometry. In heterologous expression 
systems such as the Xenopus oocyte this assumption is fairly robust when recording from 
receptors made up of a single subunit such as the homomeric a7, a8 and a9 nAChRs or 
heterologous “pair” receptors, made up from a combination of an a subunit (a2, a3 or 
a4) and a P subunit (p2 or P4) where neither individual subunit can form a functional 
receptor on its own. Also, in the case of the two “orphan” subunits, a5 and P3, which 
form neither homomeric nor “pair” receptors, “triplet” receptors can be created by co- 
injecting these subunits at high concentrations along with a functional pair combination 
(Ramirez-Latorre et al. 1996; Groot-Kormelink et al. 1998). The high concentrations of 
a5 or p3 (in our case 1:1:20) is used to ensure that as much as possible of the functional 
receptor population contains all three subunits (Groot-Kormelink et al. 1998). However 
these “simple” subunit combinations probably do not resemble the make-up of native 
receptors, given that there is strong evidence that native nAChRs can be made up of at 
least four different subunits (Conroy and Berg, 1995) subpopulations of which could
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form functional receptors in their own right. For instance, in the case of the main synaptic 
nAChR in chick parasympathetic ciliary ganglia, a suspected a3p2p4a5 receptor, the 
injection of these subunits’ cRNA into an oocyte would also result in the formation of 
sub-populations of at least a3p2 and a3p4 receptors, with possibly a3p2p4, a3p2a5 and 
a3P4a5 nAChRs as well, not to mention all the possible variations in stoichiometry 
ratios. Any a3p2p4a5 receptors would likely be a minority population and would almost 
certainly not be readily distinguishable from the other subpopulations present.
Another situation in which our capability of expressing recombinant receptors is 
insufficient is when we want to study channelopathy mutations that have autosomal 
dominant inheritance (such as Autosomal Dominant Nocturnal Frontal Lobe Epilepsy). 
Affected patients carry both the wild-type and the mutant alleles and their nicotinic 
receptors in are thought to contain a mixed population of both the mutated subunits (a4 
usually) and the corresponding wild-type subunits (see Rozycka et al. 2003 for an 
overview). Such a complicated receptor could not be homogenously expressed in 
heterologous expression systems using traditional techniques. Further work has shown 
that even the “simple” combinations mentioned earlier are more complicated than they 
appeared at first. For instance, a9 can form homomers and also a pair receptor with alO 
(Grantham et al. 2004) and similarly the a l  is now known to form a non-functional 
receptor with p3 (Palma et al. 1999), work which I have expanded on in Chapter 6. The 
“pair” a4p2 receptor is now known to exist in two possible forms that differ in their 
stoichiometry and in their pharmacological properties (Nelson et al. 2003). Alternate 
stoichiometries are likely to be possible for a range of other combinations. See for 
instance, the biphasic curve for a3p2 shown in Chapter 6, which hints that it too may
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have multiple stoichiometries. In addition, Chapter 9 provides evidence that even our old 
faithful a3|34 receptor is more complicated than it first appeared.
Finally we know that when we express triplet receptors such as a3p4p3, the high 
concentration of the third subunit ensures that the majority of the receptors are triplet 
receptors, but does not guarantee that some pair receptors may not also form. Certainly 
the small currents seen in the “knocked-out” P3 combinations could just as easily be from 
residual amounts of pair receptors rather than the current from a barely functional triplet 
receptors or both. In an attempt to restrict the stoichiometry of ligand-gated and other ion 
channels concatemeric i.e. linked subunits have been examined starting with tandem 
subunits where two subunits are linked together. Tandem subunits were first used to 
prove the heteromultimeric nature of Shaker K+ channels (Isacoff et al. 1990) and have 
since been applied to cyclic nucleotide-gated channels (Vamum and Zagotta, 1996), the 
epithelial Na+ channel (Firsov et al. 1998), the mechanosensitive channel MscL of 
Escherichia coli (Blount et al. 1996), the cystic fibrosis transmembrane conductance 
channel (Zerhusen et al. 1999), P2X2 receptors (Newbolt et al. 1998) and a range of 
transport proteins (Emerick and Fambrough, 1993; Sahin-Toth et al. 1994; Kohler et al. 
2000). This eclectic mix of channels and transport proteins all share one common feature; 
the N- and C-terminals of these proteins are all intracellular allowing their linkage by 
short amino-acid linkers. It isn’t a massive leap to recognise that this technique could be 
adapted for LGICs whose proteins tend to have extracellular N- and C-terminals. As 
shown by Schorge and Colquhoun, 2003, this approach can be used even when the 
terminals are not on the same side of the membrane such as with NMDA receptors 
through the use of truncated subunits, although this was found to significantly change the
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properties of the receptor. The tandem + monomer technique has already been reported 
being successful for the study of GABAa receptors (Im et al. 1995) and the neuronal 
nicotinic a4p2 receptors (Zhou et al. 2003). So as a first step in restricting the 
stoichiometry of the other nAChRs, we attempted to create tandems of nAChR subunits.
7.2 Production of a functional nAChR tandem construct
As a starting point we decided to concentrate on the a3p4 receptor, it being the 
receptor we were most familiar with; under normal circumstances (injection of a3 and (34 
constructs in a 1:1 ratio), the a3|34 receptor has a stoichiometry in oocytes of 2a:3p 
(Boorman et al. 2000) with a probable arrangement of apapp if analogous to the muscle 
nicotinic receptor. We were aiming to produce a pure population of receptors from 
injecting a single tandem construct and a single monomer. Therefore, of the four possible 
types of a3p4 tandem construct, a3_a3, P4_p4, a3_p4 and P4_a3, only the a3_p4 and 
|34_a3 had the possibility to form a functional receptor when expressed with a single 
monomer (i.e. (34). These two tandem constructs were prepared by Dr. Paul Groot- 
Kormelink, as described in Groot-Kormelink et al. 2004. The linker used for the a3 J34 
construct was a 45 amino-acid (aa) sequence made up of the signal peptide (21 aa), the C' 
domain of the a3 (9 aa) and the linker itself (15 aa) (adapted from Im et al. 1995). For 
the P4_a3 construct a slightly longer 60 aa sequence was used due to the longer C’ 
domain of the (34 (19 aa) and the longer signal peptide (26 aa). The linker sequence was 
...AAAQQQQQQQQEFAT.... The inclusion of the signal peptide by Im et al. has been 
recently criticised (Minier and Sigel; 2004) as it may interfere with insertion etc. of the
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protein. The possible formation of a secondary structure in the signal peptide may also 
overly shorten the linker. The net effect of either of these problems would be a non­
functional tandem construct (for an example see Baumann et al. 2001), and this proved 
not to be the case for our constructs (see below).
Once the constructs were created, oocytes were injected with linked constructs of either 
a3_p4 or p4_a3 together with a p4 monomer (in a molar ratio of 2:1 tandem:monomer). 
This would potentially produce receptors looking like the two cartoons in Figure 7.1.
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AB
Figure 7.1: Representations of the putative formations of receptors created by (A)
a3_J34 + (34 and (B) (34_a3 + (34. Linkers shown by the black lines, with 
the presumed direction of linker shown by arrow. Note the differences in 
position relative to the putative binding sites (grey ovals) of the unlinked 
(34 monomer in each case.
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The a3_p4 construct failed to produce a functional channel i.e. oocytes injected 
with this combination failed to produce a response to ImM ACh (n= 5). In contrast to 
that, the p4_a3 construct produced robust expression when expressed with p4 monomer, 
giving an average maximum inward current of 2.6/uA to ImM ACh. («=TO, cRNA 
concentration 2ng:0.5ng tandem:monomer, see Table 7.1). The failure of the a3_p4 
construct could be due to its slightly shorter linker preventing assembly. This is unlikely 
as its 45 aa length is well in excess of the linker lengths that work for other LGICs e.g. 
linkers of lengths as short as 11 aa have been reported to be functional for GABAa 
tandems (albeit minus the signal peptide) (Baumann et al. 2001).
Another possibility is that a3_J34 does not express functional receptors because 
the position of the linker with respect to the agonist binding site (which differs between 
the two orientations, Zhou et al. 2003) interferes with the receptor function. A third 
possibility is that the a_p orientation does not allow the assembly of the receptor 
subunits in the correct order if neuronal nAChR assembly is analogous to the model 
postulated for muscle nicotinics (Green, 1999).
7.3 nAChR tandem constructs only produced 
functional receptors when expressed with |34 
monomers
Once we had a functional tandem construct, this allowed us to ask our first 
question, namely did the tandem strictly require the p4 subunit for function or could other 
monomers also form functional receptors with it? In order to test this, p4_a3 was
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expressed with each of all the other non-homomeric nAChR subunits i.e. a l  to a6, (32 
and p3, at the same concentration as before (2ng:0.5ng) and tested with ImM ACh, the 
results are shown in Table 7.1. As can be seen, only when the |34_a3 tandem was 
expressed with the p4 monomer were large currents observed. This was both good news 
but also a bit perplexing, on the one hand this meant that as the construct formed 
receptors with significant currents only with (34 we shouldn’t have any problems with 
contaminant and endogenous subunits and could be useful if this technique were ever to 
be extended to cells with already existing populations of ion channels that did not include 
(34. On the other hand, when the conventional expression technique is used, it is known 
that a3, a5 and p3 can form functional receptors together with a3 and P4. Hence we 
would have expected that a3, a5 and p3 subunits, at least, should also produce a 
functional receptor with significant currents when expressed with the P4_a3 tandem. In 
addition the formation of some hybrid of the tandem construct with p2 or one of the other 
a subunits wouldn’t have been too surprising (Boorman et al. 2000; Groot-Kormelink et 
al. 2001). This failure to produce functional tandem-containing “triplet” receptors is 
surprising, although explanations could include the possibility the linker was affecting 
assembly (although it leaves the question why would that affect p2 insertion but not P47), 
as mentioned earlier, or that p4 is the only subunit that can take up the position that is 
available for the monomer in the tandem expression, whereas the other subunit types 
need to occupy another position in the pentamer, i.e. one of the positions taken up by a 
linked subunit. As will be seen, some of the later work may shine a bit of light on this 
quandary. The a3_p4 construct (i.e. the one with the opposite orientation) was also
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tested with all the other non-homomeric nAChR subunits, none of which produced 
receptors with any significant function.
(34_a3 + Ana x 
(i»A)
cRNA
(«g)
n = 
oocyte
n = 
batch
0± 0 2 6 2
a2 13 ±7 2:0.5 6 2
a3 0± 0 2:0.5 6 2
a4 0± 0 2:0.5 6 2
a5 7 ± 4 2:0.5 5 2
a6 0± 0 2:0.5 5 2
P2 5 ± 5 2:0.5 6 2
P3 0± 0 2:0.5 6 2
p4 2587 ± 702 2:0.5 10 3
Table 7.1: Maximum currents (mean ± SEM) obtained by 1mM ACh application for
the f4_a3 tandem constructs expressed alone (—) or with a nicotinic 
monomer at VH = -70 mV
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7.4 No evidence of proteoysis of the tandem linker into 
functional monomeric subunits
Other questions for us were whether the tandem construct was being proteolysed 
at the linker into functional monomeric subunits (a phenomenon seen with P2Xi trimeric 
receptors at low efficiency, Nicke et al. 2003) and whether tandem-only receptors were 
possible, the so-called dipentamers (as was later reported by Zhou et al. 2003). In order 
to test these possibilities both the tandems alone and the a3_p4 and (34_a3 tandems 
together were expressed in oocytes («=6-9) none of which produced functional receptors 
(data not shown). The failure of the f34_a3 tandem to produce functional receptors with 
any of the other monomers (Table 7.1) was already evidence that proteolysis was not 
occurring (or more accurately, if it was occurring, it was not producing functional 
monomers) and this is supported by the inability of either tandem to produce a functional 
receptor when expressed on its own.
7.5 No evidence of the formation of dipentamers
This failure, together with the failure of the two tandems to produce a functional 
receptor when co-injected, also meant it was unlikely that a3*p4 tandem (where * means 
constructs of either orientation) constructs were able to form the dipentamers seen with 
a4*p2 tandem constructs by Lindstrom and his colleagues.
Production of monomer subunits from tandem constructs could only be by 
breakdown at the level of either cRNA or protein. Further evidence for lack of 
breakdown into functional monomers was provided by cRNA gel-electrophoresis results
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confirming the absence of any monomer cRNA from p4_a3 preparations (Figure 7.2A, 
courtesy of Dr Paul Groot-Kormelink) and by Western blots from both oocytes and HEK 
cells, as these failed to show any evidence of monomer protein in cells expressing only 
(34_a3 (Figure 7.2B, courtesy of Dr Paul Groot-Kormelink). However, it must be noted 
that, while (34 monomer protein was detected by this technique in the control cells (lane 
(34), the antibodies used failed to produce a signal from tandem proteins (lane T). This 
has been reported before for G A B A a tandems (Baumann et al. 2001) and could be due to 
insufficient amounts of antigen being formed to be detected above background by the 
antibodies used or by deformation of the epitope region by the presence of the linker.
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Figure 7.2: cRNA gel-electrophoresis (A) and Western Blots of expressed proteins in 
oocytes (B) and HEK293 cells (C). Approximately 1/^ g of a3 (1), (34 (2), 
a3J34 tandem (3) and p4_a3 tandem (4). Beside the RNA ladder (M) 
were separated on a 1.5% agarose-gel (A). The Western Blot in B was 
obtained from oocytes injected with MilliQ water only (MQ), p4 only or 
P4_a3 tandem (T) and the Western in C is from HEK293 cells transfected 
with no DNA (ND), a3 only, p4 only or p4_a3 tandem (T). Detection by 
P4 antibody and visualisation by chemoluminesence. Bands for the p4 
subunit were detected at the expected size of 56kD for both blots after 
30s exposure. No breakdown products were observed for the tandem 
subunit in either blots, even for longer exposure times up to 1 h. Note 
that the tandem fusion protein (predicted size of 115 kD) was not 
detected by the p4 antibody used.
7.6 Production of other functional nAChR tandem 
constructs
The same techniques were used to create and test other nAChR tandems, o f a p a  
+ p template. The linker regions are summarised in Table 7.2, all contain the same 15 aa 
linker section as the a3*p4 constructs.
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Tandem C’ domain Linker Signal peptide Total
ct3_|34 9 15 21 45
(34_a2 19 15 29 63
(34_a3 19 15 26 60
|34_a4 19 15 28 62
(34_a6 19 15 25 59
|32_a2 23 15 25 63
p2_a3 23 15 29 67
p2_a4 23 15 28 66
P2-a6 23 15 25 63
Table 7.2: Linker regions of tandems from presumed -NH2 end of TM4 region
(extracellular region) of the first subunit up to start of the mature second 
subunit.
The response to ImM ACh of these tandem constructs with and without the 
appropriate monomer is shown in Table 7.3 and Figure 7.3. As can be seen, while none 
of the a6-containing constructs produced functional receptors, all the other constructs of 
the form P4_a + (34 produced large inward currents, whereas the (32-containing 
constructs were less successful with only the p2_a4 producing significant amounts of 
current (even that was far less than what was seen for the (34 constructs). Several of the
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constructs also generated significant amounts of current when injected alone, particularly 
the p2_a4, so there is a strong possibility of either proteolysis or, as reported by Zhou et 
al. 2003, the formation of dipentamers by these constructs.
= Tandem + p monomer 
= Tandem only
(34_a2 (34_a3 |34_a4 p2_a4
Figure 7.3: Maximum currents obtained from application of 1mM ACh on tandem 
constructs expressed in oocytes with and without the appropriate p2 or p4 
monomer (2ng// :^0.5ng///l).
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Combo Imax (nA) to 
1 mM ACh
cRNA
injected
n
(oocytes)
n
(batches)
p2_a2 0 ± 0 0.5 ng 6 2
p2_a2 + p2 0 ± 0 2 ng: 0.5 ng 5 2
p2_a3 0 ± 0 0.5 ng 5 2
p2_a3 + p2 6 ±4 2 ng: 0.5 ng 5 2
p2_a4 99 ±35 0.5 ng 6 2
p2_a4 + p2 216 ±46 2 ng: 0.5 ng 6 2
p2_a6 0 ± 0 0.5 ng 6 2
p2_a6 + p2 0 ± 0 2 ng: 0.5 ng 6 2
P4_a2 1077 ±287 0.5 ng 5 2
p4_a2 + p4 7044 ±912 2 ng: 0.5 ng 5 2
p4_a3 1.7 ±5 0.5 ng 9 3
P4_a3 + p4 882 ± 195 2 ng: 0.5 ng 5 2
p4_a.4 678 ±496 0.5 ng 5 2
P4_a4 + p4 3079 ±693 2 ng: 0.5 ng 7 2
p4_a6 0 ± 0 0.5 ng 6 2
p4_a6 + p4 0 ± 0 2 ng: 0.5 ng 5 2
Table 7.3: Maximum inward current (mean ± SEM) produced by bath-applied 1mM
ACh on a series of tandem constructs expressed, with and without the 
appropriate monomer, in oocytes held at VH = -70mV. Note the failure of 
some constructs to produce current and the relatively large currents seen 
with some tandem-only injections.
The possibility that for some tandem constructs, we may encounter the formation 
of tandem-only receptors and/or proteolysis re-affirmed our decision to concentrate on 
the (34_a3 construct.
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7.7 Receptors formed by p4_a3 tandem constructs 
have similar macroscopic pharmarmacologicai 
properties to receptors formed by a3 and p4 
monomers
Having shown that p4_a3 tandems produced functional receptors that were 
faithful to (34 monomers, unable to form dipentamers and didn’t appear to proteolyse, the 
most important question then was, do these receptors have the same properties as the 
analogous a3(34 monomeric receptor? Dose-response curves were obtained for both 
types of receptors and as can be seen by Figure 7.4 both the shape of the responses and 
the pooled and fitted dose-response curves are indistinguishable, (a3p4: EC5o = 134 ± 5 
//M , »H = 1.70 ± 0.10, «=9; P4_a3 + P4: EC50 = 122 ± 8 jjM, nH = 1.98 ± 0.21, n=4).
161
\ s
a3 + p4
50 100 200 500 1000 nM
V
s i
60s
50 100 200 500 1000 pM
V
P4_a3 + p4
1.0 *
04
0 2 -
00
100 100010
ACh concentration (pM) 
(log scale)
Figure 7.4: ACh concentration-response curves of a3(34 nAChR expressed in 
oocytes from monomer or tandem constructs are indistinguishable. (A) 
Traces are inward current recorded at a holding potential of -70mV in 
response to bath-applied ACh. (B) ACh concentration-response curves 
from experiments such as the ones shown in A, performed in oocytes 
injected with either a3 or (34 monomer cRNAs (filled circles, /?=9) or 
|34_a3 tandem together with (34 monomer cRNAs (open circles, n=4). Full 
sets of peak responses to ACh from each oocyte were fitted with the Hill 
equation and normalised to the fitted maximum response before pooling. 
The curves shown are the results of the fitted data.
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7.8 Tandem-containing receptors have the same 
number and ratio of a3 and 04 subunits forming the 
channel pore as receptors produced by monomers
Everything appeared to be going to plan and this was as much validation of 
tandem-containing LGICs as any group had ever done. Nevertheless, we decided to 
check that the stoichiometry of the receptors formed was the 2a:3(3 seen with a3(34 
monomeric-construct receptors through the use of our 9' LT mutation (Boorman et al. 
2000). Figure 7.5 is taken from Boorman et al. 2000 and shows the effect of mutating 
either all the a or all the p subunits with a 9' LT TM2 mutation. This mutation is thought 
to disrupt the closed state of the receptor resulting in a reduction in the ECso value of the 
receptor (Revah et al. 1991). The degree of reduction is thought to be proportional to the 
number of copies of the mutation present in the channel pore. Using this mutation for the 
study of stoichiometry also relies on the assumption that the different possible positions 
of the mutation are equivalent. As can be seen in Figure 7.5 a larger shift was produced 
by the mutation being present in the p4 subunit than the a3 and the degree of shift 
corresponded well with a stoichiometry of 2a:3p.
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Figure 7.5: Stoichiometry of a304 nAChR expressed in oocytes from monomers 
cRNA is 2a:30. Curves show normalised inward current recorded at a 
holding potential of -70mV in response to bath-applied ACh for a3 + (34 
wildtype (circles,), a3LT + (34 (squares) and a3 + |34LT (triangles). Full sets 
of peak responses to ACh from each oocyte were fitted with the Hill 
equation as a free fit and normalised to the fitted maximum response 
before pooling. The curves shown are the results of the fitted data. Note 
the greater increase in ACh sensitivity when p4 was mutated, (from 
Boorman et al. 2000)
Therefore we created a (34_a3LT mutant construct and expressed it at the usual 2:1 
molar ratio with p4 monomer. If  the resulting receptor has the same stoichiometry as the 
monomeric receptors, this should produce a channel containing two copies of the a3LT 
subunit. Similarly the p4LT_a3 was also created and expressed with p4LT monomer to 
hopefully produce a receptor containing 3 P4LT subunits. Figure 7.6 shows the traces and
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dose-response curves obtained from these two receptor combinations. When Fig. 7.6 is 
compared to Fig. 7.5 it can be seen the two graphs appear very similar, even the 
“discrepancy” of the decrease in Hill slope seen for three copies of the mutation in Figure 
7.5 is reproduced by the all-p4LT mutations curve in Figure 7.6 (this decrease might be 
due to the impact of mono-liganded, or even spontaneous, openings of receptors 
containing three or more mutations). The numbers are summarised in Table 7.4 and as 
can be seen neither the EC$o nor Hill slope values differ significantly between the 
monomeric receptors and the corresponding tandem-construct receptor (unpaired two- 
tailed Student’s t-test). The difference in the actual EC so values between the Boorman 
results and the tandem were probably due to the differences in protocol covered in 
Chapter 4, but the relative changes in values caused by the mutations are remarkably 
consistent.
At this stage it certainly seemed that the (34_a3 tandem receptor had the same 
stoichiometry of the a3(34 receptor, or more precisely, that it incorporated two a and 
three p subunits in the channel-gating domain. Furthermore, it appeared that the use of 
concatenated subunits didn’t interfere with the effect of the 9' TM2 LT mutations, 
suggesting that the presence of the linker hadn’t greatly disrupted the either the binding 
or gating function of the receptor.
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Figure 7.6: The effects of inserting a L9'T reporter mutation into all the a or all the (3 
subunits in tandem construct receptors. (A) Examples of inward currents 
elicited by bath-applied ACh in oocytes expressing p4LT_a3 + f34LT (top) or 
P4_oc3lt + p4 (bottom). (B) Concentration-response curves from oocytes 
injected with p4LT_a3 + p4LT cRNAs (filled triangles, n = 7) or p4_a3LT + 
P4 cRNAs (filled squares, n = 8). The concentration-response curve for 
the p4_a3 + p4 wildtype nAChR is shown for reference (dotted line). The 
EC5o shifts produced by the mutations are similar to those observed in a3 
+ p4 receptors (see Figure 7.5) and suggest that the channel gate is 
made up of two a and three p subunits both in linked-subunit and 
monomer construct receptors.
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EC50
(MM)
/iH n Probable no. of 
mutations
p  value 
(monomer 
vs tandem)
EC50 nH
ct3p4 180 ± 17 1.81 ±0.09 7 0 - -
a3LTp4 5.8 ± 1 1.15 ±0.08 6 2 - -
<x3P4lt 0.75 ± 0.05 0.92 ± 0.08 4 3 - -
P4 a3 + p4 122 ±8 1.98 ±0.21 4 0 NS NS
P4 a3LT + p4 3.81 ±0.18 1.34 ±0.06 8 2 NS NS
P4lt a3 + p4LT 0.68 ± 0.02 0.98 ± 0.03 7 3 NS NS
Table 7.4: Comparison of the EC50 values and Hill slopes of the wildtype, all a and
all p mutant receptors for both monomer and tandem construct receptors. 
Note the comparable amounts of shift for the all a and all p mutations 
between both types of receptor construct. Statistical analysis by unpaired 
two-tailed Student’s t-test. NS = not significant.
7.9 Reporter mutations revels that tandem-containing 
receptors are misassembled
The final and most vital test to check that the use of concatenated subunits had 
effectively restricted stoichiometry was to ensure that each concatenated receptor 
contained only one monomer and two tandem constructs. A moment’s thought should 
allow the realisation that although mutating all the a subunits proves the, at least partial, 
incorporation of the tandem construct, the mutation of all the p subunits cannot identify 
where the individual p4 subunits come from, either from the monomer or from the 
tandem. To check this it is necessary to mutate either just the monomer or just the 
tandem’s P4 subunits. If  the receptor is forming correctly, the p4LT_a3 + p4 should 
produce a leftward shift comparable to that obtained for the p4_a3LT + p4 and if our
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findings are transferable from Boorman et al. 2000 then the p4_a3 + p4LT should be 
similar to the a3p4p3VT receptor in producing a leftward parallel shift intermediate 
between the wildtype and “two-mutations” curves. Figure 7.7 shows the traces and 
curves obtained for p4LT_a3 + p4, as can be seen the curve (solid line) bears no 
resemblance to the expected two-mutation curve (dash and dot) and instead is virtually 
indistinguishable from the wild type line (dotted line) (p4_a3 + P4: ECso = 122 ± 8 //M, 
«H = 1.98 ± 0.21, «=4; p4LT_a3 + p4: EC50 = 100 ± 4 juM, nH = 1.55 ± 0.10, «=11). 
There is possibly a small shift but it is barely significant and certainly nowhere near the 
~30-fold shift we were expecting. From this data it would appear that the p4 subunits of 
the tandem construct are not in the channel in the majority of receptors formed and that 
the bulk of the p4 subunits in the receptors must be non-mutated monomers.
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Figure 7.7: Low ACh sensitivity of linked subunit receptors carrying the L9T mutation 
in the tandem p4 only. (A) Examples of inward currents elicited by bath- 
applied ACh in oocytes expressing p4LT__a3 + (34. (B) Data from oocytes 
injected with (34LT_a3 + (34 cRNAs (filled squares, n = 7). The
LTconcentration-response curve for p4_oc3 + p4 (dotted line) and P4_a3 
p4 (dashed line) are shown for comparison purposes: the later showing 
the EC50 shift expected from two L9'T mutations.
This problem was confirmed when just the monomer was mutated. As mentioned 
above, had the receptor been forming properly, we would expect (34_a3 + P4lt to 
produce a curve intermediate between the wild-type and two-mutation curves, the dashed 
line in Figure 7.8 shows their geometric mean (22 /uM) as a guideline of where a one-
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mutation copy curve ought to be. However, the actual data from p4_a3 + p4LT shows a 
biphasic curve. The top part of the curve is near where the one-mutation guideline but 
the larger part of the curve (average = 58.6 ± 7.3 %, 77=13) was closer to the expected 
curve for three mutations. This is agrees with our interpretation of the results of mutating 
only the tandem (34 subunits, and confirms that the majority of the P4 subunits in the 
channel derived from the monomer construct i.e. mutated rather than from the tandem i.e. 
non-mutated. Fitting the curve with a two-component Hill equation gave ECso values of 
0.67 ± 0.1 and 31.7 ± 1.9 //M  ( 77= 8 ) .  As can be seen the values of the two components 
are close to the values obtained for three mutations (p4LT_a3 + p4LT; EC50 = 0.68 ± 0.02 
//M, «h = 0.98 ± 0.03, «=7) and to that expected and calculated for a one mutation curve 
(22 //M) by taking the geometric mean between no-mutation and two-mutation curves. 
However there was a large amount of variability from one oocyte to the next in the 
proportion of the two components. Thus the higher ACh sensitivity accounted for 21 to 
100 % of the total current (77 =13; cfr. 59% average). For display purposes, a subset of 
four oocytes with roughly comparable high- and low-sensitivity components was used to 
illustrate the biphasic nature of p4_a3 + P4LT in Figure 7.8.
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Figure 7.8: Inserting the L9T reporter mutation in the p4 monomer subunit of linked 
subunit in nAChRs reveals multiple receptor population. (A) Examples of 
inward current elicited by bath-applied ACh in oocytes expressing p4_oc3 
+ p4LT. (B) Concentration-response curves for oocytes injected with 
p4_a3 + p4LT cRNAs (filled circles, n=4). The initial fit was a 
simultaneous fit of a two component Hill equation to each dose-response 
curve, with the constraint of equal EC50 and Hill slope across oocytes (the 
proportion of the first component was allowed to vary). The three dotted 
curves shown for reference are, respectively, (right to left), the 
concentrations-response curves for no mutations (P4_a3 + p4), two 
mutation copies (p4_a3LT + p4) or three mutation copies (p4LT_ a3 + 
P4LT). The dashed curve shows the concentration-response curve 
expected for complete tandem incorporation as depicted in the cartoon 
(i.e. one mutation copy) calculated from the geometric mean of the none 
and two mutation curves.
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This hypothesis was confirmed with experiments carried out on oocytes injected 
with (34_a3LT + (34LT at a molar ratio of 2:1. If  everything was working correctly you 
would expect this to form a receptor containing three mutations which should be 
comparable to the |34LT_a3 + (34LT or the a3p4LT receptors.
a3a3 <x3
Figure 7.9: Diagrammatic representation of how the misassembly of a
tandem-containing receptor results in the tandems 04 subunits 
“hanging-out”. Note that there are two possible forms of 
misassembly, the partial misassembly (centre) with one tandem 
hanging out and the full misassembly (right) with both tandems 
hanging out. This would result in the incorrect no. of mutation 
being incorporated into the receptor if just the monomer or tandem 
P4 subunits are mutated (see Figure 7.11D, E & F).
However, if our interpretation of the data from the experiments with the tandem- 
and monomer-only mutations is correct, it implies that of the tandem construct “hanging 
out” this would produce a mixed population of receptors with the majority of |34_a3LT + 
p4LT receptors would contain four or five copies of the mutation (Figure 7.11). Receptors 
with more than three mutations are likely to give rise to a significant amount of
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spontaneous activity, which would manifest itself as high cell mortality and a high 
holding current which should be sensitive to a nicotinic channel blocker such as
• • • LTtrimetaphan. Certainly our previous attempts to record from oocytes injected with a3 + 
p4LT (expected to contain 5 mutations) resulted in a mortality rate of 16 out of 17 
oocytes, over multiple injection batches. Even incubation with 10//M trimetaphan 
starting immediately after injection could not totally abolish mortality. With trimetaphan 
incubation, we still observed a 20% mortality with an average holding current of -2663 ± 
339 nA for the survivors (n=5) rendering them unusable. These data can be compared 
with the 100% survival rate, and low holding current (-90 ± 24 nA; n=5) seen for wild- 
type a3p4 receptors in trimetaphan. Sure enough, p4_a3LT + p4LT injected oocytes had a 
survival rate of 43% (n= 14) and an average holding current of -550 ± 75 nA (n=6) in the 
survivors. If  injected cRNA levels were doubled to 8ng:2ng (tandem:monomer) this 
mortality rate reached 100% («=10) good evidence that this mortality was due to 
spontaneously opening channels. This holding current was decreased 46 ± 6 % (n=3) by 
application of 10 juM trimetaphan (Figure 7.10), a phenomenon not seen with receptors 
(both monomeric and concatemeric) with three or less mutations. Average mortality 
rates and holding currents for a range of injected oocytes are summarised in Table 7.5. 
Out of the p4_a3LT + p4LT oocytes which survived, some were healthy enough for us to 
obtain dose-response curves even if the holding currents were too high to allow enough 
confidence that the oocytes’ were clamped at precisely the correct voltage to allow them 
to be “officially” accepted. The properties of these dose-response curves tallied 
reasonably well with a receptor containing three copies of the mutation {ECso = 1.35, nW 
-  0.8, n=6). It appears, for whatever reason, these cells survived because they produced a
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greater proportion of correctly assembled receptors which were less prone to spontaneous 
opening and so produced curves closer to what was expected. In fact, if anything, these 
receptors had ECso values higher than what was expected for three mutations, an 
observation we now believe we can explain and will below.
200 nA
60s
ImMACh 10/A/I ImMACh
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Figure 7.10: Representative trace obtained from an oocyte injected with p4_a3LT + 
(34lt to bath applications of 1mM ACh and 10/A/I Trimetaphan. Note the 
agonist-like response to Trimetaphan and the full reversibility of its action. 
10/A/I Trimetaphan didn’t produce any response in any receptor complex 
known to have three or less mutations.
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Mean lH 
(nA)
Mortality
(%) n —
MQ -92 ± 13 0 11
a3 + 34 -122 ± 2 6 10 20
a3LT + P4LT - 94 17
a3 + P4(in Tri) -90 ± 24 0 5
a3LT + p4LT (in Tri) -2663 ± 339 100 5
|34a3 + p4 -130 ± 3 3 - 4
P4LTa3 + p4LT -549 ± 102 - 7
p4a3LT + P4lt -550 ± 75 75 24
(Low concentration) -550 ± 75 57 14
(High concentration) - 100 10
Table 7.5: Summary of the mean holding current, lH (± SEM) and mortality rates of a
oocytes for a range of injected combinations. A cell was classed as 
“dead” if it had lysed or had a holding current in excess of 1 //A. Also given 
are the values for cells incubated in 10/zM trimetaphan after injection “(in 
Tri)”. The results for p4_a3LT + P4LT are also separated into “low 
concentration” (4ng:1ng) and “high concentration” (8ng:2ng) injections.
I  rp  I T I T
Constructs for the remaining combination |34 _a3 + P4 was not even
prepared as we decided early on that it would shed no light on the receptor’s 
stoichiometry or this problem with mis-assembly and in all likelihood would experience 
all the problems with high mortality rates and holding currents seen with a3LT + p4LT and 
(S4_a3LT + (34l t .
Figure 7.11: (following page) Diagrammatic representations of different nAChR 
assemblies which may be formed by complete (left) or partial 
(centre and right) incorporation of linked constructs into the 
receptor. B-F show the effects of introducing a reporter mutation 
(a Thr in the 9' position of the second transmembrane domain) in 
different subunits. The number under each cartoon shows the 
number of mutation copies expected to be in the channel gate for 
each receptor assembly. Note that no heterogeneity in the 
number of mutation copies is predicted if all a, all p or no subunits 
are mutated (A-C) in accord with the experiments shown in 
Figures 7.4 and 7.6. Mutating p only in the monomer construct or 
only in the tandem construct (D and E) can detect the different 
receptor forms (Figures 7.7 and 7.8). If receptors are expressed 
in which both the tandem a and p monomer bear the mutation, 
some receptors will bear five copies of the mutation (F).
175
^  P4_a3tandem + 04
04LT_a3 tandem + 04'
^  04_a3LT tandem + 04
04_a3 tandem + 04'
1 2 3
^ 04LT_a3 tandem + 04
2  1 0
^ 04_a3u tandem + 04lT
7.10 Discussion
The cartoon in Figure 7.11 summarises our interpretation for our observations 
when mutations were inserted in the different subunits with (34_a3 tandem receptors. As 
can be seen the problem of incomplete incorporation would not be apparent when the 
subunits expressed were either all wildtype, or when all a  or all (3 were mutated (7.11 A, 
B & C), This is because, whatever the exact formation of the receptors, the same number 
of mutations would be present in the gate of each receptor assembly. Mutation of just the 
monomer (7.1 ID ) or just tandem (7.1 IE) p4 subunits would produce the unexpected 
shifts we saw in Figures 7.7 and 7.8 whilst 7.1 IF shows how receptors with more than 3 
mutations would be produced.
At the time of publication there was one inconsistency in our data we had 
difficulty explaining. The (34LT_a3 + p4 data suggest that in the majority of receptors all 
the p4 subunits came from the monomer. If  that has been the case for (34_a3 + (34lt , we 
should have seen a single component curve representing receptors with three mutant 
subunits. The biphasic curves obtained suggested at least two stoichiometries were 
present and it was assumed this was due to the presence of both the correctly assembled 
(one mutation) and completely incorrectly (three mutations) receptors. The intermediate 
stoichiometry (two copies of the mutation, with one p4 subunit coming from a tandem 
and the other two coming from the monomer), couldn’t be ruled out because of the 
limited sensitivity of fitting multiple components to a dose-response curve. There was 
great variability in the proportion of the two main components present, with three of the
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13 oocytes tested having just the high sensitivity component i.e. the majority of,receptors 
being totally mis-assembled, just like p4LT_a3 + p4, in those that did display two- 
components the high sensitivity component still made up the majority of the receptors 
(-60%). This inconsistency was only a minor irritant and didn’t detract from our main 
conclusion that tandem constructs can mis-incorporate and therefore can not be trusted to 
restrict stoichiometry. Later work, covered in the next chapter, may go some way into 
resolving this apparent inconsistency.
The assumption in the interpretation is that the same mutation has the same effect 
regardless of which subunit carries it and where the subunit is within the receptor. This 
assumption could not be tested until the use of concatenated subunits, and there was 
evidence for and against it. On the one hand, in Boorman et ah 2000 for instance, the 
effect of mutating an individual a3 subunit (dose ratio = 6.11) was comparable to 
mutating an individual p4 subunit (dose ratio = 6.63) although it must be borne in mind 
that these finding were the averages of two or three mutations and as such may obscure 
individual variations due to exact subunit position not to mention the possibility and 
effect of multiple a3p4 stoichiometries. However, in the muscle nicotinic receptor 
mutations of the 12' residue in TM2 has a greater effect for the 8 than for the a subunit 
(Grosman and Auerbach, 2000). Of course the problem with the evidence that the effect 
of the mutations were not equivalent in muscle receptors subunit is that the actual subunit 
with the mutations differs from position to position. One of the whole points of using 
concatenated subunits was to answer this equivalent/non-equivalent dilemma. As will be 
shown in the next chapter, we have since discovered that a TM2 9' leucine to threonine 
mutation of p4 is less effective if the p4 is the non-binding site p4 subunit, with a dose-
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ratio of around 3.2 rather than the ~6.6 expected. This position corresponds to that taken 
by p3 and is the subunit provided by the monomer in a correctly assembled tandem 
receptor.
In that case a reappraisal of Figure 7.8 shows that the component that was 
originally suspected of being the correctly-formed, one-mutation, receptor is more likely 
to be the partially mis-assembled, two mutation receptor meaning the correctly formed 
receptor must only constitute a very small sub-population of the receptors formed and 
whose component is probably “smeared” into the two-component curve thus making its 
ECso slightly higher that that predicted for two mutations.
This reappraisal helps to resolve better the apparent discrepancy between Figures 
7.7 and 7.8 as both now represent receptor populations where the large majority of 
receptors are mis-assembled. This realisation that the mutated monomer (34 subunit in a 
correctly assembled receptor has only a limited effect on the receptors ECso also explains 
the observation with p4_a3LT + P4LT receptors, that whilst the majority of oocytes 
expressed mostly mis-assembled receptors resulting in spontaneous openings and high 
cell mortality those few cells which, for what ever reason, produced correctly assembled 
receptors and survived to be recorded from, produced curves with a higher ECso than 
would be expected from three mutations. What in fact we were seeing was the addition 
of the less effective non-binding site p4 mutations with the two a3 subunit mutations to 
produce a curve only slightly to the left of that obtained from the two a3 subunits 
mutated alone. If  what we suspect is correct about the non-equivalence of mutations in 
concatenated subunits applies to monomeric subunits this would explain why the all a- 
and all p- mutant curves for both tandem- and monomer-containing receptors match so
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well as the net effect of this non-equivalence would apply to both sets of receptors and 
would average out.
An argument could be made that, like the a4p2 receptor (Nelson et al. 2003), 
a3p4 receptors may not be all of a 2a:3p stoichiometry but instead might display 
alternate stoichiometries, the most likely one being a 3a:2p one and this might be a 
contributory factor to the problems seen with our research on tandem constructs of the 
a3p4 receptor. This possibility was examined in detail (see Chapter 9): although our data 
show that a3p4 can produce receptors of a 3a:2p stoichiometry, this only occurs in 
oocytes when the conditions are changed to force it, with extreme expression ratios. 
Under normal conditions the vast majority of a3p4 receptors produced by oocytes have a 
stoichiometry of 2a:3p. This was confirmed in our paper, Boorman et al. 2000. 
Examination of our data also helps to rule out alternate stoichiometries in the tandem 
experiments as a significant factor. Firstly, for a3p4 tandem-constructs to produce a 
functional receptor with 3a, the third a would have to be provided by the tandem either 
through proteolysis or through the creation of a dipentamer, neither of which we could 
detect. Secondly, p4_a3 + a3 does not produce significant amounts of functional 
receptors. Finally, it is hard to see how the clear cut differences witnessed in Figure 7.6 
between all-a and all-p mutated receptors could occur if the two different ratio 
stoichiometries were both present in significant amounts even with the complicating 
factor of non-equivalence. If  both stoichiometry ratios were present you’d expect both 
the all-a and all-p mutants to average out at two and a half mutations each, with the non­
equivalence factors probably cancelling out, causing the two dose-response curves for 
these receptors to be identical. There was no evidence of this and therefore we can
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conclude that, irrespective of the problems in interpreting the data, .alternate 
stoichiometries are not a significant factor in these p4_a3 tandem-construct receptors.
Although the mis-assembly of tandem constructs is the simplest explanation of 
the problems with our data, a more convoluted hypothesis is that the receptors are 
forming correctly but that the linker has changed the properties of the receptor so as to 
produce the odd results we see in Figures 7.7, 7.8 and Table 7.5. Although we have no 
direct evidence against this, it is hard to see how such an effect could explain why the 
receptors appear to be assembling correctly when all the a or all the (3 subunits were 
mutated in Figures 7.4 and 7.6 yet misbehave when it came to mutating the monomer or 
tandem alone. Even if this more unlikely hypothesis was correct, it would imply that 
tandem-containing receptors were acting differently from monomeric. In itself this 
would mean the tandem technique had failed to reproduce a monomeric-like channel.
These findings on their own are disappointing for our hopes of using concatamers 
as a tool for restricting the stoichiometry of a3p4* receptors, but they may have a wider 
importance namely is this problem unique to P4_a3 constructs or is it common to all 
tandem constructs? Problems had already been noted with proteolysis (P2Xj receptors, 
Stoop et al. 1999; Nicke et al. 2003), dipentamers (a4*p2, Zhou et al. 2003) and mis- 
assembly (K+ channels, Liman et al. 1992). Furthermore the initial work on cyclic 
nucleotide-gated channels using concatenated subunits has since been contradicted by 
more recent findings (Zimmerman, 2002) and rearrangement of the tandem dimer has 
been reported in GABAa constructs (Baumann et al. 2001). So can we conclude that 
these problems are endemic to the use of all tandem concatemers? Well at the moment 
we can’t say for sure: however, the fact that these errors have emerged every time these
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problems have been checked for is worrying. What adds to this worry is the fact the 
receptors superficially appeared to be working perfectly and the problem with mis- 
assembly only became apparent after an extensive amount of work. It was dangerously 
tempting to have just carried out the basic tests on the tandem constructs i.e. check there 
was no proteolysis and that the tandem receptor was similar to the monomeric receptor 
and then assumed everything else was fine, publish and carry on our research with our 
work based on flawed assumptions. The majority of concatemer construct research has 
just carried out these basic tests and then leap-frogged onto doing more “interesting” 
work with the assumption that everything is OK. For absolute peace of mind, however, 
these other groups should return to their basic work on concatemers and ensure that their 
stoichiometries are correct. This however is unlikely to happen and this means a large 
body of research from the last decade may be fatally flawed.
I shall use a more recent paper as an example of this. It has been suggested that 
the rearrangement of tandem dimers and dipentamers only occurs if monomer subunits 
are also expressed and as such only dimer/triplet combinations i.e. a dual and triple 
subunit constructs should be used (Minier and Sigel, 2004). It could be argued that the 
problems we see were only due to the presence of monomers and may have been avoided 
had we used a dual and triplet construct combination. The Berezhnoy et al. paper of 
2005 is a study of the benzodiazepine action on GABAa channels and uses a y2_p2_al 
and P2_al combination of concatenated constructs to restrict stoichiometry and allow the 
mutation of a single a subunit at a time, therefore only affecting one binding site. 
Amongst the findings of this paper was one glaring inconsistency, which the Authors 
could not explain but however was perfectly understandable if their constructs were not
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assembling correctly and as such might render their entire findings null and void. They 
used tandems and trimers to restrict the stoichiometry of the GABAa receptor so that an 
inserted mutation would only be present in just the benzodiazepine-binding site and so 
the covalent modification of the receptor by the NCS-compound should be prevented by 
the presence of the benzodiazepine, Ro-15-1788. In fact the NCS-compound caused 
covalent modification even in the presence of Ro-15-1788 and was only blocked when 
GABA was present as well. This indicates that the mutation wasn’t restricted to just the 
BZD site and was present in the GABA-binding site and therefore the receptor was 
misassembled, probably with hanging subunits. They tried to explain away their problem 
citing thermal mobility of the receptor. This demonstrates that the problem with mis- 
assembly is wider spread than just the |34_a3 constructs, is affecting the interpretation of 
data and can also affect the dimer/triplet combinations suggested as a solution to some of 
the tandem approach’s problems.
So can the use of tandem (and triplet) constructs be saved?
One possible remedy would be to change the linker. Lengthening the linker is 
more likely to increase mis-assembly, but it is possible that shortening the linker may 
restrict the assembly better so the p4 subunit of the tandem is preferentially inserted 
ahead of rogue |34 monomers. However against this possibility we must count the fact 
that maybe the a3_p4 construct did not work because the a3_p4 linker (45 residues) was 
too short (cfr. the 60 residue in the p4_a3 linker). Also there is the possibility that shorter 
linkers may encourage the formation of dipentamers and tandem-only receptors. The
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inclusion of the signal peptide could also be reconsidered, although it is hard'to predict 
what its effects are removing it may cause proteolysis or affect membrane insertion, 
subunit assembly etc. Paradoxically though, via the creation of secondary structures, the 
signal peptide may actually shorten the linker, which in this context can only be 
beneficial and problems with proteolysis, subunit assembly etc. are not what we are faced 
with. The main practical problem is that the amount of work needed to create the new 
constructs, test them for function and then check their stoichiometry in assembling is 
prohibitive: the amount of work covered in this chapter took over two years, on and off, 
and as such would be unlikely to be worth it even if it succeeded.
Another possibility would be to change the tandem:monomer ratio injected. The 
choice of a molar 2:1 ratio for the injection was based on the assumption that tandem 
fusion proteins were translated with the same efficiency as the equivalent weight of 
monomer cRNA would produce. If  this was the case exactly twice as many tandem 
constructs would be created as monomers avoiding any excess or rogue subunits to be left 
without a receptor. This assumption appears flawed in hindsight, the tandem + monomer 
combinations injected produced substantially lower currents than the equivalent amount 
of monomer cRNA did. The less efficient translation efficiency of concatenated 
constructs has also been reported elsewhere (e.g. 5:1 ratio needed for triplet:tandem 
receptors Baumann et al. 2001). Also, as will be seen in the next Chapter the efficiency 
of expression of the more complicated constructs is massively lower than that of 
monomers. The net result of this is that maybe our 2:1 ratio resulted in an effective 
excess of p4 monomers, which might explain why the mis-assembled stoichiometries 
appear to the preferred formation of receptor. Therefore, a possible way forward may lie
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in increasing the relative amount of tandem injected (or decreasing the amount of 
monomer). The problems with this would be, first, the prohibitive amount of work 
required to optimise the correct ratios and secondly the possibility of going too far the 
other way and producing an excess of tandems which could result in the formation of 
dipentamers.
Even if either of these modifications solved the problem of mis-incorporation of 
(34_a3 tandem constructs, it wouldn’t change the wider point that the rest of the 
“tandem” field have, for the most part, not optimised their linkers or injection ratios and 
as such may still have drawn erroneous conclusions from their data. To go back and 
check all these different constructs and modify their parameters would be a Herculean 
task. Instead we decided to take the approach covered in the next Chapter, the creation of 
a pentameric construct.
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CHAPTER 8
The Creation and Evaluation of 
Pentameric Constructs of a LG 1C
186
This work has been published as:-
Groot-Kormelink P.J, Broadbent S.D., Beato M, and Sivilotti L.G.
Constraining the expression of nicotinic acetylcholine receptors using pentameric 
constructs. Mol Pharm. (2006) 69(2): 558-63. (see White, 2006 for a review).
As discussed in the last chapter, an important aim of heterologous expression is 
the production of receptors with the complex stoichiometries of native receptors and the 
patterns of mutations seen in channelopathies. This problem was thought to have been 
solved by the development of concatenated subunit techniques. As detailed in the 
previous chapter, problems have now become apparent which may throw the whole 
concatenated approach and the findings obtained from them into doubt. Possible 
solutions to these problems were covered at the end of Chapter 7. With a tremendous 
amount of work, extreme vigilance and exhaustive controls, it could be possible to use 
tandem and triplet constructs and be sure that the receptors produced do have the 
stoichiometry and make-up wanted. Alternatively, the problems uncovered could be 
circumvented by producing a pentameric construct. In this chapter I shall record our 
attempts to produce a functional pentameric concatemer of a nAChR free of the problems 
associated with the tandem and triplet concatemers.
It had always been a long-term goal to use the tandem and triplet concatemers as 
stepping-stones for the production of a pentameric concatemer i.e. a functional channel 
made up of five linked subunits. Such molecules are not totally unknown in nature; the 
voltage-gated sodium channel is comprised of a large 260kDa channel-forming a subunit 
in association with one or more auxiliary p subunits. This a subunit is made up of four
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linked domains (I-IV) each made up of six transmembrane segments (S1-S6) (see Figure 
8.1) and as such is analogous to other receptor channels made up of concatenated 
monomers (compare with the cartoon in Figure 8.2).
Figure 8.1: Schematic representation of the sodium-channel subunits The a subunit 
of the Nav1.2 channel is illustrated together with the (31 and (32 subunits, 
(from Yu and Catterall 2003)
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BFigure 8.2: A) Linear representation of the pentamer construct in the cell membrane. 
Inserted linkers indicated by black rectangles.
B) Expected orientation of the (34p4a3p4a3 construct. Linkers shown by 
arrows.
Even without the tandem/triplet problems of dipentamers, proteolysis and mis- 
assembly reported by Zhou et al. 2003, Nicke et al. 2003 and Groot-Kormelink et al. 
2004, functional pentamers may well be preferable as they may in principle offer a far 
greater control of stoichiometry and allow the precise insertion of one or more mutations 
anywhere within the receptor complex.
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8.1 Creation of a pentameric channel
As in previous work, we focussed on the a3(34 receptor, as this was the 
combination we were most familiar with, was thought at the time to have a set 
stoichiometry, had produced functional p4_a3 tandem-containing receptors and we 
already had existing a3*(34 trimer constructs. These trimer constructs had been produced 
and partially tested before the project was abandoned due to the mis-assembly of the 
tandem constructs. Some trimer + dimer combinations (p4_a3_p4 + P4_a3 and 
p4J34_a3 + p4_a3) had been found to express functional receptors, producing currents 
in the tens-of-nA range for a 10ng:2ng injection (« = 2). Due to the “success” of tandems 
of the p a orientation and the initial findings from the trimer + dimer work, a pentamer 
construct of the stoichiometry p4_p4_a3_p4_a3 (ppapa) was created.
The pentamer constructs were produced by Dr Paul Groot-Kormelink as described 
previously: the existing dimer and trimer cDNAs were linked into a pentameric construct 
which was then used to prepare the cRNA.
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8.2 Comparison of the pentameric vs the monomeric 
receptor
These constructs were injected into oocytes, which were then tested for ACh 
sensitivity. The (3(3apa construct was found to produce sizeable inward currents of a 
similar shape to those seen for a3 + p4 and P4_a3 + p4 receptors.
The first question is whether it does resemble the monomeric receptor. Figure 8.3 
shows the traces and concentration-response curves obtained for the monomeric a3p4 
(1:9 ratio) receptor and the PPaPa receptor. The 1:9 a3p4 ratio is used in the 
comparison, in order to ensure the majority of the monomeric construct receptors were of 
the same 2a:3p stoichiometry as the PPaPa receptor (it will be shown in Chapter 9 that 
a3p4 can also form receptors of a 3a:2p stoichiometry and that at 1:1 ratio a small 
proportion of these may be present). As can be seen, the responses are very similar both 
in time course and ACh sensitivity. Analysis of the concentration-response curves 
revealed small differences in the ECso values (137.8 ± 13.7 //M  vs. 95.0 ± 10.7 //M, n=6 
and 4, for the monomer and pentamer constructs, respectively; /?<0.05, two-tailed Student 
t-test), but not in the Hill slopes of the two receptors (1.79 ± 0.14 and 1.71 ± 0.13, 
difference not significant, unpaired two-tailed Student’s t-test). The pentamer values do 
not compare too badly with the wildtype p4_a3 + P4 receptor either {ECso = 122 ± 8 juM, 
«H = 1.98 ± 0.21, n=4, differences not significant, unpaired two-tailed Student’s t-test). 
This is not a perfect match but it is reasonable for a linked receptor.
It would not be too surprising if it turned out the pentamer linkers have affected 
the properties of the channel. Other possible explanations include the presence of small 
residual populations of the 3a:2(3 receptor, which would be expected to increase the ECso
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value in the monomer-injected oocytes. This is pretty unlikely as receptor heterogeneity 
should also decrease the Hill slope.
Another possibility is that that the monomeric 2a:3p receptor (but not the 
pentamer-expressed receptor) might exist in different topologies, with slightly different 
properties. Different formations of the 2a:3p receptor sound unlikely but can not be 
ruled out at this stage; a monomeric receptor of a pppaa formation seems unlikely but 
must be borne in mind.
The responses produced by the ppapa injection were large enough to allow us to 
obtain concentration-response curves (mean /max = 222 ± 49, n= 13) with individual /max 
values reaching up to a respectable 610nA. These results were however achieved by 
injecting high cRNA concentrations (100 ng//A) and we found that further increasing the 
cRNA concentration up to 2 and 3 jug/ju\ (the realistic upper limit of cRNA 
concentration), failed to increase the size of current produced (if anything it declined).
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Figure 8.3: a3p4 neuronal nicotinic receptors expressed from the pentameric cRNA 
construct have ACh sensitivity similar to that of receptors expressed from 
monomeric cRNA constructs
(a, b) examples of current responses elicited by increasing ACh 
concentrations on the two types of receptors
(c) concentration-response curves for a3 + p4 (monomeric) receptors and 
for the a3 + p4 (pentameric) receptors (n = 4 and 6, respectively). Lines 
are fits of the data with the Hill equation.
All responses were recorded from Xenopus oocytes voltage clamped at - 
70 mV in nominally calcium-free solution.
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8.3 Action of a competitive antagonist on the 
pentameric receptor
The EC50 and Hill slope of a receptor are fairly unsatisfactory ways of comparing 
receptors. A much more robust comparison can be obtained by measuring the shift 
produced by a competitive antagonist in the concentration dependence of agonist 
responses (i.e. dose-ratios). We have in the past done this for the competitive antagonist 
trimetaphan and a3(34 receptors expressed from unlinked constructs (Boorman et al. 
2003). We now found that dose-ratios to 0.2 /iM  trimetaphan are very similar in 
pentamer-expressed receptors, with values of 4.35 ± 0.38 (n = 10) and 5.01 ± 0.37 (n = 4) 
for unlinked and linked constructs, respectively. Because the magnitude of this shift is a 
direct expression of antagonist affinity, this indicates that the (overlapping) 
agonist/antagonist binding site is very similar in the two types of recombinant receptors.
8.4 Does the pentamer assemble correctly?
Thus, we have shown that the pentamer constructs form receptors similar to 
monomeric receptors in its ACh and trimetaphan sensitivity. However, having detected 
mis-assembly of tandem-containing receptors, we now have to make sure that the same 
does not apply to pentameric construct receptors and that these receptors contain the 
correct complement of subunits as dictated by the construct design. This also entails 
checking that there is no significant proteolysis (at least into functional fragments) and no 
formation of dipentamer receptors etc.
First we checked if the in vitro synthesised cRNA was of the correct length and 
that no RNA breakdown had happened. Conceivably, if there is sufficient contamination
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by breakdown products, the functional receptors we observed may not be produced by the 
linked, five-subunit construct as we wish, but by the contaminant. The cRNA gel 
electrophoresis experiment shown in Figure 8.4 allowed us to discount this possibility: all 
the constructs used showed one clean band of the appropriate molecular weight on the 
gel, indicating that construct impurity or breakdown was not a problem at RNA level.
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Figure 8.4: RNA gel-electrophoresis of capped cRNA constructs used for Xenopus 
laevis oocyte injections. Approximately 1 pg of a3 (1), (34 (2), (34_a3LT 
tandem (3), a3LT (4), (34LT (5), (34J34_a3_(34_cx3 penta (6),
(34LT_(34_a3_p4_a3 mutant penta (7), (34_f34_a3_(34_a3LT mutant penta 
(8), and p4LT_p4_a3J34_a3LT mutant penta (9) were separated on a 1.5% 
agarose-gel. The 0.24-9.5 Kb RNA ladder is indicated on the left. The 
predicted cRNA sizes are; 1.8 kb for a3 and p4 monomers, 3.4 kb for 
p4_a3 tandem, and 8 kb for the pentameric constructs.
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It is of course possible that problems may arise after the cRNA is injected into the 
oocyte: our pentameric fusion protein may not really assemble as a pentamer because 
either the cRNA is broken down in the oocyte or because degradation occurs at protein 
level. It is important to assess whether this happens, because such a process could in 
principle render pointless our effort in constraining the topology and composition of the 
receptor. A straightforward way of testing this would be to check the size of either the 
individual proteins (by Western Blotting) or the assembled complex (by sucrose-gradient 
separation). However, these methods are not very sensitive and cannot differentiate 
between total receptor protein and surface-expressed functional receptors. A small 
quantity of breakdown products could be enough to produce the functional channels 
observed and still escape biochemical detection. Similarly, Western Blotting may pick up 
rogue functional monomer subunits but, given that the epitope recognised by the antibody 
can be masked in linked subunits, wouldn’t necessarily detect functional dimer or trimer 
fragments, as mentioned in the last chapter and reported elsewhere (Baumann et al. 
2001). We therefore decided to perform a more sensitive functional test to check for the 
presence of breakdown products and incomplete incorporation, and chose a reporter 
mutation approach using the L9T TM2 mutation.
Co-injecting the pentameric construct with excessive levels of mutated monomer 
or tandem construct would “kill two birds with one stone”.
One possibility was that the channels we are detecting are the result of the 
pentamer being proteolysed into functional monomeric, dimeric, trimeric and even 
tetrameric fragments which then reassemble into a receptor (obviously with 
unconstrained stoichiometry). By co-injecting with an excess amount of mutated
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subunits (note that the mutated subunit alone is incapable of forming a receptor 
homomerically) these proteolytic fragments would preferentially form receptors with the 
mutated subunits resulting in receptors incorporating one or more of the L9'T mutations. 
Therefore the concentration-response curves of these mis-assembled receptors would 
display a shift in their ECso values. Even if our assumption that the mutated subunits 
were not in excess we would still expect a sizeable subpopulation of the formed receptors 
to contain the mutations and therefore the concentration-response curves would at least 
become multi-phasic. Injection with a high concentration of a3LT should detect any 
rogue p4 monomers, p4_p4 dimers or P4_p4_a3_p4 tetramers and it would also show if 
any 3a:2p receptors were forming, possibly by co-assembling with p4_a3 and a3_p4 
dimers or p4_a3_p4_a3 tetramers. Injection with a high concentration of p4LT should 
detect any rogue a4 monomers, p4_a3 dimers, a3_p4 dimers, a3_p4_a3 trimers or 
P4_a3_p4_a3 tetramers. Even unexpected formations of, say, a trimer-only receptor 
formed by partial incorporation of constructs leaving hanging subunits should be 
detected. Of the different possible functional fragments there was one which wouldn’t be 
detected by co-injection with a single a3LT or p4LT subunit, the p4J34_a3 fragment. 
Such a fragment could however assemble into a receptor with its cleaved end P4_a3 
dimer or form a receptor with another trimer, leaving a hanging subunit. Obviously we 
couldn’t co-inject the pentamer with both a3LT and p4LT monomers as these could form 
receptors in their own right. Therefore, in order to check for this fragment we also co­
injected the pentamer with excess p4_a3LT tandem. This could assemble with the 
P4_p4_a3 fragment, to form a receptor containing a single a3LT mutation.
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The other possibility was that unconstrained receptors could form because of 
multiple pentameric fusion proteins participating to the same receptor assembly. At one 
end of the spectrum, it may be only two pentamers and a single hanging subunit, at the 
other it could five individual pentamers coming together and contributing one subunit 
each. These in turn could in principle produce higher order structures with “rafts” of 
pentamers forming multiple channels. It is hard to know whether these channels would 
be functional or indeed if their low level of function is the cause of the low functional 
“expression” of pentamers discussed at the end of this chapter. The real nightmare 
scenario would be a combination of both functional proteolytic fragments and pentamer 
rafts producing a complete mess which somehow still seemed to resemble the monomeric 
receptor in pharmacological properties. Such scenarios do not sound likely, but our 
experience with mis-assembled tandem receptors taught us to take nothing for granted. 
For example, who would have believed that not only was the completely mis-assembled 
tandem receptor possible but was actually the preferred stoichiometry! Either way all our 
hopes of constraining stoichiometry would go out of the window.
These possibilities ought also to be detected by the co-injection of mutated 
subunits in excess, as these should be the preferential candidates for mis-incorporation 
and should produce mutation-containing receptors causing changes in the concentration- 
response curves of the resulting receptors.
As previously noted, the efficiency of expression appears to be impaired for 
concatenated subunits. An alternative explanation could be that expression has not been 
affected greatly by linking, but that receptors made up by concatenated subunits are less 
functional than monomeric receptors, with a lower Popen, for instance. This appears
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unlikely: concatenated subunit receptors have ECso that is very similar to monomeric 
construct receptors and this could not be if their maximum Popen were grossly reduced. 
Also when Dr. Marco Beato attempted to perform single-channel studies on pentamer- 
injected oocytes he found that the large majority of the patches pulled were “blank” 
rather than that they were expressing “low Popen” functional receptors, further anecdotal 
evidence that the low currents seen are a problem with expression rather than function 
(see discussion at the end of this chapter).
An important decision in the experimental design is how much mutant monomer 
should be injected in these tests vs. the pentamer. Because efficiency of expression and 
incorporation are much greater for monomer construct, deciding simply considering the 
ratio between the quantity of cRNA injected for monomer and pentamer grossly 
underestimates the size of the excess in monomer. A better quantification of that is given 
by the level of functional expression achieved by the different constructs. The top traces 
of Figure 8.5 show that functional expression of monomers (estimated by measuring 
maximum ACh responses to ImM) is approximately an order of magnitude larger than 
that of monomer plus pentamer, even though the actual ratio of cRNA concentration was 
actually 0.25ng:100ng (mutated subunit:pentamer). Thus, 0.25 ng of a3LT, p4LT or 
p4_a3LT cRNA produced several juA of current if injected together with the appropriate 
wild type monomer at the correct concentration (5570 ± 890 nA, n = 10, 2342 ± 393 nA, 
n=6 and 1790 ± 500 nA, n=8 respectively) but only half a //A if injected with pentamer 
cRNA (570 ± 151, 621 ±97 and 119 ± 38 nA, respectively).
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Figure 8.5: Example traces give an estimate of the extent of the functional excess of a3LT, p4LT and (34__a3LT subunit cRNA 
injected, compared to the pentamer, by showing that the same quantity of monomer or tandem cRNA 
produced very large functional responses if co-expressed with the appropriate monomer.
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Figure 8.6: (previous page) Expression of an excess of a3LT (Top), (34LT (Middle) or 
|34_a3LT (Bottom) together with the pentamer construct does not result in 
incorporation of the mutant monomers into functional receptors. The 
concentration response curves obtained from receptors expressed after 
co-injection of mutant monomer with wild-type pentamer constructs (full 
circles and continuous lines, n=4 for all) were not significantly different 
from those obtained after expression of wild-type pentamer alone (dashed 
curves) (unpaired two-tailed Student’s t-test).
Figure 8.6 shows the concentration-response curves obtained when the pentamer 
was injected with high concentrations of mutated monomer or tandem. As can be seen 
there is very little difference between the dose-response curves obtained from the 
pentamer in the absence or presence of high concentrations of “loose” mutated subunits 
(wild-type pentamer alone, i.e. P4_f34_a3_(34_a3: EC so = 95.0 ± 10.7 //M  = 1.71 ±
0.13, «=4; wild-type pentamer + a3LT: ECso = 95.0 ± 10.7 fiM t?h = 1.35 ± 0.13,77 = 4; 
wild-type pentamer + p4LT: ECs0 = 75.8 ± 5.1 //M  77h = 1.39 ± 0.11, 77=4; wild-type 
pentamer + (34a3LT: ECs0 = 71.0 ± 6.7 //M  77h = 1.32 ± 0.14, 77=4, differences not 
significant, unpaired two-tailed Student’s t-test). If  there were any breakdown or mis- 
assembly, these curves would be expected to be closer to those obtained from receptors 
containing one, two or even three copies of the mutation.
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Figure 8.7: Expression of a vast excess of a3LT (Top) or (34LT (Bottom) together with the
pentamer construct results in partial incorporation of the mutant monomers into 
functional receptors. The concentration response curves obtained from 
receptors expressed after co-injection of mutant monomer with wild-type 
pentamer constructs (full circles and continuous lines, n = 4  for all) differ from 
those those obtained after expression of wild-type pentamer alone (dashed 
curves).
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If  the injected concentration of rogue monomer (a3LT or (34LT) was further 
increased to the equivalent of that needed to produce over twenty-five-fold the current of 
that produced by the injected pentamer RNA concentration (wild-type pentamer 
P4p4a3p4a3 + a3LT: 7max = 326 ± 147 nA; a3LT + p4: 7max = 7235 ± 1187 nA; wild-type 
pentamer + p4LT: 7max = 525 ± 196; a3 + p4LT: 50 //M  produced a current in excess of 13 
//A, amplifier saturated) some mis-assembly could be produced (Figure 8.7). As can be 
seen, the pentamer plus a3LT curve was significantly different from the wild-type 
pentamer (ECso' P < 0.001, n^. not significant, unpaired two-tailed Student’s t-test)
LTshifted to where we would predict an a3p4 monomeric receptor containing a single a3 
mutation would be. This suggests that a single rogue mutant monomer subunit was
T r-T
incorporated into most or all of pentameric construct receptors. The pentamer plus p4 
curve was intermediate between the wild-type pentamer and the predicted single P4LT 
mutation curve indicating partial mis-assembly although neither ECso nor Hill slope 
values were significantly different from the wild-type pentamer (unpaired two-tailed 
Student’s t-test). These results are not really worrying as they conclusively prove there 
is no complete breakdown and they show that, if mis-assembly was occurring when we 
injected less monomer in the experiments shown in Figure 8.6, it would have been 
detected.
These results are very reassuring and suggest that gross misassembly of the 
pentamer constructs is unlikely to occur in normal circumstances.
These experiments may also provide some insight into the post-translational 
assembly of receptor complexes. The most likely explanation of the a3LT subunit
204
induced mis-assembly was that it replaced the “trailing” a3 subunit as replacement of the 
“central” a3 would necessitate the disruption of the receptor complex and the 
replacement of the missing subunits with either a triplet fragment or another pentamer, an 
overly complicated hypothesis none of which we have any evidence for. A similar line of
LTreasoning would conclude that the most likely p4 subunit to be displaced by a single p4 
monomer would be the “leading” p4 subunit. The shallow slope of the pentamer plus 
p4LT curve of Fig. 8.7 would indicate a mixed population of receptors, most probably a 
roughly equal split between correctly assembled pentamers and receptors with a single 
incorporated p4LT monomer, rather than a single population of pentamers all 
incorporating one p4LT monomer but with a lesser effect on the EC50 value due to 
mutation non-equivalence. It is tempting to conclude from this that the “trailing” 
subunits may be more “floppy” i.e. more easily displaced than the “leading” subunits.
These experiments not only suggest that there is no breakdown, but also confirm 
that the receptor expressed from pentamer constructs contains the pentameric fusion 
protein in its entirety, as intended, in all but the most extreme circumstances. If  this was 
not the case and more than one pentamer participated to the formation of a single 
receptor, for instance contributing one or two subunits, we would expect to see 
preferential incorporation of monomer or tandem constructs into such receptors and 
therefore shifts in the dose-response curves. Having developed a functional pentamer, 
shown it resembles monomeric receptors and, after exhaustive testing, found no 
significant evidence of breakdown or mis-assembly can we use pentamers to help study 
LGICs.
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8.5 Testing a pentamer mutant construct
As mentioned earlier one of the big unknowns about LGICs is whether the effect 
of mutations in specified subunits is equivalent, and independent of subunit type and 
position. This was one of the questions we hoped would be answered by the 
development of functional pentamers. Therefore we decided to apply the pentamer 
technique first to producing functional pentamers with mutations in specified positions.
Incidentally, these experiments could act as a further control to ensure that there 
was no significant pentamer breakdown or mis-assembly, because if these phenomena 
were occurring it would be likely that mutated pentamers would produce multi-phasic or 
surprisingly shifted concentration-response curves.
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Figure 8.8: Example traces and concentration-response curves showing the effect of 
inserting two TM2 leucine-to-threonine 9' mutations into the pentamer 
construct, (filled squares, continuous line, n = 4), where the dotted line is 
the 36-fold shift, expected on the basis of the previous data (Boorman et 
al. 2000), from the wildtype pentamer (dashed line).
The first mutated construct to be tested was the p4p4a3p4a3 pentamer with its 
first (34 and last a3 subunit mutated at 9' from leucine to threonine ((34LT(34a3(34a3LT). 
This was chosen because it was the easiest construct to produce. Future work will deal 
with other two-mutant pentamers such as (34(34a3LT(34a3LT, p4LTp4LTa3p4a3 or 
p4LTp4a3(34 LTa3. The obvious term of comparison are two-mutant a3LTp4, a3LTp4p3 
and a3p4LTp3 monomeric receptors. Figure 8.8 shows the traces and concentration-
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response curve obtained for p4LTp4a3p4a3LT. As can be seen from the graph the degree 
of shift produced by the two mutations in the pentamer was almost identical to that 
calculated (from Boorman et al. 2000) for the combined effect of a single a3 and (34 
mutant subunit (EC50 = 2.03 ± 0.46 //M , n = 4 vs 2.19 //M  calculated). The Hill slope is a 
little bit reduced when compared to the calculated two mutation curve but the calculated 
curve was generated on the assumption that the two-mutation curve would be parallel to 
the wildtype pentamer curve («h = 1 -67), of course as has been discussed earlier receptors 
with mutations tend to have reduced Hill slope possibly due to monoliganded and 
spontaneous openings. Hence the Hill slope of (34LT(34a3(34a3LT (0.9 ± 0.16, n = 4) 
compares reasonably well to the Hill slopes values we have recorded for other two- 
mutation a3(34 monomeric receptors (a3LTJ34 1:1, 1.15 ± 0.08, n = 6, a3LTp4 1:9, 1.32 ± 
0.07, n = 5). It must be borne in mind that these two-mutant monomeric receptors, 
although providing better expected Hill slope guidelines than the calculated curve, aren’t 
perfect comparisons as they are taking from receptors with two a3 mutations rather than 
the single a3 and p4 of the pentamer.
Overall, these findings suggests that the presence of the linkers has not 
significantly altered the properties of the receptor and as such mutated pentamer 
constructs provide a good model for nAChR LGICs with complicated patterns of 
mutations.
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8.6 Checking the equivalence of individual s\ibunit 
mutations
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Figure 8.9: (previous page) Non-equivalent effects of TM2 L9'T mutations inserted 
into a single a or a single p subunit.
(A) Example current responses elicited by increasing concentrations of 
ACh.
(B) Comparison of the concentration-response relation for pentamer- 
expressed receptors bearing an L9'T mutation on a single a subunit 
(p4_p4_a3_p4_a3LT) or a single p subunit (P4LT_p4_a3J34_a3). Note 
that the increase in agonist sensitivity produced by a single mutation copy 
is greater if the mutation is in a (filled triangles, n=4). This single­
mutation shift is greater than the approximately 6-fold shift expected from 
previous experiments in which all a or all p were mutated (shown for 
reference by the dotted line, (Boorman et al. 2000). Conversely, the 
increase in ACh sensitivity is less than expected when the mutation is 
inserted in p (filled circles, n=5).
Having shown that the pentamer produced a reasonable model of a two-mutant 
LGIC, we then produced pentameric constructs with either the first p4 subunit or the last 
a3 subunit mutated to test, for the first time, the assumption on equivalence of effect of 
9' mutations. The traces and curves obtained are shown in Figure 8.9. The graph shows, 
the actual effects of mutating a single subunit in a specified position and as can be seen 
while the p4(34a3(34a3LT (EC50: 5.9 ± 0.2 juM, n = 4) produced a greater than expected 
shift (around 16-fold compared to the 6-fold expected from the Boorman interpolation), 
the f34LTp4a3p4a3 (ECsC 28.5 ± 1.8 pM, n = 5) produced a smaller shift of around 3- 
fold (EC50: p  < 0.005, «h; not significant, unpaired two-tailed Student’s t-test). The net 
effect of combining these two mutations would be to produce an intermediate shift close 
to that seen for the two mutations together as seen for p4LTp4a3p4a3LT in Figure 8.8.
It is not clear yet why a mutation in that particular a3 should be more potent than 
a mutation in the neighbouring p4: clearly considerable further work is needed, and each 
subunit will have to be mutated in turn alone and in combination with other mutations. 
The differences could be due to differences in their proximity to the binding sites or some
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other important region of the receptor or it could reflect some difference imthe exact 
positioning of the 9' residues of each subunit in the channel. It can not be ruled out at 
this point that this difference is not due to some artefact caused by the linkers in the 
pentamer and their effects on the insertion or activity of the receptor.
All the curves produced by mutated pentamers were well fitted by one-component 
fits which further indicates there was no significant breakdown or misassembly of the 
pentamers.
8.7 Discussion
The low currents obtained from pentamer constructs are a serious limitation of the 
technique. As discussed above, it is likely to be due to low surface expression, maybe 
because of poor translation of such large constructs. This is a serious limitation, given 
that one of our aim was to use linked-subunit receptors for single-channel work. This 
phenomenon of low currents was a common feature and was to dog the whole project; it 
may be related to the decrease in expression levels noted for tandems and triplets and 
commented on in Chapter 7. The cause of this low current is unclear, it maybe due to 
proteolysis (although, as shown, there is no evidence of functional proteolysed 
fragments), a “maxing-out” of protein production or the resulting pentameric receptor 
may just have a low Popen or channel conductance. For the sake of brevity I shall refer 
to the level of currents seen as “expression” levels although they may not actually be due 
to low expression levels but may be due to low Popen, conductance etc. Attempts at 
single-channel recordings from pentamer-injected oocytes provides some evidence that 
this problem is due to expression level, given that as many as 95% of the patches pulled
211
were “blank” whilst the “non-blank” patches contained receptor channels with normal 
Popen and channel conductance values.
How to increase expression? We haven’t explored the relation between quantity 
of cRNA injected and expression enough to be sure, but given we found that increasing 
cRNA concentration slightly decreased current levels, it is possible that there is a “bell 
curve” relationship between concentration of cRNA injected and receptor expression 
levels. It could well be that the quantity we injected was not optimal and expression 
levels may be increased, counter-intuitively, by injecting less cRNA. Another possible 
avenue to explore would be molecular biological techniques, for instance we saw a trend 
towards a small increase in 7max (from 293 ± 71 to 351 ± 52, n = 5-6) when cRNA created 
with an extra 1//1 GTP as suggested in the mMESSAGE mMACHINE Kit instruction 
manual for optimising the yield of long transcripts. While the aim of the work covered in 
this chapter was proof of concept, optimising expression will be important as the low 
“expression” levels witnessed were about 10-fold too low to allow single-channel work.
In summary, we have shown that the concatemer approach can be extended to 
produce constructs of up to five subunits which produce functional receptors. While 
expression of such a complete-receptor concatemer has been obtained for other types of 
channel, notably potassium channels see for instance (Liman et al., 1992) and TRP 
channels (Hoenderop et al., 2003), to our knowledge this is the first time that this 
approach has been used in the nicotinic superfamily of ligand-gated channels. These 
receptors appear to be similar to those obtained with monomeric constructs, and do not 
appear to suffer from the problems noted for other, smaller constructs. Though there is a 
small difference in the ECso of the pentameric and monomeric construct receptors these
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results compare well with those obtained by Sigel and co-workers in their expression of 
GABAa receptors from trimer + dimer constructs (Baumann et al., 2002). Use of these 
constructs can be exploited for a huge variety of experiments that were simply not 
possible until now. As such this technique could provide a powerful tool for 
electrophysiological studies of recombinant receptors in heterologous expression 
systems. With the recent development of higher throughput, automated recording 
systems for Xenopus oocytes such as the Roboject, the ability to produce native-like, 
complicated receptors containing multiple subunits with specified mutations in 
heterologous systems should also be of great use to the pharmaceutical industry.
213
CHAPTER 9
Alternate Stoichiometries of the a3(34
nAChR
A manuscript on the findings in this chapter is in preparation.
A substantial body of biochemical and electron microscopy work has shown the 
muscle nicotinic receptor to be a heteropentamer with a stoichiometry of al|31y(8/s) at a 
ratio of 2:1:1:1 (for a review see Karlin, 1991) and this has been accepted for over two 
decades (Lindstrom et al. 1979). In comparison the stoichiometry of the neuronal 
nAChRs is still the subject of much research and debate. Early work showed that the a2, 
a3 and a4 subunits when co-expressed in oocytes individually with p2 produced 
receptors with two conductances. Varying the injection ratios of a2(32 changed the 
proportion of each conductance present indicative of two different stoichiometries (Papke 
et al 1989). Estimating the proportion of different channel types by counting single 
channels is difficult and prone to errors. Furthermore these experiments had low n and 
showed poor quality of the recordings. It is not therefore surprising that these data had 
little impact on the general opinion that all types of nicotinic receptors, including the 
neuronal receptors, have only a single stoichiometry. Further work on oocyte-expressed 
chick a4p2 receptors using site-directed mutagenesis suggested a stoichiometry ratio of 
2:3 (Cooper et al. 1991; see also Anand et al, 1991) and this was thought to hold for all 
the neuronal nicotinics, especially since the two alpha, three non-alpha subunit 
stoichiometry tallies well with the muscle nAChR stoichiometry. In addition to that, two 
a subunits would form two ligand binding sites in agreement with Hill slope values, 
which also suggested that neuronal nAChRs required the binding of two ACh molecules. 
Nevertheless, the expression of rat a4p2 subunits has since been shown to produce 
receptors with two apparent stoichiometries with distinct pharmacologies, most likely
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2a:3p and 3a:2p (Zwart & Vijverberg, 1998). Reporter mutation work, -however, 
confirmed that in oocytes at equimolar injection ratios, the stoichiometry of the a3p4 
receptor is 2a:3p (Boorman et al. 2000). Most recently, extensive work has shown that 
human a4p2 does exist in two stoichiometries when expressed in HEK cells and the 
relative proportions of each stoichiometry could be forced and changed, not only by 
changing injection ratios but also by changing temperature and through exposure to 
nicotine (Nelson et al. 2003).
Following on from our work in 2000 (Boorman et al. 2000), the use of first 
tandem then pentameric constructs had confirmed that an a3p4 nAChR with two 
a subunits is functional and resembles the receptor expressed by oocytes injected at an 
a:p 1:1 ratio. However, as shown earlier, a3p2 and a4p2 dose-response curves are 
biphasic (and become monophasic when p3vs is co-expressed) suggesting that at a 1:1 
ratio these two combinations were likely to exist in two stoichiometries. The questions I 
address in this chapter are:-
1) What is the a3p4 primary stoichiometry?
2) Can that stoichiometry be changed?
3) If  so, what effect does changing the stoichiometry have on that receptor?
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9.1 Primary Stoichiometry of the a3|34 nAChR: 
expression of wild-type subunits at 1:1 ratio
In Boorman et al. 2000, reporter mutations showed that the injection of a3 and (34 
subunits at equimolar ratios produced a receptor which displayed a greater shift when the 
mutation was present in the (34 subunit then the a3 subunit (Figure 9.1). Comparison of 
the dose-ratio values gave the likeliest stoichiometry to be the 2a:3(3 as seen with oocyte- 
expressed chick a4(32 by Cooper et al.
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Figure 9.1: ACh-concentration-response curves showing the effect of incorporation of 
the 9' LT mutation into the a3 (open squares) and (34 (open triangles) 
subunits compared with the wildtype (open circles). Pooled normalised 
curves were fitted with a Hill equation as a free fit (n=4-7). Note the 
greater effect of the mutation in p4 than a3, consistent with there being 
more (3 than a subunits present in the receptor, (from Boorman et al. 
2000)
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Our first set of experiments was to characterise the receptors produced by 
injecting the wild-type subunits at ratios of 1:9 and 9:1. If  the a3p4 can only adopt one 
stoichiometry we would expect to see the same dose-response curves irrespective of 
subunit ratio.
This was not what we observed. Figure 9.2 shows the curves obtained for the 1:1 
injection ratio of a3f34 compared to those produced by 1:9 and 9:1.
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Figure 9.2: Comparison of ACh-concentration-response curves obtained from 
oocytes injected with a3(54 cRNA at either an equimolar (1:1 black line, 
circles) or extreme ratio (1:9, red line squares; 9:1, blue line, diamonds). 
Pooled normalised curves were fitted with a Hill equation as a free fit 
{n=4-5). There is a clear difference between the curves. Note that the 
equimolar curve, although intermediate between the two extreme ratio 
curves, is most similar to the 1:9 wildtype curve.
As can be seen there are marked differences between some o f the curves. 
Receptors expressed from a 9:1 ratio are much less sensitive to ACh than the 1:9 
receptors and their dose-response curve has a steeper H ill slope (p<0.01 and /?<0.05, two- 
tailed Student’s /-test). While the dose-response curve for 1:9 receptors looks somewhat 
to the left o f the 1:1 curve and appears steeper, the two curves are close to each other, and 
neither o f these differences is significant.
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Comparison of the parameters fitted to the different curves show that the curve for 
the 1:1 injection ratio receptor (ECso = 172 ± 8 pM, «h = 1.56 ± 0.07, n=5) is 
intermediate to the receptors produced by the 1:9 (ECso = 138 ± 14 pM, nH= 1.79 ± 0.11, 
n=4) and 9:1 (ECso = 310 ± 28 //M, «H = 2.41 ± 0.21, n=4) injection ratios, and that the 
1:1 injection ratio is most similar to the 1:9 receptors the differences not reaching 
significance whereas the 9:1 injection ratio is significantly different from both (unpaired, 
two-tailed Student’s t-test, Table 9.1).
Injected
combination
ECso 
(pM) ± SEM
Hill slope 
± SEM
n
p  value 
(vs 1:1)
p  value 
(vs 1:9)
EC50 nn ECso
a3(34 (1:9) 138 ± 14 1.79 ±0.11 4 NS NS - -
a3(34 (1:1) 172 ±80 1.56 ±0.07 5 - - - -
a3(34 (9:1) 310 ± 28 2.41 ±0.21 4 < 0.005 < 0.005 < 0.005 <0.05
Table 9.1: Comparison of the EC50 and Hill slopes for a3 + p4 receptors produced
by cRNA injected into oocytes at different ratios. Note the significant 
differences between the 9:1 injection ratio and the 1:1 and 1:9 injection 
ratios. Statistical analysis by unpaired two-tailed Student’s t-.test. NS = 
not significant.
We already know that at 1:1 injection ratio most of the receptors are 2a:3P; if we 
want to interpret the trend towards a lower ECso in the 1:9 receptors, it is possible that 
these receptors contain a small but sizeable proportion of 3a:2(3 receptors and that this 
decreases or disappears when we inject 1:9 ratios. The 9:1 receptors are likely to 
represent a majority of 3a:2f3 receptors (this will be proven in the next section). The 
lower Hill slope of the 1:1 injection ratio could be the product of a two-component curve 
where the two components, representing the two stoichiometries, are too close to be
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separated. Our data resemble the findings of Nelson et al. 2003 who found that the 
2a:3p form of a4p2 had higher ACh sensitivity. Thus, a3p4 receptor stoichiometry in 
oocytes can be changed and forced by varying the injection ratios.
All this worked on the assumption that the only possible stoichiometries were 2:3 
or 3:2 (i.e. that 4:1 and 1:4 stoichiometries are not possible) and that the extreme ratios 
used would produce pure populations of a certain stoichiometry. To confirm that the two 
stoichiometries were 2:3 and 3:2 and to check that the two extreme ratios were producing 
fairly pure populations we then decided to repeat the reporter mutation experiments 
carried out on a3p4 (1:1 ratio) as reported in Boorman et al. 2000 on the 1:9 and 9:1 
receptors.
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9.2 Investigating the Stoichiometry of the a3p4 
Receptor (Injection Ratio 1:9) by the LT Reporter 
Mutation
a3LTp4 and a3p4LT subunit combinations were injected into oocytes at a ratio o f 
1:9, the curves obtained are shown in Figure 9.3.
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Figure 9.3: ACh-concentration-response curves showing the effect of incorporation of 
the 9' LT mutation into the a3 (blue line, circles) and (34 (red line, squares) 
subunits compared with the wildtype (black line, rhombuses) for a3p4 
receptors injected at a ratio of 1:9. Pooled normalised curves were fitted 
with a Hill equation as a free fit (/?=4-5). Note the greater effect of the 
mutation in (34 than a3, consistent with there being more (3 than 
a subunits present in the receptor with the same pattern as seen in Figure 
9.1.
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IT ITAs shown by the figures, the curves produced by the a3 P4 and a3(34 at a 1:9 
injection ratio reproduced the same pattern seen in Boorman et al. 2000 with the 1:1 ratio 
(even down to the shallowing of the Hill slope for the p4LT mutation), with the largest 
shifts produced by the insertion of the mutation into the p4 subunit (EC50 = 0.92 ±0.13 
juM, «h = 0.90 ±0.12,72=4) rather than the a3 (EC$0 = 4.48 ± 0.38 /zM, «h = 1.33 ± 0.09, 
77=5). By eye, the similarity in the magnitude of the shifts to those observed by Boorman 
et al 2000, suggests that there is a 2a:3p stoichiometry rather than something more 
extreme such as la:4p. This is confirmed when the dose ratios are calculated from 
parallel fits (see Table 9.1). The best match came with the 2a:3p stoichiometry even 
though the shallowing of the a3p4LT curve produced a poor parallel fit.
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9.3 Investigating the Stoichiometry of the a3p4 
Receptor (Injection Ratio 9:1) by the LT Reporter 
Mutation
T T  T TThe injection ratios were then reversed to 9:1 for a3 (34 and a3(34 
combinations. The resulting curves are shown in Figure 9.4.
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Figure 9.4: ACh-concentration-response curves showing the effect of incorporation of 
the 9' LT mutation into the a3 (blue line, circles) and (34 (red line, squares) 
subunits compared with the wildtype (black line, rhombuses) for a3(34 
receptors injected at a ratio of 9:1. Pooled normalised curves were fitted 
with a Hill equation as a free fit (n=4-5). Note the greater effect of the 
mutation in a3 than (34 the exact opposite of what is seen with the 1:1 and 
1:9 ratios, this is consistent with there being more copies of a3 in the 
receptor than (34.
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Comparing Figure 9.4 with Figures 9.1 and 9.3 shows the pattern of shifts of the 
mutations has entirely changed and the largest effect is now seen with the insertion of the 
a3LT mutation (ECso = 7.2 ± 0.2 pM, nw = 1.91 ± 0.05, n - 5) rather than the (34LT (ECso =  
38.8 ± 1.4 pM, = 2.05 ± 0.15, n=4). Once more the stoichiometry which gives the 
best dose-ratios calculated from parallel fits was the 2:3 stoichiometry but this time with 
3a to 2p (Table 9.2).
Injected
combination
ECso 
(pM) ± SEM
Dose ratio Square root of 
dose ratio
Cube root of 
dose ratio n
a3p 4(l:l)* 180± 17 1 - - 1
a3LTp4 (1:1)* 5.8 ± 1.0 37.3 6.11 3.34 6
a3ft4LT (1:1)* 0.75 ± 0.05 292 17.1 6.63 4
a3p4 (1:9) 138 ± 14 1 - - 4
a3LTp4 (1:9) 4.48 ± 0.38 34.2 5.85 3.25 5
a3p4LT (1:9) 0.92 ±0.13 417 20.4 7.47 4
a3J34 (9:1) 310 ± 28 1 - - 4
a3LTp4 (9:1) 7.21 ±0.21 47.6 6.90 3.04 5
a3p4LT (9:1) 38.8 ± 1.4 9.26 3.62 2.10 4
Table 9.2: Effect of incorporation of 9' threonine mutations into different subunits at
different injection ratios. Dose ratios were estimated from fits in which the 
curves were constrained to have the same slope and expressed in 
relation to curves produced by receptors with 5 leucines at 9' (dose ratio = 
1). Assuming equivalence of the mutation the square root and cube root 
of the dose ratio of the correct stoichiometry should be similar. Note that 
for the 1:1 and 1:9 injection ratios the most similar combination of dose 
ratios (marked in bold) is produced by two copies of a3 and three copies 
of p4 while for the 9:1 ratio the most similar combination is produced by 
three copies of a3 and two copies of p4. The EC50 and the Hill slopes for 
the two extreme ratios are significantly different for both a3LTp4 (p < 0.001 
and p < 0.05, respectively, two-tailed Student’s t-test) and a3p4LT (p < 
0.005 and p < 0.05, respectively, two-tailed Student’s t-test). Data marked 
with * reproduced from Boorman et al 2000.
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One of the noticeable features of the 3a:2(3 stoichiometry was the steepness of the 
Hill slopes, which lead us to wonder whether the 3 alpha form of the a3p4 nAChR had 
three binding sites? This is a line of speculation we have not yet had an opportunity to 
follow further.
9.4 Expression of a Pentameric 3-alpha a3|34 Receptor
Given our success with our work on pentameric constructs for a3p4 receptors in 
their 2a:3p form, we wondered whether it would be possible to produce a pentameric 
receptor made up by three a3 subunits and two P4 subunits. If  such a functional receptor 
could be produced would it resemble the 3a:2p monomeric receptors we had produced 
with the 9:1 injection ratio? There are two ways 3a and 2p subunits could be arranged 
around the pore, namely either with all three a subunits together e.g. a_a_a_p_p or with 
two together and one separated by p subunits (a sort of “negative” of the putative 2a:3p 
formation) e.g. a_a_p_a_p.
We thought the likeliest arrangement would be the a_a_p_a_p template. Given 
that we found that of the two tandem constructs a3_p4 and P4_a3 only the latter 
produced functional receptors, we would expect to see a similar picture for pentameric 
constructs and that only some of the possible pentameric constructs (ct_a_p_a_p, 
a_p_a_p_a, P_a_p_a_a and P_a_a_p_a) that follow this chosen pattern would 
express. With our experience with functional constructs of the p_a template and the 
functional P_P_a_P_a pentamer we decided to test the nearest variation, 
P4_a3_a3_p4_a3. High concentrations of this pentamer construct were injected into
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oocytes (i.e. lOng-lOOOng, 77=6-24) and were tested for function. As with the 2a 
pentamer constructs, low expression levels were a problem (average /max= 97 ± 14 nA 
«=12), but the receptor was found to be functional and full dose response curves were 
obtained (Figure 9.5.). The variation a_p_a_(3_a did not express functional receptors
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Figure 9.5: ACh-concentration-response curves comparing the (34J34_a3J34_a3
pentamer construct (dashed line) with the wildtype p4_a3_a3J34_a3 
(black line, squares). Pooled normalised curves were fitted with a Hill 
equation as a free fit (r?=6-12). Note the only minor differences between 
the two constructs.
Figure 9.5, shows there was a small shift in the EC5o of the 3a pentamer (EC50 = 
124 ± 11 juM, «h = 1.74 ± 0.19,77= 12) compared to that of the 2a pentamer (ECso = 95 ±
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11 //M, «h = 1-71 ±0.13, n=6). Not only was this shift too small and variable to reach 
significance (two-tailed Student’s t-test), but also this was nowhere near as large as the 
shift observed in receptors expressed from monomer construct. In addition to that, the 
Hill slope was nowhere as steep as in the monomer-expressed 9:1 receptor.
Possibly another variation on the a _ a j_ a j  or even the a _ a _ a J J  template 
would produce results more similar to that obtained from the monomeric receptors but 
without further work, it is hard to give a convincing explanation of these differences, 
other than just say that this may be a flaw in the use of pentameric constructs, in that they 
don’t always reproduce the properties of monomeric receptors. However, one thing this 
work does show is that it is possible to produce other functional pentameric constructs 
other than p4_(34_a3 J34_a3.
My initial work on the two stoichiometries of a3f34 has been expanded on by 
other members of my group, I will briefly summarise their findings below to help put my 
work into context; even though I have had only been marginally involved in this work.
9.5 Differences in Pharmacology Between the Two 
Stoichiometries
My colleague Skevi Krashia checked the potency ratios of a variety of nAChR 
agonists on the two different stoichiometries in oocytes to produce the following rank 
orders of potency (n = 6-19).
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For the 1:9 injection ratio:-
epibatidine »  lobeline > nicotine ~ cytisine > DMPP ~ ACh »  carbachol 
For the 9:1 injection ratio:-
epibatidine »  lobeline > DMPP > nicotine > cytisine > ACh »  carbachol
The most obvious changes being the increases in relative potencies of DMPP and 
cytisine as well as large changes in the absolute values for each agonist (data not shown), 
From this it was clear that the two different stoichiometries have distinctly different 
pharmacologies.
9.6 The Stoichiometry of the a3p4 Receptor when 
Expressed in HEK Cells
My colleagues Seb Kracun and Giovanna Hofmann attempted to repeat this 
experiment in HEK cells and although experimental problems meant they were unable to 
fully characterise all the combination ratios, examining the HEK cells transfected at 1:1 
shows the primary a3p4 stoichiometry to be the 3a:2|3 form, the opposite of the findings 
in oocytes (Figure 9.6 & Table 9.3) and that if forced the other stoichiometry can be 
formed.
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Figure 9.6: ACh-concentration-response curves showing the effect of incorporation of 
the 9' LT mutation into the a3 (blue circles) and p4 (red squares) subunits 
compared with the wildtype (black squares) when expressed in HEK cells 
at a ratio of 1:1. Pooled normalised curves were fitted with a Hill equation 
as a free fit (/?=7-8). Note the greater effect of the mutation in a3 than (34, 
consistent with there being more a than p subunits present in the 
receptor, the opposite to what is seen in oocytes. Data courtesy of Seb 
Kracun and Giovanna Hofmann.
230
ECso 
(pM) ± SEM
nH 
± SEM
Dose
ratio
Square 
root of 
dose ratio
Cube root 
of dose 
ratio
. n
a3(34 91.1 ± 10.7 1.65 ±0.23 1 - - 8
a3p4LT 18.6 ±1.6 1.52 ±0.13 5.1 2.26 1.72 7
a3LT|34 5.5 ±0.9 1.27 ±0.04 18.6 4.31 2.65 7
Table 9.3: Effect of incorporation of 9' threonine mutations into different subunits
expressed at a 1:1 ratio in HEK cells. Dose ratios were estimated from 
fits in which the curves were constrained to have the same slope and 
expressed in relation to curves produced by receptors with 5 leucines at 
9' (dose ratio = 1). Assuming equivalence of the mutation the square root 
and cube root of the dose ratio of the correct stoichiometry should be 
similar. Note that the most similar combination of dose ratios (marked in 
bold) is produced by three copies of a3 and two copies of (34.
Our group have attempted to examine single channel recordings from both 
stoichiometries, with and without mutations, in order to see if there is any marked 
difference. However as of writing, this has yet to be analysed and so I will go no further 
into it.
9.7 Discussion
The results of expressing extreme injection ratios in oocytes confirm that a3(34 is 
capable of adopting two stoichiometries with distinct properties and that the relative 
proportions of each receptor population can be changed by changing the transfection 
ratios. The follow up work has shown the two receptors have distinct pharmacologies, 
that the predominant stoichiometry in mammalian cell lines is 3a:2(3.
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The reporting of the presence of two stoichiometries for a4p2, also thought to be 
2<x:3|3 and 3a:2p, and the ability for them to be changed led Nelson et al. to indulge in 
some interesting speculation (Nelson et al. 2003).
It is known that during development the majority of muscle nicotinic receptor 
change their formation by one subunit, a y subunit is replaced by an s subunit (Naranjo & 
Brehm, 1993). This confers a number of changes in the resulting receptor properties, the 
adult receptor has a reduced sensitivity to ACh with shorter mean opening time and 
increased desensitisation. This change is thought to mark the change in the receptor from 
embryonic volume transmission to adult synaptic transmission (Sanes & Lichtman, 
2001). In volume transmission in embryonic muscle the distances between site of ACh 
release can be large therefore it is beneficial for the receptor to be activated by relatively 
low concentrations of ACh. In comparison, in synaptic receptors as the concentration of 
ACh in the cleft is high and the distance low there is less need for such a sensitive 
receptor and were a highly ACh-sensitive receptor present there would be the risk of 
inappropriate activation caused by the firing of neighbouring neurones. The nature of 
the signal is different as well, synaptic transmission should be faithful, produce large 
currents in the target muscle fibre but only for a short period before shutting off, whereas 
in volume transmission longer, more sustained signalling is required. These requirements 
nicely dove-tail with the properties of embryonic vs. adult muscle nicotinic receptors.
When compared with the different properties of the two stoichiometries of a4p2 
neuronal nicotinics it was clear that the 2a:3p stoichiometry with its higher ACh- 
sensitivity and lower conductance resembles the embryonic muscle nicotinics while the 
3a:2p (low ACh-sensitivity, high conductance) resembles the adult. Nelson et al.
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speculated that the 2a:3p stoichiometry might represent the pre-terminal' form of 
nAChRs where transmitter diffuses from adjacent synapses whereas the 3a:2p is optimal 
where a4p2 serves a traditional postsynaptic role. However without knowing the 
physiological concentrations of ACh present in the synaptic cleft and extrasynaptically 
we cannot say whether this is correct. Similarly we can only speculate whether the 
developmental change postulated by Sanes and Lichtman (2001) in ganglionic nicotinics 
has a parallel in the CNS receptors.
As well as being of interest in the stoichiometry and developmental studies of 
nAChRs the presence of two changeable stoichiometries for a4p2 may be of great 
importance in the action of nicotine in smoking and particularly the effect of nicotine 
exposure on the unborn. To these findings we now add proof of there being two 
stoichiometries for a3p4.
In Boorman et al. 2000, it was found that a 1:1 injection ratio of a3 and P4 
produced a receptor with a 2a:3p stoichiometry. The new work broadly confirms this, in 
that it is clear from Figure 9.2 that the 1:1 injection ratio produces a dose-response curve 
that is very close to the curve produced by the 1:9 injection ratio, which corresponds to 
the 2a:3p stoichiometry. A question that arises is whether the 1:1 receptors are a mixed 
population of the two a3p4 stoichiometries, with the majority of the 2a:3p form. If  that 
is the case, can we estimate how many receptors are of the other, 3a:2p form, or at least 
how much of the current is carried by them? If  we can assume that the extreme injection 
ratios produce pure stoichiometries, the greatest difference between the EC so of the 2a vs 
the 3a form is seen when we express a3p4LT and it is approximately 8-fold (i.e. 0.92 vs 
7.21 //M, respectively). Nevertheless, it is hard to see how we could reliably fit the p4LT
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curve resulting from 1:1 injections with two components (Fig. 9.1) and this indicates that 
the proportion of 3a receptors is too small to be detected, with this mutation and this 
technique.
It is apparent that in oocytes injected with equimolar concentrations of cRNA 
produce mixed populations of different stoichiometries for the a4p2 nAChRs and 
possibly the a2p2 and a3p2 as well, whereas the a3p4 appears to form a fairly pure 
population of the 2a:3p stoichiometry. We do not know the reason for the difference 
between the different subunit combinations. In contrast HEK cells predominantly 
express the 3a:2p form of a3p4. This difference in stoichiometry depending on the 
expression system used may be due to differences in the respective cell-types membrane 
insertion, protein assembly etc. machinery or could just reflect differences in expression 
efficiency between, for instance, a3 and P4 DNA vs. RNA constructs.
An alternative explanation is that the difference is due to the difference in 
incubation temperature for mammalian cell lines and oocytes, in a manner similar to that 
reported by Nelson et al (2003)
One observation that can be made about a3p4 having two distinctly different 
stoichiometries is that this may provide the p3 subunit with an additional unexpected 
role. As noted earlier the a3p4p3 triplet receptor is infuriatingly similar to the a3p4 
receptor injected into oocytes at a 1:1 ratio i.e. mostly the 2a:3p form. We have also 
shown that there is a considerable difference in the properties between the 2a:3p and the 
3a:2p forms of the a3p4 receptor. This all suggests a possible role for the p3 subunit in 
native nAChRs. A neuron expressing a3p4 without the presence of p3 would produce a 
receptor population mostly made up from the 3a:2p form of the receptor with the
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resulting lower sensitivity to ACh, different pharmacology etc. typical' of this 
stoichiometry. Conversely, a neuron expressing a3p4 with p3 would mostly express a 
population of receptors of the a3p4p4 (2:2:1) form which has similar characteristics to 
the 2a:3p form of the a3p4 receptor when it comes to ACh sensitivity and 
pharmacology. Therefore it is possible, if not yet proven, that P3 expression may be a 
mechanism by which the relative proportions of 3a:2p and 2a:3p-like a3p4 nAChRs are 
controlled. What the physiological significance of such a control mechanism would be is 
currently not clear. Even without a clear physiological role if the effect of nicotine on 
a4p2 is replicated in a3p4 this could be a source of pharmacologically induced plasticity 
and so may be important in nicotine addiction.
The most pessimistic conclusion would be that in recombinant receptors we see 
different stoichiometries simply because we are expressing the minimally functional 
subunit combination, which may never be found in neurones, in which only one of the 
stoichiometries may be produced.
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CHAPTER 10 
Summary
Chapter 2 outlined the main aims of my project, so to what extent have these 
aims been met?
The primary aim of my PhD was to examine which combinations of nAChR 
subunits could form receptor complexes with the P3 subunit and what effect did the 
p3’s insertion have on the properties of these receptors. We believe the evidence 
presented here, through both the knock-out of receptors when co-injected with p3 and 
their recovery by the p3vs mutation, shows that, in the oocyte at least, p3 can form 
receptor complexes with a2p2, a2p4, a3p2, a4p2, a4p4 and a l  subunits. These 
receptors are present in the membrane of the cell but are virtually non-functional, 
probably because of a P3-induced decrease in the P0pen values of these receptors. This 
effect can also be observed in native a7-type receptors from primary hippocampal 
cultures. We have also begun to show the possibility that the p3 subunit is a vital 
requirement in producing functional receptors containing the a6 subunit. All this 
along with our previous findings on the effect of p3 on the a3p4 receptor suggests an 
intriguing and significant role of the P3 subunit. Whereas the a3p4 nAChR, the main 
peripheral nervous system nicotinic receptor, is unaffected by the insertion of a p3 
subunit to an almost infuriating degree, all the other nAChRs combinations (which are 
likely to represent the central nervous system receptor types) are almost totally 
“knocked-out” by the p3 subunit. The only exception is a6 receptors whose function 
appears to be dependent on P3’s presence. What makes this a6 finding to be of 
particular interest is the high degree of overlap between a6 and p3 expression (Le 
Novere et al. 1996). It is still unclear what the exact role of the P3 subunit is, 
particularly the relevance of a6 versus the other CNS nAChRs findings. Nevertheless
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it is plausible that control of p3 expression could give neurones a tremendous amount 
of control over nicotinic transmission both in a general sense (of increasing and 
decreasing total-cell nicotinic current) and in a more selective way, namely to control 
which nAChR subtypes are functional in a given cell at a given time. This selection 
between PNS and CNS nicotinic transmission might be an important factor in the 
control of nicotinic activity in development and p3 could provide both general and 
highly specific temporal and spatial control over nAChR-mediated current.
nAChRs are thought to have a general modulatory role over the actions of a 
wide range of neurones which release a host of different neurotransmitters. Thus, p3 
levels may provide a means of controlling a large number of neuronal systems and as 
such may have a pivotal role in neuronal development, neuronal activity, 
neuropathology and neuropharmacology.
Of the other secondary aims of the project, the development of the TM2 9' P3 
mutations have proven their worth in researching the action of p3 on nAChRs and 
while, as events transpired, the Delilah mutants where found to be unnecessary for the 
research of the majority of the nAChR combos we examined they may still prove to 
be a useful research tool in the examination of the a6/p3 story. Our work on tandem 
constructs has highlighted a possible major flaw in the interpretation of the results 
obtained using these, a finding which could undermine the validity of a large amount 
of work carried out, not only on nAChRs, but also other LGICs, VGICs and transport 
proteins which have utilised this approach. Having uncovered this problem with 
tandems we have then developed a possible solution in the form of pentameric 
constructs which, even if tandems were flawless, provided a superior amount of 
control over receptor stoichiometry and despite exhaustive testing have not been 
shown to suffer the problems associated with tandem constructs. This pentamer
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approach has the potential to revolutionise the use of heterologous expression systems 
to model native type receptors and other proteins far beyond just the nicotinics or 
even the LGICs as a whole.
Our other work has also produced interesting findings. The discovery of 
multiple a3p4 subunit stoichiometries and the evidence of this also being present in 
a3p2 receptors, and perhaps others, supports the findings of Nelson et al. 2003 with 
a4p2. These authors have hypothesised that these two stoichiometries are important 
for the role of nAChRs in embryonic vs mature CNS and in volume vs synaptic 
transmission and that they can be affected by nicotine exposure. If  this hypothesis is 
correct, then this may underlie an important effect in nicotine addiction and may be of 
great importance in the development of the nicotinic system, even for peripheral 
receptors
I hope you will agree this all adds up to a fairly constructive PhD research
project.
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CHAPTER 11 
Future Work
Below follow a list of potential avenues of future research:-
Beta3
Is the stoichiometry of all the 03-containing triplet receptors 2:2:1?
What is the stoichiometry of a703 receptors? Is this changeable?
Is the P3 KO effect seen in other native type tissues?
What regulates P3 levels and do they change in disease states, development, 
pharmaceutical treatment or smoking?
Are our initial findings on the role of P3 with a6 correct?
Will Delilah-mutated p3 subunits knock out functional a6p3* receptors?
Can the Delilah mutations be used to produce functional knock-down in 
organotypic preparations?
Pentamers
Can we increase pentamer expression level enough to facilitate more efficient 
single channel recording and other research?
Can we create pentamers with more complicated stoichiometries?
Can we use pentamers to further explore the non-equivalence of mutations 
story?
Can we use pentamers to examine the difference between the nAChRs binding 
sites?
Can we express pentameric constructs in other cell lines?
Can we create pentamers of other types of LGIC?
Can we adapt pentamers to help us with our research on p3, stoichiometries 
and our other lines of work?
Stoichiometry
Do the other nAChRs have variable stoichiometries?
What governs the control of stoichiometry? What role does nicotine, 
temperature etc. play?
Do other heteromeric LGICs display this variability?
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